5 '-modified carbocyclic ribonucleotide derivatives and methods of use
By modifying the 5’-terminus of RNA, the problem of RNA easy to degrade in vivo is solved, its stability and functional efficacy are improved, and effective degradation of mRNA and Ago2 binding is improved.
Patent Information
- Application Number
- CN202380029632.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-22
- Filing Date
- 2023-02-22
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively degrade mRNA through chemical modification of RNA, and the modified RNA is easily degraded by phosphatase in the body, affecting its bioavailability.
Cyclopentyl-based nucleotide modifications, such as nucleotides containing 4'-ethylphosphonate, were developed to modify the 5'-terminus of RNA, enhancing its stability to nucleases and phosphatases, At the same time, maintain or improve binding affinity with Ago2.
It improves the metabolic stability and functional efficacy of RNA, prolongs its duration in vivo, and reduces the negative impact on gene target knocking.
Smart Images

Figure CN118922431A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims priority to and the benefit of U.S. Application No. 63 / 312,554, filed on February 22, 2022, the entire contents of which are incorporated herein by reference.
[0003] Incorporation of Sequence Listing
[0004] The contents of the electronic sequence listing (SANB_005_001WO_SeqList_ST26.xml; size: 105,372 bytes; and creation date: February 17, 2023) are incorporated herein by reference in its entirety.
[0005] background
[0006] Argonaute 2 (Ago2) belongs to the AGO protein family and plays an important role in small RNA (smRNA) biogenesis. Ago 2 is a key component of the RISC-loading complex (RLC) and binds double-stranded RNA (dsRNA) for loading into the RISC complex to be processed into target mRNA for degradation. The composition of nucleotides in RNA molecules has been shown to affect the binding of RNA to Ago2. A variety of modifications to the structure of nucleotides in RNA molecules have been tested. Therefore, there is still a need for RNA with improved performance and / or stability for degrading mRNA by chemical modification of RNA, such as modification of the main chain of RNA. The present application addresses this demand.
[0007] Overview
[0008] The present disclosure relates to the modification of the 5'-terminal nucleotide of oligonucleotides such as RNA. More specifically, the present disclosure relates to cyclopentyl-based nucleotides as described herein, such as cyclopentyl-based nucleotides comprising 4'-ethylphosphonate or 4'-vinylphosphonate. Oligonucleotides (e.g., RNA) comprising cyclopentyl-based nucleotides of the present disclosure exhibit favorable properties, such as enhanced metabolic stability to nucleases and phosphatases, while maintaining or further improving RISC binding affinity and intrinsic potency.
[0009] In some aspects, the present disclosure provides a compound of Formula (I) or Formula (II):
[0010]
[0011] or a pharmaceutically acceptable salt thereof, wherein:
[0012] B is H or a nucleobase moiety;
[0013] X is H, halogen or -OR X;
[0014] R X is H, C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 aryl), wherein the C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 Aryl) is optionally substituted with one or more R Xa replace;
[0015] Each R Xa are independently halogen, C1-C6 alkyl or -O-(C1-C6 alkyl), wherein C1-C6 alkyl or -O-(C1-C6 alkyl) is optionally substituted with one or more halogen;
[0016] Y is H, C1-C6 alkyl optionally substituted by one or more halogens, -P(R Y )2、-P(OR Y )(N(R Y )2)-P(=O)(OR Y )R Y 、-P(=S)(OR Y )R Y 、-P(=O)(SR Y )R Y ,-P(=S)(SR Y )R Y 、-P(=O)(OR Y )2、-P(=S)(OR Y )2, -P(=O)(SR Y )2、-P(=S)(SR Y )2 or a hydroxyl protecting group;
[0017] Each R Y is independently H or C1-C6 alkyl optionally substituted by one or more halogen or cyano;
[0018] Z is -P(R Z )2、-P(OR Z )(N(R Z )2)-P(=O)(OR Z )R Z 、-P(=S)(OR Z )R Z 、-P(=O)(SR Z )R Z ,-P(=S)(SR Z )R Z 、-P(=O)(OR Z )2、-P(=S)(OR Z)2, -P(=O)(SR Z )2 or -P(=S)(SR Z )2;
[0019] Each R Z is independently H or C1-C6 alkyl optionally substituted by one or more halogen or cyano;
[0020] R 1 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens;
[0021] R 2 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens;
[0022] R 3 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens;
[0023] R 4 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens;
[0024] Indicates single or double bonds; and
[0025] Each R 6 is independently H, halogen or C1-C6 alkyl optionally substituted with one or more halogens.
[0026] In some aspects, the present disclosure provides a nucleic acid agent or a pharmaceutically acceptable salt thereof, wherein the nucleic acid agent comprises:
[0027] An oligonucleotide comprising one or two 5'-terminal units, wherein each 5'-terminal unit is independently:
[0028]
[0029] The variables B and R 1 , R 2 , R 3 , R 4 , R 6 , X and Z are described herein, and ## indicates an attachment to the rest of the oligonucleotide.
[0030] In some aspects, the present disclosure provides a conjugate or a pharmaceutically acceptable salt thereof, wherein the conjugate comprises:
[0031] (i) a nucleic acid agent, the nucleic acid agent comprising:
[0032] An oligonucleotide comprising one or two 5'-terminal units covalently attached to the oligonucleotide, wherein each 5'-terminal unit is independently:
[0033]
[0034] The variables B and R 1 , R 2 , R 3 , R 4 , R 6 , X, and Z are described herein, and ## indicates an attachment to the rest of the oligonucleotide; and
[0035] (ii) one or more ligands, said one or more ligands being covalently attached to the nucleic acid agent.
[0036] In some aspects, the present disclosure provides compounds that are isotopic derivatives of the compounds disclosed herein.
[0037] In some aspects, the present disclosure provides pharmaceutical compositions comprising a compound, nucleic acid agent, or conjugate described herein.
[0038] In some aspects, the disclosure provides a method of modulating expression of a target gene in a subject, the method comprising administering to the subject a conjugate described herein.
[0039] In some aspects, the disclosure provides a method of delivering a nucleic acid agent to a subject, the method comprising administering to the subject a conjugate described herein.
[0040] In some aspects, the disclosure provides a method of treating or preventing a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a conjugate described herein.
[0041] In some aspects, the disclosure provides the conjugates described herein for use in modulating expression of a target gene in a subject.
[0042] In some aspects, the present disclosure provides a conjugate described herein for use in delivering a nucleic acid agent to a subject.
[0043] In some aspects, the disclosure provides a conjugate described herein for use in treating or preventing a disease in a subject in need thereof.
[0044] In some aspects, the disclosure provides use of a conjugate described herein in the manufacture of a medicament for modulating expression of a target gene in a subject.
[0045] In some aspects, the disclosure provides use of a conjugate described herein in the manufacture of a medicament for delivering a nucleic acid agent to a subject.
[0046] In some aspects, the disclosure provides for use of a conjugate described herein in the manufacture of a medicament for treating or preventing a disease in a subject in need thereof.
[0047] Unless otherwise defined, all technical terms and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the field to which the present disclosure belongs. In this specification, unless the context clearly specifies otherwise, the singular form also includes the plural. Although methods and materials similar or equivalent to the methods and materials described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference. It is not recognized that the references cited herein are prior art of the claimed invention. In the case of a conflict, the present specification including the definition will prevail. In addition, materials, methods and examples are only illustrative and are not intended to be restrictive. In the case of a conflict between the chemical structure and the name of the compound disclosed herein, the chemical structure will prevail.
[0048] Other features and advantages of the disclosure will be apparent from the following detailed description and claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1A and Figure 1B is a series of graphs showing gene silencing activity of siRNA compounds in the liver on day 5 following a single 0.5 mg / kg sc injection of CD-1 female mice followed by HDI dosing on day 4 (human gene plasmid, 20 μg).
[0051] Figure 2A-2E is a series of graphs showing the gene silencing activity of siRNA compounds in multiple extrahepatic tissues at day 10 following a single 3 mg / kg sc injection in CD-1 female mice.
[0052] Details
[0053] Chemical modification has been introduced into oligonucleotides to introduce properties that may be desired under certain conditions, for example, to stabilize against nucleases or other enzymes that degrade or interfere with the structure or activity of oligonucleotides. For example, synthetic oligonucleotides are usually terminated with 5'-hydroxyl groups or 3'-hydroxyl groups. The terminal hydroxyl group can be replaced with a phosphate group, which can be used, for example, to attach a joint, an adaptor or a marker or for the direct connection of an oligonucleotide to another nucleic acid. In addition, it has been reported that the 5'-terminal phosphate group enhances the interaction between certain nucleic acid inhibitor molecules and Ago2. However, oligonucleotides with 5'-phosphate groups are generally susceptible to degradation via phosphatases or other enzymes, which can limit their bioavailability in vivo. Therefore, it is desirable to develop modifications to the 5'-terminal nucleotides of oligonucleotides such as nucleic acid inhibitor molecules, which provide the functional effects of phosphate groups, but are more stable under environmental conditions that the oligonucleotides will be exposed to when applied to a subject. Such phosphate analogs will be more resistant to phosphatases and other enzymes, while minimizing the negative effects on the function of the oligonucleotides (for example, when used as RNAi inhibitor molecules, minimizing any reduction in gene target knockdown).
[0054] Limited methods for modifying the 5'-terminal nucleotide of oligonucleotides have been reported. However, there remains a need for novel phosphate mimetic derivatives of 5'-terminal nucleotides and conjugates thereof that are metabolically stable, for example, to nucleases and phosphatases, while having maintained or improved RISC binding affinity and intrinsic potency of the oligonucleotide.
[0055] The present disclosure provides phosphate mimetic derivatives of 5'-terminal nucleotides. Without wishing to be bound by theory, it is understood that when incorporated into an oligonucleotide (e.g., at the 5'-end of the antisense strand), the phosphate mimetic derivatives can improve Ago2 binding / loading and enhance the metabolic stability of the oligonucleotide, thereby enhancing the efficacy and duration of the oligonucleotide (e.g., siRNA molecule).
[0056] The present disclosure also provides nucleic acid agents and conjugates containing phospho-mimetic derivatives for nucleic acid delivery. The present disclosure also relates to the use of phospho-mimetic derivatives, nucleic acid agents and conjugates, for example, in delivering nucleic acids and / or treating or preventing diseases.
[0057] 5'-Terminal Unit Compounds of the Disclosure
[0058] In some aspects, the present disclosure provides a compound of Formula (I) or Formula (II):
[0059]
[0060] or a pharmaceutically acceptable salt thereof, wherein:
[0061] B is H or a nucleobase moiety;
[0062] X is H, halogen or -OR X ;
[0063] R X is H, C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 Aryl), wherein C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 Aryl) is optionally substituted with one or more R X a replace;
[0064] Each R X a is independently halogen, C1-C6 alkyl or -O-(C1-C6 alkyl), wherein C1-C6 alkyl or -O-(C1-C6 alkyl) is optionally substituted with one or more halogen;
[0065] Y is H, C1-C6 alkyl optionally substituted by one or more halogens, -P(R Y )2、-P(OR Y )(N(R Y )2)-P(=O)(OR Y )R Y 、-P(=S)(OR Y )R Y 、-P(=O)(SR Y )R Y ,-P(=S)(SR Y )R Y 、-P(=O)(OR Y )2、-P(=S)(OR Y )2, -P(=O)(SR Y )2、-P(=S)(SR Y )2 or a hydroxyl protecting group;
[0066] Each R Y is independently H or C1-C6 alkyl optionally substituted by one or more halogen or cyano;
[0067] Z is -P(R Z )2、-P(OR Z )(N(R Z )2)-P(=O)(OR Z )R Z 、-P(=S)(OR Z )R Z 、-P(=O)(SR Z )RZ ,-P(=S)(SR Z )R Z 、-P(=O)(OR Z )2、-P(=S)(OR Z )2, -P(=O)(SR Z )2 or -P(=S)(SR Z )2;
[0068] Each R Z is independently H or C1-C6 alkyl optionally substituted by one or more halogen or cyano;
[0069] R 1 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens;
[0070] R 2 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens;
[0071] R 3 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens;
[0072] R 4 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens;
[0073] Indicates single or double bonds; and
[0074] Each R 6 is independently H, halogen or C1-C6 alkyl optionally substituted with one or more halogens.
[0075] It should be understood that for the compounds of the present disclosure, the variables B, X, R X , R X a, Y, R Y , Z, R Z , R 1 , R 2 , R 3 , R 4 and R 6 can be selected from the groups described herein where applicable, and for variables B, X, R X , R X a, Y, R Y , Z, R Z , R 1 , R 2 , R 3 , R 4 and R 6Any group described in any of the above may be combined with any group described herein for variables B, X, R X , R X a, Y, R Y , Z, R Z , R 1 , R 2 , R 3 , R 4 and R 6 Any combination of one or more of the groups described in the rest of the description.
[0076] Variables B, X, R Y , R Xa , Y, R Y , Z and R Z
[0077] In some embodiments, B is H.
[0078] In some embodiments, B is a nucleobase moiety.
[0079] As used herein, the term "nucleobase moiety" refers to a nucleobase that is attached to the rest of a compound, for example via an atom of the nucleobase or a functional group thereof.
[0080] In some embodiments, the nucleobase moiety is adenine (A), cytosine (C), guanine (G), thymine (T), or uracil (U).
[0081] In some embodiments, the nucleobase moiety is a modified nucleobase.
[0082] In some embodiments, the modified nucleobase is 5-methylcytosine.
[0083] In some embodiments, the modified nucleobase is hypoxanthine, xanthine, or 7-methylguanine.
[0084] In some embodiments, the modified nucleobase is 5,6-dihydrouracil, 5-methylcytosine, or 5-hydroxymethylcytosine.
[0085] In some embodiments, the nucleobase moiety is an artificial nucleobase.
[0086] In some embodiments, the artificial nucleobase is isoguanine, isocytosine, 2-amino-6-(2-thienyl)purine, or pyrrole-2-carbaldehyde.
[0087] In some embodiments, X is H.
[0088] In some embodiments, X is not H.
[0089] In some embodiments, X is halogen (eg, F, Cl, Br, or I).
[0090] In some embodiments, X is F or Cl.
[0091] In some embodiments, X is F.
[0092] In some embodiments, X is -OR X .
[0093] In some embodiments, X is -OH.
[0094] In some embodiments, X is not -OH.
[0095] In some embodiments, X is -O-(C1-C6 alkyl) (e.g., wherein the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, or hexyl).
[0096] In some embodiments, X is -OCH3.
[0097] In some embodiments, X is -O-(C1-C6 alkyl)-O-(C1-C6 alkyl) (e.g., wherein the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, or hexyl).
[0098] In some embodiments, X is -OCH2CH2OCH3.
[0099] In some embodiments, X is optionally replaced by one or more R Xa Substituted-O-(C1-C6 alkyl)-(C6-C 10 aryl).
[0100] In some embodiments, X is -O-(C1-C6 alkyl)-(C6-C 10 aryl).
[0101] In some embodiments, X is
[0102] In some embodiments, X is optionally replaced by one or more R Xa Replaced
[0103] In some embodiments, X is optionally substituted with one or more halogens.
[0104] In some embodiments, X is optionally substituted with one or more C1-C6 alkyl or -O-(C1-C6 alkyl) wherein the C1-C6 alkyl or -O-(C1-C6 alkyl) is optionally substituted by one or more halogens.
[0105] In some embodiments, R X It's H.
[0106] In some embodiments, R X Not H.
[0107] In some embodiments, R X is optionally replaced by one or more R Xa Substituted C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl).
[0108] In some embodiments, R X It is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted with one or more halogen (e.g., F, Cl, Br or I) or -O-(C1-C6 alkyl) (e.g., wherein the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted with one or more halogen.
[0109] In some embodiments, R X is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl).
[0110] In some embodiments, R X It is methyl, ethyl or propyl.
[0111] In some embodiments, R X It's methyl.
[0112] In some embodiments, R X is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) substituted by one or more halogen (e.g., F, Cl, Br or I).
[0113] In some embodiments, R XIt is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) substituted by one or more -O-(C1-C6 alkyl) (e.g., wherein the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl), wherein -O-(C1-C6 alkyl) is optionally substituted by one or more halogens.
[0114] In some embodiments, R X is optionally replaced by one or more R Xa Substituted-(C1-C6 alkyl)-(C6-C 10 aryl).
[0115] In some embodiments, R X is -(C1-C6 alkyl)-(C1-C6 alkyl)-substituted with one or more halogen (e.g., F, Cl, Br or I), C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl), or -O-(C1-C6 alkyl) (e.g., wherein the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl). 10 aryl), wherein C1-C6 alkyl or -O-(C1-C6 alkyl) is optionally substituted with one or more halogens.
[0116] In some embodiments, R X It is -(C1-C6 alkyl)-(C6-C 10 aryl).
[0117] In some embodiments, at least one R Xa is a halogen (eg, F, Cl, Br or I).
[0118] In some embodiments, at least one R Xa It is F or Cl.
[0119] In some embodiments, at least one R Xa is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted with one or more halogen (e.g., F, Cl, Br or I).
[0120] In some embodiments, at least one R Xa is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl).
[0121] In some embodiments, at least one R Xa is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) substituted by one or more halogen (e.g., F, Cl, Br or I).
[0122] In some embodiments, at least one R Xa is -O-(C1-C6 alkyl) optionally substituted with one or more halogen (eg, F, Cl, Br or I).
[0123] In some embodiments, at least one R Xa It is -O-(C1-C6 alkyl).
[0124] In some embodiments, at least one R Xa is -O-(C1-C6 alkyl) substituted by one or more halogens (eg, F, Cl, Br or I).
[0125] In some embodiments, Y is H.
[0126] In some embodiments, Y is not H.
[0127] In some embodiments, Y is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).
[0128] In some embodiments, Y is C1-C6 alkyl (eg, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, or hexyl).
[0129] In some embodiments, Y is methyl, ethyl, or propyl.
[0130] In some embodiments, Y is -P(R Y )2、-P(OR Y )(N(R Y )2)-P(=O)(OR Y )R Y 、-P(=S)(OR Y )R Y 、-P(=O)(SR Y )R Y ,-P(=S)(SR Y )R Y 、-P(=O)(OR Y )2、-P(=S)(OR Y )2, -P(=O)(SR Y)2、-P(=S)(SR Y )2.
[0131] In some embodiments, Y is -P(R Y )2.
[0132] In some embodiments, Y is -PH2.
[0133] In some embodiments, Y is -P(OR Y )(N(R Y )2).
[0134] In some embodiments, Y is -P(OH)(NH2).
[0135] In some embodiments, Y is -P(O(C1-C6 alkyl))(N(C1-C6 alkyl)2), wherein the C1-C6 alkyl is optionally substituted with one or more halogen or cyano.
[0136] In some embodiments, Y is -P(=O)(OR Y )R Y .
[0137] In some embodiments, Y is -P(=O)(OH)(C1-C6 alkyl), wherein the C1-C6 alkyl is optionally substituted with one or more halogen or cyano.
[0138] In some embodiments, Y is -P(=S)(OR Y )R Y .
[0139] In some embodiments, Y is -P(=S)(OH)(C1-C6 alkyl), wherein the C1-C6 alkyl is optionally substituted with one or more halogen or cyano.
[0140] In some embodiments, Y is -P(=O)(SR Y )R Y .
[0141] In some embodiments, Y is -P(=O)(SH)(C1-C6 alkyl), wherein the C1-C6 alkyl is optionally substituted with one or more halogen or cyano.
[0142] In some embodiments, Y is -P(=S)(SR Y )R Y .
[0143] In some embodiments, Y is -P(=S)(SH)(C1-C6 alkyl), wherein the C1-C6 alkyl is optionally substituted with one or more halogen or cyano.
[0144] In some embodiments, Y is -P(=O)(OR Y )2.
[0145] In some embodiments, Y is -P(=O)(OH)2.
[0146] In some embodiments, Y is -P(=S)(OR Y )2.
[0147] In some embodiments, Y is -P(=S)(OH)2.
[0148] In some embodiments, Y is -P(=O)(SR Y )2.
[0149] In some embodiments, Y is -P(=O)(SH)2.
[0150] In some embodiments, Y is -P(=S)(SR Y )2.
[0151] In some embodiments, Y is -P(=S)(SH)2.
[0152] In some embodiments, Y is a hydroxy protecting group (eg, silyl, Tr, DMTr, acyl, or benzyl).
[0153] In some embodiments, Y is silyl (eg, trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, or triisopropylsilyl).
[0154] In some embodiments, Y is triphenylmethyl (Tr) or 4,4'-dimethoxytrityl (DMTr).
[0155] In some embodiments, Y is optionally substituted acyl (eg, optionally substituted acetyl) or benzyl.
[0156] In some embodiments, Y is not a hydroxy protecting group (eg, silyl, Tr, DMTr, acyl, or benzyl).
[0157] In some embodiments, at least one R Y It's H.
[0158] In some embodiments, each R Y It's H.
[0159] In some embodiments, at least one R Yis C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted by one or more halogen (e.g., F, Cl, Br or I) or cyano.
[0160] In some embodiments, each R Y is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted by one or more halogen (e.g., F, Cl, Br or I) or cyano.
[0161] In some embodiments, at least one R Y is H, and at least one R Y is a C1-C6 alkyl group optionally substituted by one or more halogen or cyano groups (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl).
[0162] In some embodiments, when X is -OH, then Y is not H or a hydroxy protecting group (eg, silyl, Tr, DMTr, acyl, or benzyl).
[0163] In some embodiments, when X is -OH, then Y is C1-C6 alkyl, -P(R Y )2、-P(OR Y )(N(R Y )2)-P(=O)(OR Y )R Y 、-P(=S)(OR Y )R Y 、-P(=O)(SR Y )R Y ,-P(=S)(SR Y )R Y 、-P(=O)(OR Y )2、-P(=S)(OR Y )2, -P(=O)(SR Y )2 or -P(=S)(SR Y )2.
[0164] In some embodiments, when Y is H or a hydroxy protecting group (eg, silyl, Tr, DMTr, acyl, or benzyl), then X is not -OH.
[0165] In some embodiments, when Y is H or a hydroxy protecting group (eg, silyl, Tr, DMTr, acyl, or benzyl), then X is H, halogen, or -OR X , and RX is C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 Aryl), wherein C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 Aryl) is optionally substituted with one or more R Xa replace.
[0166] In some embodiments, Z is -P(R Z )2.
[0167] In some embodiments, Z is -PH2.
[0168] In some embodiments, Z is -P(OR Z )(N(R Z )2).
[0169] In some embodiments, Z is -P(OH)(NH2).
[0170] In some embodiments, Z is -P(O(C1-C6 alkyl))(N(C1-C6 alkyl)2), wherein the C1-C6 alkyl is optionally substituted with one or more halogen or cyano.
[0171] In some embodiments, Z is -P(=O)(OR Z )R Z .
[0172] In some embodiments, Z is -P(=O)(OH)(C1-C6 alkyl), wherein the C1-C6 alkyl is optionally substituted with one or more halogen or cyano.
[0173] In some embodiments, Z is -P(=S)(OR Z )R Z .
[0174] In some embodiments, Z is -P(=S)(OH)(C1-C6 alkyl), wherein the C1-C6 alkyl is optionally substituted with one or more halogen or cyano.
[0175] In some embodiments, Z is -P(=O)(SR Z )R Z .
[0176] In some embodiments, Z is -P(=O)(SH)(C1-C6 alkyl), wherein the C1-C6 alkyl is optionally substituted with one or more halogen or cyano.
[0177] In some embodiments, Z is -P(=S)(SR Z )R Z .
[0178] In some embodiments, Z is -P(=S)(SH)(C1-C6 alkyl), wherein the C1-C6 alkyl is optionally substituted with one or more halogen or cyano.
[0179] In some embodiments, Z is -P(=O)(OR Z )2.
[0180] In some embodiments, Z is -P(=O)(OH)2.
[0181] In some embodiments, Z is -P(=O)(O(C1-C6 alkyl))(OH).
[0182] In some embodiments, Z is -P(=O)(OCH3)(OH).
[0183] In some embodiments, Z is -P(=O)(O(C1-C6 alkyl))2.
[0184] In some embodiments, Z is -P(=O)(OCH3)2.
[0185] In some embodiments, Z is -P(=S)(OR Z )2.
[0186] In some embodiments, Z is -P(=S)(OH)2.
[0187] In some embodiments, Z is -P(=O)(SR Z )2.
[0188] In some embodiments, Z is -P(=O)(SH)2.
[0189] In some embodiments, Z is -P(=S)(SR Z )2.
[0190] In some embodiments, Z is -P(=S)(SH)2.
[0191] In some embodiments, at least one R Z It's H.
[0192] In some embodiments, each R Z It's H.
[0193] In some embodiments, at least one R Z is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted by one or more halogen (e.g., F, Cl, Br or I) or cyano.
[0194] In some embodiments, at least one R Z is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl).
[0195] In some embodiments, each R Z is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted by one or more halogen (e.g., F, Cl, Br or I) or cyano.
[0196] In some embodiments, each R Z is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl).
[0197] In some embodiments, at least one R Z is H, and at least one R Z is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted by one or more halogen (e.g., F, Cl, Br or I) or cyano.
[0198] In some embodiments, at least one R Z is H, and at least one R Z is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl).
[0199] Variable R 1 , R 2 , R 3 , R 4 and R 6
[0200] In some embodiments, R 1 It's H.
[0201] In some embodiments, R 1 is a halogen (eg, F, Cl, Br or I).
[0202] In some embodiments, R 1 It is F or Cl.
[0203] In some embodiments, R 1is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted with one or more halogen (e.g., F, Cl, Br or I).
[0204] In some embodiments, R 1 is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl).
[0205] In some embodiments, R 1 is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) substituted by one or more halogen (e.g., F, Cl, Br or I).
[0206] In some embodiments, R 2 It's H.
[0207] In some embodiments, R 2 is a halogen (eg, F, Cl, Br or I).
[0208] In some embodiments, R 2 It is F or Cl.
[0209] In some embodiments, R 2 is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted with one or more halogen (e.g., F, Cl, Br or I).
[0210] In some embodiments, R 2 is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl).
[0211] In some embodiments, R 2 is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) substituted by one or more halogen (e.g., F, Cl, Br or I).
[0212] In some embodiments, R 3 It's H.
[0213] In some embodiments, R 3 is a halogen (eg, F, Cl, Br or I).
[0214] In some embodiments, R 3 It is F or Cl.
[0215] In some embodiments, R 3 is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted with one or more halogen (e.g., F, Cl, Br or I).
[0216] In some embodiments, R 3 is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl).
[0217] In some embodiments, R 3 is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) substituted by one or more halogen (e.g., F, Cl, Br or I).
[0218] In some embodiments, R 4 It's H.
[0219] In some embodiments, R 4 is a halogen (eg, F, Cl, Br or I).
[0220] In some embodiments, R 4 It is F or Cl.
[0221] In some embodiments, R 4 is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted with one or more halogen (e.g., F, Cl, Br or I).
[0222] In some embodiments, R 4 is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl).
[0223] In some embodiments, R 4 is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) substituted by one or more halogen (e.g., F, Cl, Br or I).
[0224] In some embodiments, each R 6 It's H.
[0225] In some embodiments, at least one R 6is halogen (e.g., F, Cl, Br or I) or C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted with one or more halogen (e.g., F, Cl, Br or I).
[0226] In some embodiments, at least one R 6 is a halogen (eg, F, Cl, Br or I).
[0227] In some embodiments, at least one R 6 It is F or Cl.
[0228] In some embodiments, at least one R 6 is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) optionally substituted with one or more halogen (e.g., F, Cl, Br or I).
[0229] In some embodiments, at least one R 6 is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl).
[0230] In some embodiments, at least one R 6 is C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl) substituted by one or more halogen (e.g., F, Cl, Br or I).
[0231] In some embodiments, R 1 , R 2 , R 3 , R 4 and R 6 Each of them is H.
[0232] Exemplary embodiments of compounds
[0233] In some embodiments, the compound has Formula (I'-1), Formula (I'-2), Formula (II'-1), or Formula (II'-2):
[0234]
[0235] or a pharmaceutically acceptable salt thereof.
[0236] In some embodiments, the compound has Formula (IA) or Formula (II-A):
[0237]
[0238] or a pharmaceutically acceptable salt thereof.
[0239] In some embodiments, the compound has Formula (I-A'-1), Formula (I-A'-2), Formula (II-A'-1), or Formula (II-A'-2):
[0240]
[0241] or a pharmaceutically acceptable salt thereof.
[0242] In some embodiments, the compound has Formula (IB-1), Formula (IB-2), Formula (II-B-1), or Formula (II-B-2):
[0243]
[0244]
[0245] or a pharmaceutically acceptable salt thereof.
[0246] In some embodiments, the compound has Formula (I-B'-1), Formula (I-B'-2), Formula (I-B'-3), Formula (I-B'-4), Formula (II-B'-1), Formula (II-B'-2), Formula (II-B'-3), or Formula (II-B'-4):
[0247]
[0248]
[0249] or a pharmaceutically acceptable salt thereof.
[0250] In some embodiments, the compound is:
[0251]
[0252]
[0253] or a pharmaceutically acceptable salt thereof, wherein:
[0254] Y is -P(R Y )2、-P(OR Y )(N(R Y )2)-P(=O)(OR Y )R Y 、-P(=S)(OR Y )R Y 、-P(=O)(SR Y )R Y ,-P(=S)(SR Y )RY 、-P(=O)(OR Y )2、-P(=S)(OR Y )2, -P(=O)(SR Y )2、-P(=S)(SR Y )2 or a hydroxy protecting group (e.g., a silyl group (e.g., trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl or triisopropylsilyl), triphenylmethyl (Tr), 4,4'-dimethoxytrityl (DMTr), a substituted acyl group (e.g., an optionally substituted acetyl group) or a benzyl group);
[0255] Each R Y is independently H or C1-C6 alkyl optionally substituted by one or more halogen or cyano;
[0256] Z is -P(R Z )2、-P(OR Z )(N(R Z )2)-P(=O)(OR Z )R Z 、-P(=S)(OR Z )R Z 、-P(=O)(SR Z )R Z ,-P(=S)(SR Z )R Z 、-P(=O)(OR Z )2、-P(=S)(OR Z )2, -P(=O)(SR Z )2 or -P(=S)(SR Z )2; and
[0257] Each R Z is independently H or C1-C6 alkyl optionally substituted with one or more halogen or cyano.
[0258] In some embodiments, the compound is:
[0259]
[0260]
[0261]
[0262]
[0263]
[0264]
[0265] or a pharmaceutically acceptable salt thereof, wherein B is adenine (A), cytosine (C), guanine (G), thymine (T) or uracil (U).
[0266] In some embodiments, the compound is selected from the compounds described in Table E and pharmaceutically acceptable salts thereof.
[0267] Table E
[0268]
[0269]
[0270]
[0271]
[0272]
[0273]
[0274] In some aspects, the disclosure provides a compound that is an isotopic derivative (eg, an isotopically labeled compound) of any one of the compounds of the formulae disclosed herein.
[0275] It should be understood that isotopic derivatives can be prepared using any of a variety of art-recognized techniques. For example, isotopic derivatives can generally be prepared by implementing the procedures disclosed in the schemes and / or embodiments herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
[0276] In some embodiments, the isotopic derivative is a deuterium-labeled compound.
[0277] In some embodiments, the isotopic derivative is a deuterium-labeled compound of any of the compounds of the formulae disclosed herein.
[0278] As used herein, the term "isotopic derivative" refers to a derivative of a compound in which one or more atoms are isotopically enriched or labeled. For example, an isotopic derivative of a compound of Formula (I) or Formula (II) is isotopically enriched with one or more isotopes or labeled with one or more isotopes compared to the corresponding compound of Formula (I) or Formula (II). In some embodiments, an isotopic derivative is enriched in one or more isotopes selected from 2 H. 13 C. 14 C. 15 N. 18 O. 29 4. 32P and 34 One or more atoms of S or selected from 2 H. 13 C. 14 C. 15 N. 18 O. 29 4. 32 P and 34 In some embodiments, the isotopic derivative is a deuterium-labeled compound (i.e., enriched with respect to one or more atoms of S). 2 H). In some embodiments, the compound is 2 H-labeled compound. In some embodiments, the compound is 13 C-labeled compounds or 14 C-labeled compound. In some embodiments, the compound is 18 In some embodiments, the compound is 123 I-labeled compounds, 124 I-labeled compounds, 125 I-labeled compounds, 129 I-labeled compounds, 131 I-labeled compounds, 135 I-labeled compound or any combination thereof. In some embodiments, the compound is 31 P-labeled compounds or 32 In some embodiments, the compound is 33 S-labeled compounds, 34 S-labeled compounds, 35 S-labeled compounds, 36 S-labeled compound or any combination thereof.
[0279] It should be understood that isotopic derivatives can be prepared using any of a variety of art-recognized techniques. For example, isotopic derivatives can generally be prepared by implementing the procedures disclosed in the schemes and / or embodiments described herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
[0280] It will also be appreciated that isotopic substitution may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
[0281] For the avoidance of doubt, it should be understood that where in this specification a group is defined by "described herein", that group encompasses the first and broadest definition as well as each and all specific definitions for that group.
[0282] It will be understood that although the compounds disclosed herein may be presented in a particular configuration. Such a particular configuration should not be construed as limiting the disclosure to one or another isomer, tautomer, regioisomer or stereoisomer, nor does it exclude mixtures of isomers, tautomers, regioisomers or stereoisomers. In some embodiments, the presentation of a compound herein in a particular configuration is intended to encompass and refer to each of the available isomers, tautomers, regioisomers and stereoisomers of the compound, or any mixture thereof; and the present presentation is also intended to refer to the specific configuration of the compound.
[0283] It will be understood that although compounds disclosed herein may be presented without a specified configuration (e.g., without a specified stereochemistry), such presentation is intended to encompass all available isomers, tautomers, regioisomers, and stereoisomers of the compound. In some embodiments, presentation of a compound without a specified configuration herein is intended to refer to each of the available isomers, tautomers, regioisomers, and stereoisomers of the compound, or any mixture thereof.
[0284] As used herein, the term "isomerism" means a compound with the same molecular formula but different in the order of its atomic bonding or different in the arrangement of its atoms in space. Compounds with the same molecular formula but different in the nature or order of its atomic bonding or different in the arrangement of its atoms in space are referred to as "isomers". Isomers that are different in the arrangement of its atoms in space are referred to as "stereoisomers". Stereoisomers that are not mirror images of each other are referred to as "diastereomers", and stereoisomers that are non-superimposable mirror images are referred to as "enantiomers". When a compound has an asymmetric center (for example, it is bonded to four different groups), paired enantiomers are possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by the R and S sorting rules of Cahn and Prelog or by the way in which molecules rotate the plane of polarized light and are designated as right-handed or left-handed (i.e., respectively (+) isomers or (-) isomers). Chiral compounds can exist as individual enantiomers or as mixtures thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".
[0285] The compounds of the present disclosure may have one or more asymmetric centers; therefore such compounds may be produced as individual (R)-stereoisomers or (S)-stereoisomers or as mixtures thereof. Unless otherwise indicated, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures thereof (racemic or otherwise). The methods for determining stereochemistry and separating stereoisomers are well known in the art (see the discussion in Chapter 4 of "Advanced Organic Chemistry", Fourth Edition J. March, John Wiley and Sons, New York, 2001), for example, by synthesizing from optically active starting materials or by splitting racemic forms. Some of the compounds of the present disclosure may have geometric isomer centers (E-isomers and Z-isomers). It should be understood that the present disclosure encompasses all optical isomers, diastereomers and geometric isomers and mixtures thereof having inflammasome inhibitory activity.
[0286] As used herein, the term "chiral center" refers to a carbon atom that is bonded to four different substituents.
[0287] As used herein, the term "chiral isomer" means a compound having at least one chiral center. Compounds having more than one chiral center may exist as individual diastereomers or as a mixture of diastereomers (referred to as a "diastereomeric mixture"). When there is one chiral center, the stereoisomers may be characterized by the absolute configuration (R or S) of the chiral center. Absolute configuration refers to the arrangement of the substituents attached to the chiral center in space. The substituents attached to the chiral center under consideration are arranged according to the sequence rules of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. ed. 1966, 5, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116).
[0288] As used herein, the term "geometric isomer" means diastereomers whose existence is due to hindered rotation around a double bond or a cycloalkyl linker (e.g., 1,3-cyclobutyl). These configurations are distinguished in their names by the prefixes cis and trans or Z and E, which indicate that the groups are on the same or opposite sides of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.
[0289] It should be understood that the compounds of the present disclosure may be depicted as different chiral isomers or geometric isomers. It should also be understood that when a compound has a chiral isomer form or a geometric isomer form, all isomer forms are intended to be included within the scope of the present disclosure, and the naming of the compound does not exclude any isomer form, and it should be understood that not all isomers may have the same level of activity.
[0290] It should be understood that the structures and other compounds discussed in this disclosure include all atropic isomers thereof. It should also be understood that not all atropic isomers may have the same level of activity.
[0291] As used herein, the term "atropisomer" is a class of stereoisomers in which the atoms of the two isomers are arranged differently in space. Atropisomers attribute their existence to restricted rotation due to hindered rotation of large groups around a central bond. Such atropisomers usually exist as a mixture, however, due to recent advances in chromatographic techniques, it has become possible to separate mixtures of two atropisomers under selected circumstances.
[0292] As used herein, the term "tautomer" is one of two or more structural isomers that exist in equilibrium, and is easily converted from one isomeric form to another isomeric form. This conversion causes the form migration of hydrogen atoms, accompanied by the conversion of adjacent conjugated double bonds. Tautomers exist as a mixture of tautomer groups in solution. In solutions where tautomerization is possible, the chemical equilibrium of tautomers will be reached. The exact ratio of tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that can be mutually converted by tautomerization is called tautomerism. In possible multiple types of tautomerism, two are usually observed. In keto-enol tautomerism, simultaneous transfer of electrons and hydrogen atoms occurs. Ring-chain tautomerism is due to the reaction of an aldehyde group (-CHO) in a sugar chain molecule with one of the hydroxyl groups (-OH) in the same molecule to give its cyclic (ring-shaped) form and produce, as presented by glucose.
[0293] It should be understood that the compounds of the present disclosure can be described as different tautomers. It should also be understood that when a compound has a tautomeric form, all tautomeric forms will be included within the scope of the present disclosure, and the naming of these compounds does not exclude any tautomeric form. It should be understood that some tautomers may have a higher level of activity than other tautomers.
[0294] It should be understood that compounds of any formula described herein include the compounds themselves, as well as their salts and their solvates, if applicable. For example, salts can be formed between anions and positively charged groups (e.g., amino groups) on the substituted compounds disclosed herein. Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, mesylate, trifluoroacetate, glutamate, glucuronide, glutarate, malate, maleate, succinate, fumarate, tartrate, toluenesulfonate, salicylate, lactate, naphthylidenesulfonate, and acetate (e.g., trifluoroacetate).
[0295] As used herein, the term "pharmaceutically acceptable anion" refers to an anion suitable for forming a pharmaceutically acceptable salt. Similarly, salts can also be formed between cations and negatively charged groups (e.g., carboxylates) on the substituted compounds disclosed herein. Suitable cations include sodium ions, potassium ions, magnesium ions, calcium ions, and ammonium cations, such as tetramethylammonium ions or diethylamine ions. Substituted compounds disclosed herein also include those salts containing quaternary nitrogen atoms.
[0296] It should be understood that the compounds of the present disclosure, such as salts of the compounds, can exist in hydrated or non-hydrated (anhydrous) forms, or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates, dihydrates, etc. Non-limiting examples of solvates include ethanol solvates, acetone solvates, etc.
[0297] As used herein, the term "solvate" means a solvent addition form containing a stoichiometric or non-stoichiometric amount of a solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thereby forming a solvate. If the solvent is water, the solvate formed is a hydrate, and if the solvent is an alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more water molecules with one molecule of a substance, wherein the water retains its molecular state as H2O.
[0298] As used herein, the term "analog" refers to a compound that is structurally similar to another compound but has a slightly different composition (such as the replacement of an atom by an atom of a different element or the presence of a particular functional group, or the replacement of a functional group by another functional group). Thus, an analog is a compound that is similar or equivalent to a reference compound in function and appearance, but not similar or equivalent to the reference compound in structure or origin.
[0299] As used herein, the term "derivative" refers to compounds having a common core structure and being substituted with various groups as described herein.
[0300] As used herein, the term "bioisostere" refers to a compound produced by exchanging one atom or group of atoms with another substantially similar atom or group of atoms. The purpose of bioisosteric replacement is to create a new compound with similar biological properties to the parent compound. Bioisosteric replacement can be based on physicochemistry or topology. Examples of carboxylic acid bioisosteres include, but are not limited to, acylsulfonamides, tetrazoles, sulfonates, and phosphonates. See, for example, Patani and LaVoie, Chem. Rev. 96, 3147-3176, 1996.
[0301] It is also understood that certain compounds of any of the formulae disclosed herein may exist in solvated as well as unsolvated forms, such as, for example, hydrated forms. Suitable pharmaceutically acceptable solvates are, for example, hydrates, such as hemihydrates, monohydrates, dihydrates, or trihydrates. It is understood that the present disclosure encompasses all such solvated forms having inflammasome inhibitory activity.
[0302] It should also be understood that some compounds of any of the formulas disclosed herein may exhibit polymorphism, and the present disclosure encompasses all such forms or mixtures thereof having inflammasome inhibitory activity. It is generally known that crystalline materials can be analyzed using conventional techniques such as X-ray powder diffraction analysis, differential scanning calorimetry, thermogravimetric analysis, diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy, near infrared (NIR) spectroscopy, solution and / or solid-state nuclear magnetic resonance spectroscopy. The water content of such crystalline materials can be determined by Karl Fischer analysis.
[0303] Any one of the compounds in the formula disclosed herein can exist with a variety of different tautomeric forms, and the reference to any one of the compounds in the formula includes all such forms. In order to avoid doubt, in the case where the compound can exist with one of several tautomeric forms and only one is specifically described or shown, yet all other forms are included by the formula disclosed herein. The example of tautomeric form includes keto, enol and enolate forms, such as in the following tautomerism pairs: ketone / enol (hereinafter described), imines / enamines, amides / imino alcohols, amidines / amidines, nitroso / oximes, thioketones / enethiol (enethiol) and nitro / acid nitro.
[0304]
[0305] Any of the compounds of the formula containing amine functions disclosed herein can also form N-oxides. Any of the compounds of the formula containing amine functions mentioned herein also include N-oxides. In the case where the compound contains several amine functions, one or more than one nitrogen atom can be oxidized to form N-oxides. Specific examples of N-oxides are N-oxides of nitrogen atoms of tertiary amines or nitrogen-containing heterocyclic rings. N-oxides can be formed by treating the corresponding amine with an oxidant such as hydrogen peroxide or peracid (e.g., peroxycarboxylic acid), see, for example, Advanced Organic Chemistry, Jerry March, 4th edition, Wiley Interscience. More particularly, N-oxides can be prepared by the procedure of LWDeady (Syn. Comm. 1977, 7, 509-514), wherein the amine compound reacts with meta-chloroperbenzoic acid (mCPBA), for example, in an inert solvent such as dichloromethane.
[0306] Compounds of any of the formulas disclosed herein can be administered in the form of a prodrug that decomposes in the human or animal body to release the compounds of the disclosure. Prodrugs can be used to alter the physical properties and / or pharmacokinetic properties of the compounds of the disclosure. Prodrugs can be formed when the compounds of the disclosure contain suitable groups or substituents to which groups that adjust properties can be attached.
[0307] Thus, the present disclosure includes those compounds of any of the formulae disclosed herein as defined above when obtainable by organic synthesis and when obtainable by cleavage of its prodrug in the human or animal body. Thus, the present disclosure includes those compounds of any of the formulae disclosed herein produced by organic synthesis means and also such compounds produced in the human or animal body by metabolism of a precursor compound, i.e., the compounds of any of the formulae disclosed herein may be synthetically produced compounds or metabolically produced compounds.
[0308] Suitable pharmaceutically acceptable prodrugs of the compounds of any of the formulae disclosed herein are prodrugs that are suitable for administration to the human or animal body without undesirable pharmacological activity and without excessive toxicity, based on sound medical judgment. Various forms of prodrugs have been described, for example, in the following documents: a) Methods in Enzymology, Vol. 42, pp. 309-396, edited by K. Widder et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Pro-drugs", H. Bundgaard, pp. 113-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984); g) T. Higuchi and V. Stella, "Pro-Drugs as Novel Delivery Systems", ACSSymposium Series, Vol. 14; and h) E. Roche (ed.), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987.
[0309] The in vivo effect of any of the compounds of the formula disclosed herein can be partially applied by one or more metabolites formed in the human or animal body after the compound of any of the formula disclosed herein is administered. As stated above, the in vivo effect of any of the compounds of the formula disclosed herein can also be applied by the metabolism of the precursor compound (prodrug).
[0310] Suitably, the present disclosure excludes any individual compound that does not possess biological activity as defined herein.
[0311] Nucleic acid agent containing 5'-terminal unit
[0312] In some aspects, the present disclosure provides a nucleic acid agent or a pharmaceutically acceptable salt thereof, wherein the nucleic acid agent comprises:
[0313] An oligonucleotide comprising one or two 5'-terminal units covalently attached to the oligonucleotide, wherein each 5'-terminal unit is independently:
[0314]
[0315] The variables B and R 1 , R 2 , R 3 , R 4 , R 6 , X, and Z are described herein, and ## indicates an attachment to the rest of the oligonucleotide.
[0316] In some embodiments, the nucleic acid agent comprises single-stranded RNA (eg, single-stranded siRNA).
[0317] In some embodiments, the nucleic acid agent comprises a single-stranded RNA (eg, a single-stranded siRNA), and a 5'-terminal unit is covalently attached to the 5'-terminal position of the single-stranded RNA (eg, a single-stranded siRNA).
[0318] In some embodiments, the nucleic acid agent comprises double-stranded RNA (eg, double-stranded siRNA).
[0319] In some embodiments, the nucleic acid agent comprises a double-stranded RNA (eg, a double-stranded siRNA) and at least one 5 '-terminal unit.
[0320] In some embodiments, the nucleic acid agent comprises a double-stranded RNA (eg, a double-stranded siRNA) and one or two 5'-terminal units.
[0321] In some embodiments, the nucleic acid agent comprises a double-stranded RNA (eg, a double-stranded siRNA) and one or two 5'-terminal units, wherein:
[0322] The 5'-terminal unit is attached to the sense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, a double-stranded siRNA); and / or
[0323] The 5'-terminal unit is attached to the antisense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, double-stranded siRNA).
[0324] In some embodiments, the nucleic acid agent comprises a double-stranded RNA (e.g., a double-stranded siRNA) and a 5'-terminal unit, wherein:
[0325] The 5'-terminal unit is attached to the sense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, double-stranded siRNA).
[0326] In some embodiments, the nucleic acid agent comprises a double-stranded RNA (e.g., a double-stranded siRNA) and a 5'-terminal unit, wherein:
[0327] The 5'-terminal unit is attached to the antisense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, double-stranded siRNA).
[0328] In some embodiments, the nucleic acid agent comprises a double-stranded RNA (e.g., a double-stranded siRNA) and two 5'-terminal units, wherein:
[0329] One 5'-terminal unit is attached to the sense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, double-stranded siRNA); and
[0330] The other 5'-terminal unit is attached to the antisense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, double-stranded siRNA).
[0331] In some embodiments, the 5'-terminal unit in the nucleic acid agent is
[0332]
[0333]
[0334] or a pharmaceutically acceptable salt thereof, wherein:
[0335] Z is -P(R Z )2、-P(OR Z )(N(R Z )2)-P(=O)(OR Z )R Z 、-P(=S)(OR Z )R Z 、-P(=O)(SR Z )R Z ,-P(=S)(SR Z )R Z 、-P(=O)(OR Z )2、-P(=S)(OR Z )2, -P(=O)(SR Z )2 or -P(=S)(SR Z )2;
[0336] Each R Z is independently H or C1-C6 alkyl optionally substituted with one or more halogen or cyano.
[0337] In some embodiments, the 5'-terminal unit in the nucleic acid agent is:
[0338]
[0339]
[0340]
[0341]
[0342]
[0343]
[0344]
[0345]
[0346]
[0347] or a pharmaceutically acceptable salt thereof, wherein B is adenine (A), cytosine (C), guanine (G), thymine (T) or uracil (U).
[0348] In some embodiments, the 5'-terminal unit in the nucleic acid agent is selected from the 5'-terminal units described in Table N.
[0349] Table N
[0350]
[0351]
[0352]
[0353]
[0354]
[0355]
[0356]
[0357]
[0358]
[0359] Conjugates containing 5'-terminal units
[0360] As used herein, the term "conjugate" refers to a compound or complex comprising a nucleic acid agent covalently attached to one or more ligands of the present disclosure and one or two 5'-terminal units.
[0361] In some aspects, the present disclosure provides a conjugate or a pharmaceutically acceptable salt thereof, wherein the conjugate comprises:
[0362] (i) a nucleic acid agent, the nucleic acid agent comprising:
[0363] An oligonucleotide comprising one or two 5'-terminal units covalently attached to the oligonucleotide, wherein each 5'-terminal unit is independently:
[0364]
[0365] The variables B and R 1 , R 2 , R 3 , R 4 , R 6 , X, and Z are described herein, and ## indicates an attachment to the rest of the oligonucleotide; and
[0366] (ii) one or more ligands, said one or more ligands being covalently attached to the nucleic acid agent.
[0367] In some embodiments, the conjugate comprises a single-stranded RNA (eg, a single-stranded siRNA), one or more ligands, and a 5 '-terminal unit.
[0368] In some embodiments, the conjugate comprises a single-stranded RNA (e.g., a single-stranded siRNA), one or more ligands, and a 5'-terminal unit, and the 5'-terminal unit is covalently attached to the 5'-terminal position of the single-stranded RNA (e.g., the single-stranded siRNA).
[0369] In some embodiments, the conjugate comprises a double-stranded RNA (eg, a double-stranded siRNA), one or more ligands, and at least one 5 '-terminal unit.
[0370] In some embodiments, the conjugate comprises a double-stranded RNA (eg, a double-stranded siRNA), one or more ligands, and one or two 5'-terminal units.
[0371] In some embodiments, the conjugate comprises a double-stranded RNA (eg, double-stranded siRNA), one or more ligands, and one or two 5'-terminal units, wherein:
[0372] The 5'-terminal unit is attached to the sense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, a double-stranded siRNA); and / or
[0373] The 5'-terminal unit is attached to the antisense strand (eg, at the 5'-terminal position) of the double-stranded RNA (eg, double-stranded siRNA).
[0374] In some embodiments, the conjugate comprises a double-stranded RNA (eg, double-stranded siRNA), one or more ligands, and a 5'-terminal unit, wherein:
[0375] The 5'-terminal unit is attached to the sense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, double-stranded siRNA).
[0376] In some embodiments, the conjugate comprises a double-stranded RNA (eg, double-stranded siRNA), one or more ligands, and a 5'-terminal unit, wherein:
[0377] The 5'-terminal unit is attached to the antisense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, double-stranded siRNA).
[0378] In some embodiments, the conjugate comprises a double-stranded RNA (eg, double-stranded siRNA), one or more ligands, and two 5'-terminal units, wherein:
[0379] One 5'-terminal unit is attached to the sense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, double-stranded siRNA); and
[0380] The other 5'-terminal unit is attached to the antisense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, double-stranded siRNA).
[0381] In some embodiments, the 5'-terminal unit in the conjugate is:
[0382]
[0383]
[0384]
[0385]
[0386]
[0387]
[0388]
[0389]
[0390]
[0391] or a pharmaceutically acceptable salt thereof, wherein B is adenine (A), cytosine (C), guanine (G), thymine (T) or uracil (U).
[0392] In some embodiments, the 5'-terminal unit in the conjugate is selected from the 5'-terminal units described in Table C.
[0393] Table C
[0394]
[0395]
[0396]
[0397]
[0398]
[0399]
[0400]
[0401]
[0402] 5'-terminal unit
[0403] As used herein, "5'-End Unit" or "5'-end unit" refers to the moiety corresponding to the phosphate mimetic derivative, wherein Y is replaced with an attachment to a nucleic acid agent.
[0404] In some embodiments, the 5'-terminal unit has formula (I), wherein Y is replaced with an attachment to a nucleic acid agent.
[0405] In some embodiments, the 5'-terminal unit has Formula (I'-1), Formula (I'-2), Formula (II'-1), or Formula (II'-2), wherein Y is replaced with an attachment to a nucleic acid agent.
[0406] In some embodiments, the 5'-terminal unit has Formula (IA) or Formula (II-A), wherein Y is replaced with an attachment to a nucleic acid agent.
[0407] In some embodiments, the 5'-terminal unit has Formula (IA'-1), Formula (IA'-2), Formula (II-A'-1), or Formula (II-A'-2), wherein Y is replaced with an attachment to a nucleic acid agent.
[0408] In some embodiments, the 5'-terminal unit has Formula (IB-1), Formula (IB-2), Formula (II-B-1), or Formula (II-B-2), wherein Y is replaced with an attachment to a nucleic acid agent.
[0409] In some embodiments, the 5'-terminal unit has Formula (I-B'-1), Formula (I-B'-2), Formula (I-B'-3), Formula (I-B'-4), Formula (II-B'-1), Formula (II-B'-2), Formula (II-B'-3), or Formula (II-B'-4), wherein Y is replaced by an attachment to a nucleic acid agent.
[0410] In some embodiments, prior to attachment, the 5'-terminal unit is a phosphate mimetic derivative described herein.
[0411] In some embodiments, prior to attachment, the 5'-terminal unit is a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
[0412] In some embodiments, prior to attachment, the 5'-terminal unit is a compound of Formula (I'-1), Formula (I'-2), Formula (II'-1), or Formula (II'-2), or a pharmaceutically acceptable salt thereof.
[0413] In some embodiments, prior to attachment, the 5'-terminal unit is a compound of Formula (IA) or Formula (II-A) or a pharmaceutically acceptable salt thereof.
[0414] In some embodiments, prior to attachment, the 5'-terminal unit is a compound of Formula (I-A'-1), Formula (I-A'-2), Formula (II-A'-1), or Formula (II-A'-2), or a pharmaceutically acceptable salt thereof.
[0415] In some embodiments, prior to attachment, the 5'-terminal unit is a compound of Formula (IB-1), Formula (IB-2), Formula (II-B-1), or Formula (II-B-2), or a pharmaceutically acceptable salt thereof.
[0416] In some embodiments, prior to attachment, the 5'-terminal unit is a compound of Formula (I-B'-1), Formula (I-B'-2), Formula (I-B'-3), Formula (I-B'-4), Formula (II-B'-1), Formula (II-B'-2), Formula (II-B'-3), or Formula (II-B'-4), or a pharmaceutically acceptable salt thereof.
[0417] In some embodiments, prior to attachment, the 5'-terminal unit is a compound selected from the group consisting of compounds described in Table E and pharmaceutically acceptable salts thereof.
[0418] Ligand
[0419] As used herein, the term "ligand" refers to a moiety that, when covalently attached to a nucleic acid agent (e.g., an oligonucleotide), is capable of mediating its entry into a target site (e.g., a target cell or a target tissue) or facilitating its delivery to a target site (e.g., a target cell or a target tissue).
[0420] In some embodiments, the ligand comprises a sugar ligand moiety (eg, N-acetylgalactosamine (GalNAc)) that can direct uptake of the oligonucleotide into the liver.
[0421] In some embodiments, the ligand binds to the asialoglycoprotein receptor (ASGPR).In some embodiments, the ligand binds to (eg, via the ASGPR) the liver, such as a parenchymal cell of the liver.
[0422] Suitable ligands include, but are not limited to, those disclosed in Winkler (Ther. Deliv., 2013, 4(7):791-809), PCT Patent Application Publication Nos. WO / 2016 / 100401, WO / 2012 / 089352, and WO / 2009 / 082607, and U.S. Patent Application Publication Nos. 2009 / 0239814, 2012 / 0136042, 2013 / 0158824, and 2009 / 0247608, each of which is incorporated by reference.
[0423] In some embodiments, the ligand comprises a carbohydrate moiety.
[0424] As used herein, "carbohydrate moiety" refers to a moiety comprising one or more monosaccharide units, each of which has at least six carbon atoms (which can be linear, branched or cyclic), each of which is bonded to an oxygen, nitrogen or sulfur atom. In some embodiments, the carbohydrate moiety comprises a monosaccharide, a disaccharide, a trisaccharide or a tetrasaccharide. In some embodiments, the carbohydrate moiety comprises an oligosaccharide containing from about 4-9 monosaccharide units. In some embodiments, the carbohydrate moiety comprises a polysaccharide (e.g., starch, glycogen, cellulose or polysaccharide gum).
[0425] In some embodiments, the carbohydrate moiety comprises a monosaccharide, a disaccharide, a trisaccharide, or a tetrasaccharide.
[0426] In some embodiments, the carbohydrate moiety comprises an oligosaccharide (eg, comprising from about four to about nine monosaccharide units).
[0427] In some embodiments, the carbohydrate moiety comprises a polysaccharide (eg, starch, glycogen, cellulose, or polysaccharide gum).
[0428] In some embodiments, the ligand is capable of binding to a human asialoglycoprotein receptor (ASGPR), such as human asialoglycoprotein receptor 2 (ASGPR2).
[0429] In some embodiments, the carbohydrate moiety comprises a sugar (eg, one, two, or three sugars).
[0430] In some embodiments, the carbohydrate moiety comprises galactose or a derivative thereof (eg, one, two, or three galactoses or a derivative thereof).
[0431] In some embodiments, the carbohydrate moiety comprises N-acetylgalactosamine or a derivative thereof (eg, one, two, or three N-acetylgalactosamines or a derivative thereof).
[0432] In some embodiments, the carbohydrate moiety comprises N-acetyl-D-galactosamine or a derivative thereof (eg, one, two, or three N-acetyl-D-galactosamine or a derivative thereof).
[0433] In some embodiments, the carbohydrate moiety comprises N-acetylgalactosamine (eg, one, two, or three N-acetylgalactosamines).
[0434] In some embodiments, the carbohydrate moiety comprises N-acetyl-D-galactosamine (eg, one, two, or three N-acetyl-D-galactosamines).
[0435] In some embodiments, the carbohydrate moiety comprises mannose or a derivative thereof (eg, mannose-6-phosphate).
[0436] In some embodiments, the carbohydrate moiety further comprises a linking moiety connecting one or more sugars (eg, N-acetyl-D-galactosamine) to the 5 '-terminal unit.
[0437] In some embodiments, the linking moiety comprises a thioether (eg, thiosuccinimide or a hydrolyzed analog thereof), a disulfide, a triazole, a phosphorothioate, a phosphodiester, an ester, an amide, or any combination thereof.
[0438] In some embodiments, the connecting moiety is a triantennary connecting moiety.
[0439] Suitable ligands include, but are not limited to, those disclosed in PCT Application Publication Nos. WO / 2015 / 006740, WO / 2016 / 100401, WO / 2017 / 214112, WO / 2018 / 039364, and WO / 2018 / 045317, each of which is incorporated herein by reference.
[0440] In some embodiments, the ligand comprises (For example, one, two, or three ).
[0441] In some embodiments, the ligand comprises (For example, one, two, or three ).
[0442] In some embodiments, the ligand comprises (For example, one, two, or three ).
[0443] In some embodiments, the ligand comprises (For example, one, two, or three ).
[0444] In some embodiments, the ligand comprises (For example, one, two, or three ).
[0445] In some embodiments, the ligand comprises (For example, one, two, or three ).
[0446] In some embodiments, the ligand comprises (For example, one, two, or three ).
[0447] In some embodiments, the ligand comprises (For example, one, two, or three ).
[0448] In some embodiments, the ligand comprises In some embodiments, the ligand comprises In some embodiments, the ligand comprises In some embodiments, the ligand comprises In some embodiments, the ligand comprises
[0449] In some embodiments, the ligand comprises
[0450] In some embodiments, the ligand comprises
[0451] In some embodiments, the ligand comprises
[0452] In some embodiments, the ligand comprises a lipid moiety (eg, one, two, or three lipid moieties).
[0453] In some embodiments, the lipid moiety comprises C8-C 24 Fatty acids, cholesterol, vitamins, sterols, phospholipids, or any combination thereof (eg, one, two, or three thereof).
[0454] In some embodiments, the ligand comprises a peptide portion (eg, one, two, or three peptide portions).
[0455] In some embodiments, the peptide portion comprises an integrin, insulin, a glucagon-like peptide, or any combination thereof (eg, one, two, or three thereof).
[0456] In some embodiments, the ligand comprises an antibody portion (eg, transferrin).
[0457] In some embodiments, the ligand comprises one, two, or three antibody moieties (eg, transferrin).
[0458] In some embodiments, the ligand comprises an oligonucleotide (eg, an aptamer or CpG).
[0459] In some embodiments, the ligand comprises one, two, or three oligonucleotides (eg, aptamers or CpGs).
[0460] In some embodiments, the ligand comprises:
[0461] one, two, or three sugars (e.g., N-acetyl-D-galactosamine);
[0462] one, two, or three lipid moieties;
[0463] one, two, or three peptide moieties;
[0464] one, two or three antibody moieties;
[0465] One, two or three oligonucleotides; or
[0466] Any combination thereof.
[0467] Other aspects of nucleic acid agents
[0468] In some embodiments, the nucleic acid agent is linked to a ligand (eg, GalNAc).
[0469] In some embodiments, the nucleic acid agent is linked to the ligand via an internal or terminal nucleotide of the nucleic acid agent.
[0470] In some embodiments, the nucleic acid agent comprises an oligonucleotide.
[0471] In some embodiments, a nucleic acid agent (eg, an oligonucleotide) comprises one or more phosphate groups or one or more phosphate group analogs.
[0472] In some embodiments, the 5'-terminal unit is attached to the oligonucleotide via a phosphate group or a phosphate group analog in the nucleic acid agent.
[0473] In some embodiments, the oligonucleotide has a length of from 1 to 100 nucleotides, from 1 to 80 nucleotides, from 1 to 60 nucleotides, or from 1 to 50 nucleotides.
[0474] In some embodiments, the oligonucleotide has a length of from 1 to 40 nucleotides, from 10 to 40 nucleotides, from 12 to 35 nucleotides, from 15 to 30 nucleotides, from 18 to 25 nucleotides, or from 20 to 23 nucleotides. In some embodiments, the oligonucleotide has a length of 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the oligonucleotide has a length of 19, 20, 21, 22, or 23 nucleotides.
[0475] In some embodiments, the nucleic acid agent comprises RNA, DNA, or a mixture thereof.
[0476] In some embodiments, the oligonucleotide comprises RNA, DNA, or a mixture thereof.
[0477] In some embodiments, the nucleic acid agent comprises RNA.
[0478] In some embodiments, the oligonucleotide is RNA.
[0479] In some embodiments, the oligonucleotide is a siRNA (e.g., a single-stranded siRNA (e.g., a hairpin single-stranded siRNA) or a double-stranded siRNA), a microRNA, an anti-microRNA, a microRNA mimetic, an anti-miR, an antagomir, a dsRNA, a ssRNA, an aptamer, an immunostimulatory oligonucleotide, a decoy oligomucleaotide, a splice-altering oligonucleotide, a triplex-forming oligonucleotide, a G-quadruplex, or an antisense oligonucleotide.
[0480] In some embodiments, the nucleic acid agent comprises double-stranded RNA (dsRNA), wherein the double-stranded RNA comprises a sense strand and an antisense strand, as described herein.
[0481] In some embodiments, the oligonucleotide is a double-stranded RNA (dsRNA), wherein the double-stranded RNA comprises a sense strand and an antisense strand, as described herein.
[0482] In some embodiments, the nucleic acid agent comprises a double-stranded siRNA (ds-siRNA), wherein the double-stranded siRNA comprises a sense strand and an antisense strand, as described herein.
[0483] In some embodiments, the oligonucleotide is a double-stranded siRNA (ds-siRNA), wherein the double-stranded siRNA comprises a sense strand and an antisense strand, as described herein.
[0484] It should be understood that the sense strand is also referred to as the passenger strand, and the terms "sense strand" and "passenger strand" are used interchangeably herein.
[0485] It will be understood that the antisense strand is also referred to as the guide strand, and the terms "antisense strand" and "guide strand" are used interchangeably herein.
[0486] In some embodiments, the oligonucleotide is an iRNA.
[0487] The term "iRNA" refers to an RNA agent that can down-regulate the expression of a target gene (e.g., siRNA), such as an endogenous or pathogen target RNA. Although not wishing to be bound by theory, iRNA can work by one or more of a variety of mechanisms, including post-transcriptional cleavage of target mRNA (referred to as RNAi in the art), or pre-transcriptional or pre-translation mechanisms. iRNA can include a single strand or can include more than one strand, for example, it can be a double-stranded iRNA. If the iRNA is a single strand, it can include a 5' modification, which includes one or more phosphate groups or one or more phosphate group analogs. In some embodiments, the iRNA is double-stranded. In some embodiments, one or both strands of the double-stranded iRNA can be modified, such as a 5' modification.
[0488] iRNA generally includes a zone with enough homology to the target gene, and has enough length in nucleotides so that iRNA or its fragment can mediate the downward regulation of the target gene. iRNA is or includes a zone that is at least partially complementary to the target RNA and fully complementary to the target RNA in some embodiments. There may not necessarily be complete complementarity between iRNA and the target, but this corresponding relationship may be enough to enable iRNA or its cleavage product to guide sequence-specific silencing, for example, by the RNAi cleavage of the target RNA (e.g., mRNA).
[0489] The nucleotides in the iRNA can be modified (for example, one or more nucleotides can include 2'-F groups or 2'-OCH3 groups, or are nucleotide substitutes). The single-stranded region or double-stranded region of the iRNA can be modified or include nucleotide substitutes, for example, one or more unpaired regions of the hairpin structure, for example, the region connecting two complementary regions, can have modifications or nucleotide substitutes. The modification that stabilizes one or more 3'-ends or 5'-ends of the iRNA is, for example, against exonucleases. The modification can include C3 (or C6, C7, C12) amino linkers, thiol linkers, carboxyl linkers, non-nucleotide spacers (C3, C6, C9, C12, abasic, triethylene glycol, hexaethylene glycol), special biotin or fluorescein reagents, which appear as phosphoramidites and have another DMT-protected hydroxyl group, allowing multiple couplings during RNA synthesis. Modifications may also include, for example, the use of modifications at the 2'OH group of the ribose, such as the use of deoxyribonucleotides such as deoxythymidine instead of ribonucleotides, and the use of modifications of phosphate groups, such as phosphorothioate modifications. In some embodiments, different chains will include different modifications.
[0490] In some embodiments, the chain is selected so that the iRNA includes a single strand or unpaired region at one or both ends of the molecule. Double-stranded iRNA can have an overhang, such as one or two 5' overhangs or 3' overhangs (e.g., at least 3' overhangs of 2-3 nucleotides). In some embodiments, the iRNA has an overhang of at least 2 (e.g., 2 or 3) nucleotides at each end, such as a 3' overhang. The overhang can be the result of one chain being longer than another chain, or the result of two chains of the same length being staggered.
[0491] In some embodiments, the length of the double-stranded region between the strands of the iRNA is between 6 nucleotides and 30 nucleotides. In some embodiments, the length of the double-stranded region is between 15 nucleotides and 30 nucleotides, most preferably 18, 19, 20, 21, 22, and 23 nucleotides. In some embodiments, the length of the double-stranded region is between 6 nucleotides and 20 nucleotides, most preferably 6, 7, 8, 9, 10, 11, and 12 nucleotides.
[0492] The oligonucleotide can be an oligonucleotide described in U.S. Patent Publication Nos. 2009 / 0239814, 2012 / 0136042, 2013 / 0158824, or 2009 / 0247608, each of which is hereby incorporated by reference.
[0493] In some embodiments, the oligonucleotide is siRNA.
[0494] In some embodiments, the oligonucleotide is a single-stranded siRNA.
[0495] In some embodiments, the oligonucleotide is a double-stranded siRNA, such as a double-stranded siRNA described herein.
[0496] As used herein, "single-stranded siRNA" is an siRNA consisting of a single strand including a double-stranded region formed by intrastrand pairing, for example, it can be a hairpin structure or a coiled handle structure or include a hairpin structure or a coiled handle structure. The single-stranded siRNA can be antisense relative to the target molecule.
[0497] The single-stranded siRNA can be long enough so that it can enter RISC and participate in the RISC-mediated cracking of the target mRNA. The length of the single-stranded siRNA is at least 14 nucleotides, and in some embodiments at least 15, 20, 25, 29, 35, 40 or 50 nucleotides. In some embodiments, the length of the single-stranded siRNA is less than 200, 100, 80, 60, 50, 40 or 30 nucleotides.
[0498] In some embodiments, the single-stranded siRNA has a length of from 10 to 40 nucleotides, from 12 to 35 nucleotides, from 15 to 30 nucleotides, from 18 to 25 nucleotides, or from 20 to 23 nucleotides. In some embodiments, the single-stranded siRNA has a length of 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the single-stranded siRNA has a length of 20, 21, 22, or 23 nucleotides.
[0499] The hairpin siRNA can have a duplex region equal to or at least 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotide pairs. The length of the duplex region can be equal to or less than 200, 100 or 50 nucleotide pairs. In some embodiments, the length of the duplex region ranges from 15 to 30, 17 to 23, 19 to 23 and 19 to 21 nucleotide pairs. The hairpin can have a single-stranded overhang or an unpaired terminal region. In some embodiments, the overhang is at least 2 (e.g., 2 or 3) nucleotides in length. In some embodiments, the overhang is located at the sense side of the hairpin, and in some embodiments is located on the antisense side of the hairpin.
[0500] In some embodiments, the oligonucleotide is a double-stranded siRNA.
[0501] As used herein, a "double-stranded siRNA" is a siRNA that includes more than one strand, and in some cases two strands, wherein hybridization between the strands can form a region of a duplex structure.
[0502] In some embodiments, the length of the sense strand of the double-stranded siRNA can be equal to or at least 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 29, 40, or 60 nucleotides. The length of the sense strand of the double-stranded siRNA can be equal to or less than 200, 100, or 50 nucleotides. The length range can be 13 to 36, 17 to 25, 19 to 23, 19 to 21, 21 to 23, or 20 to 22 nucleotides.
[0503] In some embodiments, the sense strand has a length of from 10 to 40 nucleotides, from 12 to 35 nucleotides, from 13 to 36 nucleotides, from 15 to 30 nucleotides, from 18 to 25 nucleotides, or from 20 to 23 nucleotides. In some embodiments, the sense strand has a length of from 13 to 36 nucleotides. In some embodiments, the sense strand has a length of 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the sense strand has a length of 20, 21, 22, or 23 nucleotides.
[0504] In some embodiments, the sense strand has a length of 18, 19, 20, 21, or 22 nucleotides. In some embodiments, the sense strand has a length of 20, 21, or 22 nucleotides.
[0505] In some embodiments, the length of the antisense strand of the double-stranded siRNA can be equal to or at least 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 29, 40, or 60 nucleotides. The length of the antisense strand of the double-stranded siRNA can be equal to or less than 200, 100, or 50 nucleotides. The length range can be 17 to 25, 18 to 31, 19 to 23, 19 to 21, 21 to 23, or 20 to 22 nucleotides.
[0506] In some embodiments, the antisense strand has a length of from 10 to 40 nucleotides, from 12 to 35 nucleotides, from 15 to 30 nucleotides, from 18 to 31 nucleotides, from 18 to 25 nucleotides, or from 20 to 23 nucleotides. In some embodiments, the antisense strand has a length of from 18 to 31 nucleotides. In some embodiments, the antisense strand has a length of 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the antisense strand has a length of 20, 21, 22, or 23 nucleotides.
[0507] In some embodiments, the antisense strand has a length of 20, 21, 22, 23, or 24 nucleotides. In some embodiments, the antisense strand has a length of 21, 22, or 23 nucleotides.
[0508] In some embodiments, the sense strand has a length of from 13 to 36 nucleotides and the antisense strand has a length of from 18 to 31 nucleotides. In some embodiments, the sense strand has a length of 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides and the antisense strand has a length of 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the sense strand has a length of 18, 19, 20, 21, or 22 nucleotides and the antisense strand has a length of 20, 21, 22, 23, or 24 nucleotides. In some embodiments, the sense strand has a length of 20, 21, or 22 nucleotides and the antisense strand has a length of 21, 22, or 23 nucleotides.
[0509] In some embodiments, the sense strand has a length of 18 nucleotides and the antisense strand has a length of 20 nucleotides.
[0510] In some embodiments, the sense strand has a length of 19 nucleotides and the antisense strand has a length of 21 nucleotides.
[0511] In some embodiments, the sense strand has a length of 20 nucleotides and the antisense strand has a length of 22 nucleotides.
[0512] In some embodiments, the sense strand has a length of 21 nucleotides and the antisense strand has a length of 23 nucleotides.
[0513] In some embodiments, the sense strand has a length of 22 nucleotides and the antisense strand has a length of 24 nucleotides.
[0514] The length of the double-stranded portion of the double-stranded siRNA can be equal to or at least 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 29, 40 or 60 nucleotide pairs. The length of the double-stranded portion of the double-stranded siRNA can be equal to or less than 200, 100 or 50 nucleotide pairs. The length range can be 15 to 30, 17 to 23, 19 to 23 and 19 to 21 nucleotide pairs.
[0515] In some embodiments, the siRNA is large enough that it can be cleaved by endogenous molecules, such as by Dicer, to produce smaller siRNAs, such as siRNA agents.
[0516] The sense strand and the antisense strand can be selected so that the double-stranded siRNA includes a single-stranded region or an unpaired region at one or both ends of the molecule. Therefore, the double-stranded siRNA can include a sense strand and an antisense strand, and the sense strand and the antisense strand are paired to include an overhang, such as one or two 5' overhangs or 3' overhangs or 3' overhangs of 1-3 nucleotides. The overhang can be the result that one chain is longer than the other chain, or the result that two chains of the same length are staggered. Some embodiments will have at least one 3' overhang. In some embodiments, the two ends of the siRNA molecule will have a 3' overhang. In some embodiments, the overhang is 2 nucleotides.
[0517] In some embodiments, the length of the double-stranded region is between 15 nucleotides and 30 nucleotides, or 18, 19, 20, 21, 22 and 23 nucleotides, such as within the ssiRNA range discussed above. The ssiRNA can be similar in length and structure to the product of natural Dicer processing from long dsiRNA. Also included are embodiments in which the two chains of the ssiRNA are attached, such as covalently attached. It is also contemplated that 3' overhangs and hairpins or other single-stranded structures that provide the desired double-stranded region are provided.
[0518] In some embodiments, the siRNA is dsRNA.
[0519] In some embodiments, the dsRNA comprises a sense strand having a length of from 13 to 36 nucleotides, from 15 to 30 nucleotides, from 18 to 25 nucleotides, or from 20 to 22 nucleotides.
[0520] In some embodiments, the dsRNA comprises an antisense strand having a length of from 18 to 31 nucleotides, from 19 to 27 nucleotides, from 20 to 24 nucleotides, or from 21 to 23 nucleotides.
[0521] In some embodiments, the dsRNA comprises a sense strand having a length of from 13 to 36 nucleotides, from 15 to 30 nucleotides, from 18 to 25 nucleotides, or from 20 to 22 nucleotides and an antisense strand having a length of from 18 to 31 nucleotides, from 19 to 27 nucleotides, from 20 to 24 nucleotides, or from 21 to 23 nucleotides.
[0522] In some embodiments, the dsRNA comprises a sense strand having a length of from 20 to 22 nucleotides and an antisense strand having a length of from 21 to 23 nucleotides.
[0523] In some embodiments, in a dsRNA, the antisense strand has a 3' overhang of, eg, at least 2 nucleotides.
[0524] In some embodiments, the dsRNA comprises at least one modified phosphate backbone, such as phosphorothioate, methylphosphonate, or phosphorodithioate.
[0525] In some embodiments, the dsRNA is linked to the ligand (eg, GalNAc) via an internal or terminal nucleotide of the dsRNA.
[0526] The siRNA described herein, including double-stranded siRNA and single-stranded siRNA, can mediate the silencing of a target RNA, such as mRNA, such as a transcript of a gene encoding a protein. For convenience, such mRNA is also referred to as mRNA to be silenced in this article. Such a gene is also referred to as a target gene. In general, the RNA to be silenced is an endogenous gene or a pathogen gene. In addition, RNA other than mRNA, such as tRNA and viral RNA, can also be targeted.
[0527] As used herein, the phrase "mediates RNAi" refers to the ability to silence a target RNA in a sequence-specific manner. While not wishing to be bound by theory, it is believed that the silencing uses the RNAi mechanism or process and a guide RNA, such as a 21 to 23 nucleotide ssiRNA.
[0528] In some embodiments, siRNA is "fully complementary" to a target RNA (e.g., a target mRNA) so that the siRNA silences the production of a protein encoded by the target mRNA. In another embodiment, siRNA is "precisely complementary" to a target RNA, such as a target RNA and siRNA anneal, such as to form a hybrid made exclusively of Watson-Crick base pairs in a precisely complementary region. A "fully complementary" target RNA can include an internal region (e.g., an internal region of at least 10 nucleotides) that is precisely complementary to the target RNA. In addition, in some embodiments, siRNA specifically distinguishes single nucleotide differences. In this case, siRNA mediates RNAi only when there is precise complementarity in a region of single nucleotide differences (e.g., within 7 nucleotides).
[0529] MicroRNA: MicroRNA (miRNA) is a highly conserved small RNA molecule that is transcribed from DNA in the genomes of plants and animals but is not translated into proteins. Processed miRNA is a single-stranded ~17-25 nucleotide (nt) RNA molecule that becomes incorporated into the RNA-induced silencing complex (RISC) and has been identified as a key regulator of development, cell proliferation, apoptosis and differentiation. They are believed to play a role in the regulation of gene expression by binding to the 3'-untranslated region of specific mRNA. RISC mediates the downregulation of gene expression by translational inhibition, transcript cleavage or both. RISC is also associated with transcriptional silencing in the nucleus of a variety of eukaryotic organisms.
[0530] The number of miRNA sequences identified to date is large and growing, illustrative examples of which can be found, for example, in: “miRBase: microRNA sequences, targets and gene nomenclature” Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright A J. NAR, 2006, 34, Database Issue, D140-D144; “The microRNA Registry” Griffiths-Jones S. NAR, 2004, 32, Database Issue, D109-D111.
[0531] Antisense oligonucleotide: In some embodiments, nucleic acid is an antisense oligonucleotide for a target polynucleotide. The term "antisense oligonucleotide" or "antisense" for short means an oligonucleotide complementary to a targeted polynucleotide sequence. Antisense oligonucleotides are single strands of DNA or RNA complementary to a selected sequence (e.g., target gene mRNA). Antisense oligonucleotides are considered to inhibit gene expression by binding to complementary mRNA. Binding to target mRNA can inhibit gene expression by blocking the translation of complementary mRNA chains or by causing degradation of target mRNA via binding to complementary mRNA chains. Antisense DNA can be used to target specific complementary (coding or non-coding) RNA. If binding occurs, the DNA / RNA hybrid can be degraded by enzyme RNase H. In some embodiments, antisense oligonucleotides include from about 10 to about 50 nucleotides, more preferably from about 15 to about 30 nucleotides. The term also encompasses antisense oligonucleotides that may not be precisely complementary to the desired target gene. Thus, situations are envisioned in which non-target specific activity is found with antisense, or in which an antisense sequence containing one or more mismatches to the target sequence is most preferred for a particular use.
[0532] Antisense oligonucleotides have been shown to be effective and targeted inhibitors of protein synthesis, and therefore, can be used to specifically inhibit protein synthesis of targeted genes. The effectiveness of antisense oligonucleotides for inhibiting protein synthesis is well confirmed. For example, the synthesis of polygalacturonase and muscarinic type 2 acetylcholine receptor is inhibited by antisense oligonucleotides directed to their respective mRNA sequences (U.S. Patent Nos. 5,739,119 and 5,759,829, each of which is incorporated by reference). In addition, examples of antisense inhibition have been demonstrated with nuclear protein cyclins, multidrug resistance gene (MDG1), ICAM-1, E-selectin, STK-1, striatal GABAA receptors, and human EGF (Jaskulski et al., Science. 1988 Jun 10; 240(4858): 1544-6; Vasanthakumar and Ahmed, Cancer Commun. 1989; 1(4): 225-32; Peris et al., Brain Res Mol Brain Res. 1998 Jun 15; 57(2): 310-20; U.S. Pat. Nos. 5,801,154; 5,789,573; 5,718,709 and 5,610,288, each of which is incorporated by reference). Additionally, antisense constructs have been described that inhibit and can be used to treat a variety of abnormal cell proliferations, such as cancer (U.S. Pat. Nos. 5,747,470; 5,591,317; and 5,783,683, each of which is incorporated by reference).
[0533] The method for producing antisense oligonucleotide is known in the art, and can be easily applied to produce antisense oligonucleotide targeting any polynucleotide sequence. The selection of antisense oligonucleotide sequence specific to a given target sequence is based on the analysis of the selected target sequence and the determination of secondary structure, Tm, binding energy and relative stability. Antisense oligonucleotide can be selected based on their relative inability to form dimer, hairpin or other secondary structures, which will reduce or forbid specific binding with target mRNA in host cells. The highly preferred target region of mRNA includes those regions at or near the AUG translation initiation codon and those sequences substantially complementary to the 5' region of mRNA. These secondary structure analyses and target site selection considerations can be carried out, for example, using the 4th edition and / or BLASTN2.0.5 algorithm software of OLIGO primer analysis software (Molecular Biology Insights) (Altschul et al., Nucleic Acids Res.1997, 25 (17): 3389-402).
[0534] Antagomir: Antagomir is an RNA-like oligonucleotide with multiple modifications for RNA enzyme protection and pharmacological properties, such as enhanced tissue and cell uptake. They differ from normal RNA in that, for example, sugar, phosphorothioate backbones are completely 2'-O-methylated, and, for example, a cholesterol moiety at the 3'-end. Antagomir can be used to effectively silence endogenous miRNA by forming a duplex comprising antagomir and endogenous miRNA, thereby preventing miRNA-induced gene silencing. An example of antagomir-mediated miRNA silencing is the silencing of miR-122, described in Krutzfeldt et al., Nature, 2005, 438: 685-689, which is expressly incorporated herein by reference in its entirety. Antagomir RNA can be synthesized using a standard solid phase oligonucleotide synthesis protocol. See U.S. Patent Application Publication Nos. 2007 / 0123482 and 2007 / 0213292 (each of which is incorporated herein by reference).
[0535] Antagomir can include monomeric subunits and monomers for the ligand conjugation of oligonucleotide synthesis. Exemplary monomers are described in U.S. Patent Application Publication No. 2005 / 0107325, which is incorporated by reference in its entirety. Antagomir can have a ZXY structure, such as the ZXY structure described in WO 2004 / 080406 incorporated by reference in its entirety. Antagomir can be complexed with an amphipathic part. Exemplary amphipathic parts for use with oligonucleotide agents are described in WO 2004 / 080406 incorporated by reference in its entirety.
[0536] Aptamers: Aptamers are nucleic acid or peptide molecules that bind with high affinity and specificity to a particular molecule of interest (Tuerk and Gold, Science 249:505 (1990); Ellington and Szostak, Nature 346:818 (1990), each of which is incorporated by reference in its entirety). DNA aptamers or RNA aptamers have been successfully produced that bind to many different entities from large proteins to small organic molecules. See Eaton, Curr. Opin. Chem. Biol. 1:10-16 (1997), Famulok, Curr. Opin. Struct. Biol. 9:324-9 (1999), and Hermann and Patel, Science 287:820-5 (2000), each of which is incorporated by reference in its entirety. Aptamers can be RNA or DNA based and can include riboswitches. Riboswitch is a part of mRNA molecule, which can directly bind to small target molecules and its combination with target affects the activity of gene. Therefore, mRNA containing riboswitch directly participates in regulating its own activity, which depends on the presence or absence of its target molecule. Generally, aptamers are engineered by repeated rounds of in vitro selection or equivalent SELEX (systematic evolution of ligands by exponential enrichment) to combine multiple molecular targets such as small molecules, proteins, nucleic acids and even cells, tissues and organisms. Aptamers can be prepared by any known method, including synthesis, recombination and purification methods, and can be used alone or in combination with other aptamers specific to the same target. In addition, as described more comprehensively herein, the term "aptamer" specifically includes "secondary aptamers (secondary aptamer)", which "secondary aptamers" include a consensus sequence obtained by comparing two or more known aptamers with a given target.
[0537] Ribozymes: According to another embodiment, the nucleic acid-lipid particle is associated with a ribozyme. Ribozymes are RNA molecule complexes with a specific catalytic domain that possesses endonuclease activity (Kim and Cech, Proc Natl Acad Sci USA. 1987 Dec; 84(24):8788-92; Forster and Symons, Cell. 1987 Apr 24; 49(2):211-20). For example, a large number of ribozymes accelerate phosphate transfer reactions with high specificity, often cleaving only one of several phosphates in an oligonucleotide substrate (Cech et al., Cell. 1981 Dec; 27(3Pt 2):487-96; Michel and Westhof, J Mol Biol. 1990 Dec 5; 216(3):585-610; Reinhold-Hurek and Shub, Nature. 1992 May 14; 357(6374):173-6). This specificity has been attributed to the requirement that the substrate bind to the internal guide sequence ("IGS") of the ribozyme via specific base pairing interactions prior to the chemical reaction.
[0538] At least six kinds of naturally occurring enzymatic RNAs are known to exist. Each can catalyze the hydrolysis of RNA phosphodiester bonds in trans under physiological conditions (and therefore can cleave other RNA molecules). In general, enzymatic nucleic acids first act by binding to target RNA. Such binding occurs through the target binding portion of the enzymatic nucleic acid, which is adjacent to the enzymatic portion in the molecule that plays the role of cleaving the target RNA. Therefore, the enzymatic nucleic acid first recognizes the target RNA, and then binds to the target RNA through complementary base pairing, and once bound to the correct site, it enzymatically plays the role of cleaving the target RNA. The strategic cleavage of such a target RNA will destroy its ability to guide the synthesis of the encoded protein. After the enzymatic nucleic acid binds and cleaves its RNA target, it is released from the RNA to find another target, and can repeatedly bind and cleave new targets.
[0539] For example, the enzymatic nucleic acid molecule can be formed as a hammerhead, hairpin, hepatitis delta virus, group I intron, or RNase P RNA (associated with an RNA guide sequence) or Neurospora VS RNA motif. Specific examples of hammerhead motifs are described by Rossi et al. Nucleic Acids Res. 1992 Sep 11; 20(17): 4559-65. Examples of hairpin motifs are described by Hampel et al. (European Patent Application Publication No. EP 0360257); Hampel and Tritz, Biochemistry 1989 Jun 13; 28(12): 4929-33; Hampel et al., Nucleic Acids Res. 1990 Jan 25; 18(2): 299-304 and U.S. Pat. No. 5,631,359. Examples of hepatitis delta virus motifs are described by Perrotta and Been, Biochemistry. 1992 Dec 1;31(47):11843-52; examples of RNase P motifs are described by Guerrier-Takada et al., Cell. 1983 Dec;35(3Pt 2):849-57; the Neurospora VS RNA ribozyme motif is described by Collins (Saville and Collins, Cell. 1990 May 18;61(4):685-96; Saville and Collins, Proc Natl Acad Sci USA. 1991 Oct 1;88(19):8826-30; Collins and Olive, Biochemistry. 1993 Mar 23;32(11):2795-9); and examples of group I introns are described in U.S. Pat. No. 4,987,071. The important feature of the enzymatic nucleic acid molecules used is that they have a specific substrate binding site complementary to one or more target gene DNA or RNA regions, and they have a nucleotide sequence within or around the substrate binding site that confers RNA cleavage activity to the molecule. Therefore, the ribozyme construct need not be limited to the specific motifs mentioned herein.
[0540] Methods for producing ribozymes targeting any polynucleotide sequence are known in the art.Ribozymes can be designed as described in International Patent Application Publication Nos. WO 93 / 23569 and WO 94 / 02595, each expressly incorporated herein by reference, and synthesized as described therein for in vitro and in vivo testing.
[0541] Ribozyme activity can be optimized by varying the length of the ribozyme binding arms or chemically synthesizing ribozymes with modifications that protect them from degradation by serum ribonucleases (see, e.g., International Patent Application Publication Nos. WO 92 / 07065, WO 93 / 15187, and WO 91 / 03162; European Patent Application Publication No. 92110298.4; U.S. Pat. No. 5,334,711; and International Patent Application Publication No. WO 94 / 13688, which describe a variety of chemical modifications that can be made to the sugar portion of the enzymatic RNA molecule), modifications that enhance their potency in cells, and removal of the Stem II base to shorten RNA synthesis time and reduce chemical requirements.
[0542] Immunostimulatory oligonucleotides: Nucleic acids associated with lipid particles can be immunostimulatory, including immunostimulatory oligonucleotides (ISS; single-stranded or double-stranded), which can induce an immune response when administered to a subject, which can be a mammal or other patient. ISS include, for example, certain palindromes that lead to hairpin secondary structures (see Yamamoto S., et al. (1992) J. Immunol. 148: 4072-4076, which is incorporated by reference in its entirety), or CpG motifs, and other known ISS features (such as poly-G domains, see WO 96 / 11266, which is incorporated by reference in its entirety).
[0543] The immune response may be an innate immune response or an adaptive immune response. The vertebrate immune system is further divided into an innate immune system and an acquired adaptive immune system, which is further divided into humoral cellular components. In some embodiments, the immune response may be mucosal.
[0544] In some embodiments, the immunostimulatory nucleic acid is immunostimulatory only when administered in combination with a lipid particle, but not when administered in its "free form." Such oligonucleotides are considered immunostimulatory.
[0545] When it is not necessary for the immunostimulatory nucleic acid to specifically bind to the target polynucleotide and reduce the expression of the target polynucleotide in order to stimulate an immune response, the immunostimulatory nucleic acid is considered to be non-sequence specific. Therefore, some immunostimulatory nucleic acids may comprise sequences corresponding to regions of naturally occurring genes or mRNAs, but they may still be considered to be non-sequence specific immunostimulatory nucleic acids.
[0546] In some embodiments, the immunostimulatory nucleic acid or oligonucleotide comprises at least one CpG dinucleotide. The oligonucleotide or CpG dinucleotide can be non-methylated or methylated. In another embodiment, the immunostimulatory nucleic acid comprises at least one CpG dinucleotide with methylated cytosine. In some embodiments, the nucleic acid comprises a single CpG dinucleotide, wherein the cytosine in the CpG dinucleotide is methylated. In selectable embodiments, the nucleic acid comprises at least two CpG dinucleotides, wherein at least one cytosine in the CpG dinucleotide is methylated. In another embodiment, each cytosine in the CpG dinucleotide present in the sequence is methylated. In another embodiment, the nucleic acid comprises more than one CpG dinucleotide, wherein at least one of the CpG dinucleotides comprises a methylated cytosine.
[0547] Attachment between 5'-terminal unit, nucleic acid agent and ligand
[0548] In some embodiments, the attachment between the 5 '-terminal unit and the nucleic acid agent is a bond.
[0549] In some embodiments, the attachment between the 5 '-terminal unit and the nucleic acid agent is a moiety (eg, a moiety comprising a cleavable group).
[0550] The group may be cleavable or non-cleavable. Suitable groups include, for example, -NR-, -C(=O)-, -C(=O)NH-, -S(=O)-, -S(=O)2-, -S(=O)2NH- or a chain of atoms such as, but not limited to, alkylene, alkenylene, alkynylene, arylalkylene, arylalkenylene, arylalkynylene, heteroarylalkylene, heteroarylalkenylene, heteroarylalkynylene, heterocyclylalkylene, heterocyclylalkenylene, heterocyclylalkynylene, alkylene aryl, heteroarylene, heterocyclylene, cycloalkylene, cycloalkenylene, alkylarylalkylene, alkylarylalkenylene, alkylarylalkynylene, alkenylarylalkylene, alkenylarylalkenylene, alkenylarylalkynylene, alkynylarylalkylene, alkynylarylalkenylene, alkynylarylalkynylene, alkylheteroarylalkylene, alkylheteroarylalkenylene, alkylheteroarylalkynylene, alkenylheteroarylalkylene, alkenylheteroarylalkenylene, alkenylheteroarylalkenylene, Alkynyl, alkynylheteroarylalkylene, alkynylheteroarylalkenylene, alkynylheteroarylalkynylene, alkylheterocyclylalkylene, alkylheterocyclylalkenylene, alkylheterocyclylalkynylene, alkenylheterocyclylalkylene, alkenylheterocyclylalkenylene, alkenylheterocyclylalkynylene, alkynylheterocyclylalkylene, alkynylheterocyclylalkenylene, alkynylheterocyclylalkynylene, alkylarylene, alkenylarylene, alkynylarylene, alkylheteroarylene, alkenylheteroarylene, alkynyl heteroarylene, each of which may be substituted or unsubstituted and in which one or more methylene groups may be interrupted or terminated by -O-, -S-, -S(=O)-, -S(=O)2-, -NR-, -C(=O)-, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycle, wherein R is hydrogen, acyl, aliphatic or substituted aliphatic.
[0551] A cleavable group is a group that is sufficiently stable outside the cell, but is cleaved after entering the target cell to release the two parts of the group held together. In a preferred embodiment, the cleavable group is cleaved at least 10 times or more faster, preferably at least 100 times, in the target cell or under a first reference condition (which can, for example, be selected to simulate or represent intracellular conditions) than in the blood of the subject or under a second reference condition (which can, for example, be selected to simulate or represent conditions present in blood or serum).
[0552] Cleavable groups are susceptible to cleavage agents, such as the presence of pH, redox potential or degradation molecules. Typically, cleavage agents are more prevalent or present at higher levels or activities in cells than in serum or blood. Examples of such degradation agents include: redox agents, which are selected for specific substrates or which do not have substrate specificity, including, for example, oxidases or reductases or reducing agents such as thiols present in cells, which can degrade redox cleavable groups by reduction; esterases; endosomes or agents that can produce an acidic environment, such as those that cause a pH of 5 or less; enzymes, which can hydrolyze or degrade acid cleavable groups by acting as general acids, peptidases (which can be substrate specific) and phosphatases.
[0553] Cleavable groups, such as disulfide bonds, can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH in the range of 5.5-6.0, and lysosomes have an even more acidic pH at about 5.0. Some linkers will have cleavable groups that are cleaved at a preferred pH, thereby releasing the cationic lipid from the ligand within the cell, or into a desired compartment of the cell.
[0554] The conjugate may include a cleavable group that is cleavable by a specific enzyme. The type of cleavable group incorporated into the conjugate may depend on the cell to be targeted. For example, a liver targeting ligand may be attached to a cationic lipid by a chemical moiety comprising an ester group. Hepatocytes are rich in esterases, and therefore the group is more effectively cleaved in hepatocytes than in cell types that are not rich in esterases. Other cell types rich in esterases include lung cells, renal cortical cells, and testicular cells.
[0555] When targeting peptidase-rich cell types such as hepatocytes and synoviocytes, coupling groups containing peptide bonds can be used.
[0556] In general, the suitability of candidate cleavable groups can be assessed by testing the ability of degradation agents (or conditions) to crack candidate groups. It will also be desirable to test the ability of candidate cleavable groups to resist cracking in blood or when contacting with other non-target tissues. Therefore, the relative susceptibility to cracking between the first condition and the second condition can be determined, wherein the first condition is selected to indicate the cracking in the target cell, and the second condition is selected to indicate other tissues or biological fluids, such as the cracking in blood or serum. Assessment can be carried out in a cell-free system, in cells, in cell culture, in organ or tissue culture or in whole animals. Preliminary assessment is carried out in cell-free or culture conditions and further assessment is carried out in whole animals to confirm that it may be useful. In a preferred embodiment, useful candidate compounds in cells (or under the in vitro conditions selected as the simulated intracellular conditions) are faster than cracking in blood or serum (or under the in vitro conditions selected as the simulated extracellular conditions) by at least 2 times, 4 times, 10 times or 100 times.
[0557] Redox cleavable groups. One type of cleavable group is a redox cleavable group that is cleaved when reduced or oxidized. An example of a reduction cleavable group is a disulfide linking group (-SS-). In order to determine whether a candidate cleavable group is a suitable "reduction cleavable linking group", or whether it is suitable for use with a specific iRNA portion and a specific targeting agent, the technician can refer to the method described herein. For example, the candidate can be evaluated by incubating with dithiothreitol (DTT) or other reducing agents using reagents known in the art, and the reagents simulate the cleavage rate observed in cells such as target cells. Candidates can also be evaluated under conditions selected to simulate blood or serum conditions. In a preferred embodiment, the candidate compound is cleaved up to 10% in blood. In a preferred embodiment, useful candidate compounds are degraded at least 2 times, 4 times, 10 times or 100 times faster in cells (or under in vitro conditions selected to simulate intracellular conditions) than in blood (or under in vitro conditions selected to simulate extracellular conditions). The rate of cleavage of a candidate compound can be determined using standard enzyme kinetic assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.
[0558] Phosphate-based cleavable groups. Phosphate-based cleavable groups are cleaved by agents that degrade or hydrolyze phosphate groups. Examples of agents that cleave phosphate groups in cells are enzymes in cells, such as phosphatases. In some embodiments, the phosphate-based linking group is -OP(=O)(OR k )-O-、-OP(=S)(OR k )-O-、-OP(=S)(SR k )-O-、-SP(=O)(ORk )-O-、-OP(=O)(OR k )-S-、-SP(=O)(OR k )-S-、-OP(=S)(OR k )-S-、-SP(=S)(OR k )-O-、-OP(=O)(R k )-O-、-OP(=S)(R k )-O-、-SP(=O)(R k )-O-、-SP(=S)(R k )-O-、-SP(=O)(R k )-S-or-OP(=S)(R k )-S-. In some embodiments, the phosphate-based linking group is -OP(=O)(OH)-O-, -OP(=S)(OH)-O-, -OP(=S)(SH)-O-, -SP(=O)(OH)-O-, -OP(=O)(OH)-S-, -SP(=O)(OH)-S-, -OP(=S)(OH)-S-, -SP(=S)(OH)-O-, -OP(=O)(H)-O-, -OP(=S)(H)-O-, -SP(=O)(H)-O-, -SP(=S)(H)-O-, -SP(=O)(H)-S-, or -OP(=S)(H)-S-. In some embodiments, the phosphate-based linking group is -OP(=O)(OH)-O-.
[0559] Acid cleavable groups. Acid cleavable groups are linking groups that are cleaved under acidic conditions. In preferred embodiments, acid cleavable groups are cleaved in an acidic environment with a pH of about 6.5 or less (e.g., about 6.0, 5.5, 5.0 or less), or by agents that can act as general acids such as enzymes. In cells, specific low pH organelles, such as endosomes and lysosomes, can provide a cleavage environment for acid cleavable linking groups. Examples of acid cleavable groups include, but are not limited to, esters of hydrazones, esters, and amino acids. Acid cleavable groups can have the general formula -C=NN-, C(O)O, or -OC(O). A preferred embodiment is when the carbon attached to the oxygen (alkoxy group) of the ester is an aryl group, a substituted alkyl group, or a tertiary alkyl group such as dimethylpentyl or tert-butyl. These candidates can be evaluated using methods similar to those described above.
[0560] Ester-based cleavable groups. Ester-based cleavable groups are cleaved by enzymes in cells such as esterases and amidases. Examples of ester-based cleavable groups include, but are not limited to, esters of alkylene groups, alkenylene groups, and alkynylene groups. Ester cleavable linking groups have the general formula -C(O)O- or -OC(O)-. Methods similar to those described above can be used to evaluate these candidates.
[0561] Peptide-based cleavable groups. Peptide-based cleavable groups are cleaved by enzymes in cells such as peptidases and proteases. Peptide-based cleavable groups are peptide bonds formed between amino acids to produce oligopeptides (e.g., dipeptides, tripeptides, etc.) and polypeptides. Peptide-based cleavable groups do not include amide groups (-C(O)NH-). Amide groups can be formed between any alkylene, alkenylene, or alkynylene groups. Peptide bonds are a special type of amide bond formed between amino acids to produce peptides and proteins. Peptide-based cleavable groups are generally limited to peptide bonds (i.e., amide bonds) formed between amino acids to produce peptides and proteins, and do not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula -NHCHR A C(O)NHCHR B C(O)-, where R A and R B It is the R group of two adjacent amino acids. These candidates can be evaluated using methods similar to those described above. As used herein, "carbohydrate" refers to a compound of a carbohydrate that is itself composed of one or more monosaccharide units, wherein the one or more monosaccharide units have at least 6 carbon atoms (which can be linear, branched or cyclic), each carbon atom is bonded with oxygen, nitrogen or sulfur atoms; or a compound that makes a carbohydrate portion composed of one or more monosaccharide units as a part of it, wherein the one or more monosaccharide units each have at least six carbon atoms (which can be linear, branched or cyclic), each carbon atom is bonded with oxygen, nitrogen or sulfur atoms. Representative carbohydrates include sugars (containing monosaccharides, disaccharides, trisaccharides and oligosaccharides from about 4-9 monosaccharide units) and polysaccharides, such as starch, glycogen, cellulose and polysaccharide gum. Specific monosaccharides include C5 and above (preferably C5-C8) sugars; disaccharides and trisaccharides include sugars with two or three monosaccharide units (preferably C5-C8).
[0562] Previously, it was reported that certain 1'-amino 2'-OTBS carbocyclic phosphoramidites were previously prepared and incorporated into natural oligonucleotides as handles for fluorophore conjugation for labeling oligonucleotides (Org. Lett. 2021, 23, 6735-6739, incorporated herein by reference). Without wishing to be bound by theory, the compounds, nucleic acid agents, and conjugates of the present disclosure may differ from previously reported 1'-amino 2'-OTBS carbocyclic phosphoramidites in multiple aspects, including chemical structure, conjugated oligonucleotides, uses of conjugates, and / or methods of synthesis.
[0563] Synthesis method
[0564] In some aspects, the present disclosure provides methods of making the compounds of the present disclosure.
[0565] In some aspects, the disclosure provides compounds obtainable by or obtained by a method for preparing a compound as described herein.
[0566] In some aspects, the disclosure provides intermediates as described herein, which are suitable for use in methods for preparing compounds as described herein.
[0567] The compounds of the present disclosure can be prepared by any suitable technique known in the art. Specific processes for preparing these compounds are further described in the accompanying examples.
[0568] In the descriptions of synthetic methods described herein, as well as in any referenced synthetic methods used to prepare starting materials, it is understood that all proposed reaction conditions including the choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment, and work-up procedures can be selected by one skilled in the art.
[0569] Those skilled in the art of organic synthesis understand that the functionality present on various portions of the molecule must be compatible with the reagents and reaction conditions being utilized.
[0570] It will be appreciated that, during the synthesis of the compounds of this disclosure in the process defined herein, or during the synthesis of certain starting materials, it may be desirable to protect certain substituent groups to prevent their undesirable reactions. A skilled chemist will understand when such protection is needed and how such a blocking group can be placed in place and removed later. For examples of blocking groups, see one of many general textbooks on this topic, for example, by Theodora Green (Publisher: John Wiley & Sons) 'Protective Groups in Organic Synthesis'. The blocking group can be removed by any convenient method described in the literature or known to a skilled chemist as being suitable for removing the blocking group in question, selecting such a method to achieve removal of the blocking group in the case of a group elsewhere in the minimum interference molecule. Therefore, if the reactant comprises, for example, a group such as an amino, carboxyl or hydroxyl, it may be desirable to protect the group in some of the reactions mentioned herein.
[0571] By way of example, suitable protecting groups for amino or alkylamino groups are, for example, acyl groups, for example: alkanoyl groups, such as acetyl; alkoxycarbonyl groups, for example methoxycarbonyl groups, ethoxycarbonyl groups or tert-butoxycarbonyl groups; arylmethoxycarbonyl groups, for example benzyloxycarbonyl; or aroyl groups, for example benzoyl. Suitable protecting groups for hydroxyl groups or alkylhydroxyl groups can be, for example, acetyl (Ac), benzoyl (Bz), benzyl (Bn), β-methoxyethoxymethyl ether (MEM), dimethoxytrityl (DMT), methoxymethyl ether (MOM), methoxytrityl (MMT), p-methoxybenzyl ether (PMB), p-methoxyphenyl ether (PMP), pivaloyl (Piv), tetrahydropyranyl (THP), tetrahydrofuran (THF), trityl (triphenylmethyl, Tr), silyl ether (e.g. trimethylsilyl (TMS) ether, tert-butyldimethylsilyl (TBDMS) ether, triisopropylsilyloxymethyl (TOM) ether and triisopropylsilyl (TIPS) ether), methyl ether or ethoxyethyl ether (EE). Suitable protecting groups for 1,2-diol can be, for example, acetal. A suitable protecting group for 1,3-diol may be, for example, tetraisopropyldisiloxanylidene (TIPDS).
[0572] The deprotection conditions for the blocking group above necessarily change with the selection of blocking group.Therefore, for example, acyl groups such as alkanoyl groups or alkoxycarbonyl groups or aroyl groups can be removed by, for example, hydrolysis with suitable alkali such as alkali metal hydroxides such as lithium hydroxide or sodium hydroxide.Selectively, acyl groups such as tert-butoxycarbonyl groups can be removed by, for example, processing with suitable acid such as hydrochloric acid, sulfuric acid or phosphoric acid or trifluoroacetic acid, and arylmethoxycarbonyl groups such as benzyloxycarbonyl groups can be removed by, for example, hydrogenation of palladium on carbon or by processing with, for example, the Lewis acid of tri(trifluoroacetic acid) borane through catalyst.The suitable selectable blocking group for primary amino groups is, for example, the phthaloyl group that can be removed by, for example, processing with alkylamines such as dimethylaminopropylamine or processing with hydrazine.
[0573] Suitable protecting groups for hydroxyl groups are, for example, acyl groups, for example alkanoyl groups such as acetyl, aroyl groups such as benzoyl; or arylmethyl groups, for example benzyl. The deprotection conditions for the protecting groups above will necessarily vary with the selection of the protecting groups. Thus, for example, acyl groups such as alkanoyl groups or aroyl groups can be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide (e.g., lithium hydroxide, sodium hydroxide) or ammonia. Alternatively, arylmethyl groups such as benzyl groups can be removed, for example, by hydrogenation with a catalyst such as palladium on carbon.
[0574] Suitable protecting groups for carboxyl groups are, for example, esterifying groups, for example a methyl group or an ethyl group which can be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a tert-butyl group which can be removed, for example, by treatment with an acid such as an organic acid such as trifluoroacetic acid, or for example a benzyl group which can be removed, for example, by hydrogenation over a catalyst such as palladium on carbon.
[0575] Conveniently, the reaction of the compounds is carried out in the presence of a suitable solvent, which is preferably inert under the corresponding reaction conditions. Examples of suitable solvents include, but are not limited to, hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichloroethylene, 1,2-dichloroethane, tetrachloromethane, chloroform or dichloromethane; alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF), 2-methyltetrahydrofuran, cyclopentyl methyl ether (CPME), methyl tert-butyl ether (MTBE) or dioxane; glycol ethers such as ethylene glycol mono Methyl or monoethyl ether or ethylene glycol dimethyl ether (diglyme); ketones such as acetone, methyl isobutyl ketone (MIBK) or butanone; amides such as acetamide, dimethylacetamide, dimethylformamide (DMF) or N-methylpyrrolidone (NMP); nitriles such as acetonitrile; sulfoxides such as dimethyl sulfoxide (DMSO); nitro compounds such as nitromethane or nitrobenzene; esters such as ethyl acetate or methyl acetate, or mixtures of the solvents or mixtures with water.
[0576] The reaction temperature is suitably between about -100°C and 300°C, depending on the reaction steps and conditions used.
[0577] The reaction time of the present invention is usually in the range of a fraction of a minute and a few days. ...
[0578] In addition, by utilizing the procedures described herein, in combination with ordinary skills in the art, additional compounds of the present disclosure can be readily prepared. Those skilled in the art will readily appreciate that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds.
[0579] As will be appreciated by those skilled in the art of organic synthesis, the compounds of the present disclosure are easily available through a variety of synthetic routes, some of which are illustrated in the accompanying embodiments. The technician will easily recognize which reagent and reaction conditions to use, and how to apply and adjust them in any particular case (when necessary or useful), so as to obtain the compounds of the present disclosure. In addition, some of the compounds of the present disclosure can be easily synthesized by reacting other compounds of the present disclosure under suitable conditions, such as by converting a specific functional group present in the compounds of the present disclosure or its suitable precursor molecules into another functional group via application of standard synthesis methods such as reduction, oxidation, addition or substitution reactions; those methods are well known to the technician. Similarly, the technician will apply synthetic protection (or protective) groups when necessary or useful; suitable protection groups and methods for introducing and removing them are well known to the technicians in the field of chemical synthesis, and are described in more detail in, for example, PGM Wuts, TW Greene, "Greene's Protective Groups in Organic Synthesis", 4th edition (2006) (John Wiley & Sons).
[0580] The general route for preparing the compounds of the present application is depicted in Scheme 1 herein.
[0581] Solution 1
[0582]
[0583] Biological assays
[0584] The compounds, nucleic acid agents or conjugates designed, selected, prepared and / or optimized by the methods described above can be characterized after production using a variety of assays known to those skilled in the art to determine whether the compounds, nucleic acid agents or conjugates have biological activity. For example, compounds, nucleic acid agents or conjugates can be characterized by conventional assays (including but not limited to those described below) to determine whether they have the desired activity, such as target binding activity and / or specificity and / or stability.
[0585] In addition, high throughput screening can be used to speed up the analysis using such assays. Therefore, it may be possible to rapidly screen the molecules described herein for activity using techniques known in the art. General methods for performing high throughput screening are described, for example, in Devlin (1998) High Throughput Screening, Marcel Dekker; and U.S. Patent No. 5,763,263. High throughput assays can use one or more different assay techniques, including but not limited to those described below.
[0586] A variety of in vitro or in vivo biological assays may be applicable to detecting the effects of the compounds, nucleic acid agents or conjugates of the present disclosure. These in vitro or in vivo biological assays may include, but are not limited to, enzymatic activity assays, electrophoretic mobility shift assays, reporter gene assays, in vitro cell viability assays, and assays described herein.
[0587] In some embodiments, biological assays are described in the Examples herein.
[0588] Pharmaceutical composition
[0589] In some aspects, the present disclosure provides pharmaceutical compositions comprising a compound, nucleic acid agent, or conjugate of the present disclosure as an active ingredient.
[0590] As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
[0591] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be a fluid that reaches the degree of easy injection. It must be stable under manufacturing and storage conditions, and must be preserved against the contamination of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium comprising, for example, water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol and the like) and a suitable mixture thereof. For example, by using a coating such as lecithin, by maintaining the required particle size in the case of a dispersion and by using a surfactant, suitable fluidity can be maintained. The effect of preventing microorganisms can be achieved by a variety of antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal and the like. In many cases, isotonic agents, such as sugars, polyols such as mannitol and sorbitol and sodium chloride, will preferably be included in the composition. By including an agent that delays absorption in the composition, such as aluminum monostearate and gelatin, the extended absorption of injectable compositions can be achieved.
[0592] Sterile injectable solutions can be prepared by incorporating the active compound in the desired amount into a suitable solvent (having a combination of one or more components listed above as required), followed by filtration sterilization. Typically, dispersions are prepared by incorporating the active compound into a sterile vehicle comprising an alkaline dispersion medium and other components required from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation method is vacuum drying and freeze drying, which produce a powder of the active ingredient plus any additional desired ingredients from its previously sterile filtered solution.
[0593] The formulations of the present disclosure may be in the form of an aqueous solution comprising an aqueous vehicle. The aqueous vehicle component may comprise water and at least one pharmaceutically acceptable excipient. Suitable acceptable excipients include excipients selected from the group consisting of solubilizers, chelating agents, preservatives, tonicity agents, viscosity / suspending agents, buffers, and pH adjusters and mixtures thereof.
[0594] Any suitable solubilizing agent can be used. The example of solubilizing agent includes cyclodextrin, such as cyclodextrin selected from the group consisting of hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, random methylation-β-cyclodextrin, ethylation-β-cyclodextrin, triacetyl-β-cyclodextrin, peracetylation-β-cyclodextrin, carboxymethyl-β-cyclodextrin, hydroxyethyl-β-cyclodextrin, 2-hydroxy-3-(trimethylammonium)propyl-β-cyclodextrin, glucosyl-β-cyclodextrin, sulfated β-cyclodextrin (S-β-CD), maltosyl-β-cyclodextrin, β-cyclodextrin sulfobutyl ether, branched-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, random methylation-γ-cyclodextrin and trimethyl-γ-cyclodextrin and mixtures thereof.
[0595] Any suitable chelating agent may be used. Examples of suitable chelating agents include chelating agents selected from the group consisting of ethylenediaminetetraacetic acid and its metal salts, disodium edetate, trisodium edetate and tetrasodium edetate and mixtures thereof.
[0596] Any suitable preservative may be used. Examples of preservatives include preservatives selected from the group consisting of quaternary ammonium salts such as benzalkonium halide (preferably benzalkonium chloride), chlorhexidine gluconate, benzethonium chloride, cetylpyridinium chloride, benzyl bromide, phenylmercuric nitrate, phenylmercuric acetate, phenylmercuric neodecanoate, thimerosal, methylparaben, propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethylparaben, propylaminopropyl biguanide, and butylparaben, and mixtures thereof.
[0597] The aqueous vehicle may also include a tonicity agent to adjust tonicity (osmotic pressure). The tonicity agent may be selected from the group consisting of glycols (e.g., propylene glycol, diethylene glycol, triethylene glycol), glycerol, dextrose, glycerin, mannitol, potassium chloride and sodium chloride and mixtures thereof.
[0598] In order to adjust the formulation to an acceptable pH (typically about 5.0 to about 9.0, more preferably about 5.5 to about 8.5, particularly about 6.0 to about 8.5, about 7.0 to about 8.5, about 7.2 to about 7.7, about 7.1 to about 7.9 or about 7.5 to about 8.0 pH range), the formulation may contain a pH adjusting agent. The pH adjusting agent is typically an inorganic acid or metal hydroxide base selected from the group consisting of potassium hydroxide, sodium hydroxide and hydrochloric acid and mixtures thereof, and preferably sodium hydroxide and / or hydrochloric acid. These acidic and / or alkaline pH adjusting agents are added to adjust the formulation to a target acceptable pH range. Therefore, it may not be necessary to use both an acid and a base—depending on the formulation, adding one of the acid or base may be sufficient to bring the mixture to a desired pH range.
[0599] The aqueous vehicle may also contain a buffer to stabilize the pH. When used, the buffer is selected from the group consisting of phosphate buffers (such as sodium dihydrogen phosphate and disodium hydrogen phosphate), borate buffers (such as boric acid or a salt thereof, including disodium tetraborate), citrate buffers (such as citric acid or a salt thereof, including sodium citrate) and ε-aminocaproic acid and mixtures thereof.
[0600] According to a further aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound of the present disclosure as defined above, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in combination with a pharmaceutically acceptable diluent or carrier.
[0601] The compositions of the present disclosure may be in a form suitable for oral use (e.g., as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), topical use (e.g., as creams, ointments, gels, or aqueous or oily solutions or suspensions), administration by inhalation (e.g., as finely divided powders or liquid aerosols), administration by insufflation (e.g., as finely divided powders), or parenteral administration (e.g., as sterile aqueous or oily solutions for intravenous, subcutaneous, intramuscular or intraperitoneal administration or as suppositories for rectal administration).
[0602] The compositions of the present disclosure can be obtained by conventional procedures using conventional pharmaceutical excipients well known in the art. Thus, compositions intended for oral use may contain, for example, one or more coloring agents, sweeteners, flavoring agents and / or preservatives.
[0603] An effective amount of a compound of the disclosure for use in therapy is an amount sufficient to treat or prevent, slow the progression of, and / or reduce the symptoms associated with an inflammasome-associated condition mentioned herein.
[0604] An effective amount of a compound of the disclosure for use in therapy is an amount sufficient to treat, slow the progression of, and / or reduce the symptoms associated with an inflammasome-associated condition mentioned herein.
[0605] According to well-known medical principles, the size of the dose of the compound of formula (I) or formula (II) for therapeutic or prophylactic purposes will naturally vary depending on the nature and severity of the condition, the age and sex of the animal or patient and the route of administration.
[0606] How to use
[0607] In some aspects, the disclosure provides a method of modulating (eg, reducing or eliminating) expression of a target gene in a subject, the method comprising administering a conjugate of the disclosure to the subject.
[0608] In some aspects, the disclosure provides a method of modulating (eg, reducing or eliminating) the expression of a target gene in a cell or tissue of a subject, the method comprising administering a conjugate of the disclosure to the subject.
[0609] In some aspects, the present disclosure provides a method of delivering a nucleic acid agent to a subject, the method comprising administering a conjugate of the present disclosure to the subject.
[0610] In some aspects, the present disclosure provides a method of treating or preventing a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a conjugate of the present disclosure.
[0611] In some aspects, the disclosure provides conjugates of the disclosure for use in modulating (eg, reducing or eliminating) expression of a target gene in a subject.
[0612] In some aspects, the disclosure provides conjugates of the disclosure for use in modulating (eg, reducing or eliminating) expression of a target gene in a cell or tissue of a subject.
[0613] In some aspects, the present disclosure provides conjugates of the present disclosure for use in delivering a nucleic acid agent to a subject.
[0614] In some aspects, the present disclosure provides a conjugate of the present disclosure for use in treating or preventing a disease in a subject in need thereof.
[0615] In some aspects, the disclosure provides use of a conjugate of the disclosure in the manufacture of a medicament for modulating (eg, reducing or eliminating) expression of a target gene in a subject.
[0616] In some aspects, the disclosure provides use of a conjugate of the disclosure in the manufacture of a medicament for modulating (eg, reducing or eliminating) expression of a target gene in a cell or tissue of a subject.
[0617] In some aspects, the disclosure provides use of a conjugate of the disclosure in the manufacture of a medicament for delivering a nucleic acid agent to a subject.
[0618] In some aspects, the present disclosure provides use of a conjugate of the present disclosure in the manufacture of a medicament for treating or preventing a disease in a subject in need thereof.
[0619] In some embodiments, the subject is a cell.
[0620] In some embodiments, the subject is a tissue.
[0621] In some embodiments, the subject is a human.
[0622] In some embodiments, the target gene is factor VII, Eg5, PCSK9, TPX2, apoB, SAA, TTR, HBV, HCV, RSV, PDGFβ gene, Erb-B gene, Src gene, CRK gene, GRB2 gene, RAS gene, MEKK gene, JNK gene, RAF gene, Erk1 / 2 gene, PCNA (p21) gene, MYB gene, JUN gene, FOS gene, BCL-2 gene, cyclin D gene, V EGF gene, EGFR gene, cyclin A gene, cyclin E gene, WNT-1 gene, β-catenin gene, c-MET gene, PKC gene, NFKB gene, STAT3 gene, survivin gene, Her2 / Neu gene, topoisomerase I gene, topoisomerase IIα gene, p73 gene, p21 (WAF1 / CIP1) gene, p27 (KIP1) gene, PPM1D gene, RAS gene, caveolin I gene, MIB I gene, MTAI gene, M68 gene, tumor suppressor gene mutation, p53 tumor suppressor gene, LDHA or any combination thereof.
[0623] In some embodiments, the disease is characterized by undesired expression of a target gene.
[0624] In some embodiments, administration results in reduction or elimination of expression of the target gene in the subject.
[0625] In some embodiments, the disease is a viral infection, such as an HCV, HBV, HPV, HSV, or HIV infection.
[0626] In some embodiments, the disease is cancer.
[0627] In some embodiments, the cancer is biliary tract cancer, bladder cancer, transitional cell carcinoma, urothelial carcinoma, brain cancer, glioma, astrocytoma, breast cancer, metaplastic carcinoma, cervical cancer, cervical squamous cell carcinoma, rectal cancer, colorectal cancer, colon cancer, hereditary nonpolyposis colorectal cancer, colorectal adenocarcinoma, gastrointestinal stromal tumor (GIST), endometrial cancer, endometrial stromal sarcoma, esophageal cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, ocular melanoma, uveal melanoma, gallbladder cancer, gallbladder adenocarcinoma, renal cell carcinoma, clear cell renal cell carcinoma, Wilms tumor, leukemia, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), liver cancer (liver cancer, liver carcinoma, hepatoma, hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, lung cancer, non-small cell lung cancer (NSCLC), mesothelioma, B-cell lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, T-cell lymphoma, precursor T-lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma, multiple myeloma, nasopharyngeal carcinoma (NPC), neuroblastoma, oropharyngeal cancer, oral squamous cell carcinoma, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, pseudopapillary tumor, acinar cell carcinoma, prostate cancer, prostate adenocarcinoma, skin cancer, melanoma, malignant melanoma, cutaneous melanoma, small intestine cancer, stomach cancer, gastric carcinoma, gastrointestinal stromal tumor (GIST), uterine cancer or uterine sarcoma.
[0628] In some embodiments, the cancer is liver cancer, hepatoepithelial cancer, hepatoma, hepatocellular carcinoma, cholangiocarcinoma, or hepatoblastoma.
[0629] In some embodiments, the disease is a proliferative disease, an inflammatory disease, an autoimmune disease, a neurological disease, an ocular disease, a respiratory disease, a metabolic disease, a skin disease, an auditory disease, a liver disease, a kidney disease, or an infectious disease. In some embodiments, the disease is a liver disease.
[0630] definition
[0631] Unless stated otherwise, the following terms used in the specification and claims have the following meanings set forth below.
[0632] Do not wish to be limited by this statement, it should be understood that although various options of variables are described herein, the present disclosure is intended to cover operable embodiments with combinations of these options. The present disclosure can be interpreted to exclude inoperable embodiments caused by certain combinations of these options.
[0633] As used herein, "alkyl", "C1, C2, C3, C4, C5 or C6 alkyl" or "C1-C6 alkyl" is intended to include C1, C2, C3, C4, C5 or C6 straight chain (linear) saturated aliphatic hydrocarbon groups and C3, C4, C5 or C6 branched saturated aliphatic hydrocarbon groups. For example, C1-C6 alkyl is intended to include C1, C2, C3, C4, C5 or C6 alkyl groups. Examples of alkyl groups include moieties having from one to six carbon atoms, such as, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl or n-hexyl. In some embodiments, a straight chain or branched chain alkyl has six or fewer carbon atoms (e.g., C1-C6 for a straight chain and C3-C6 for a branched chain), and in another embodiment, a straight chain or branched chain alkyl has four or fewer carbon atoms.
[0634] As used herein, the term "optionally substituted alkyl" refers to unsubstituted alkyl or alkyl groups in which the specified substituents replace one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
[0635] As used herein, the term "alkenyl" includes unsaturated aliphatic groups similar to the alkyl described above in length and possible substitution but containing at least one double bond. For example, the term "alkenyl" includes straight chain alkenyl groups (e.g., vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl) and branched alkenyl groups. In some embodiments, straight or branched alkenyl groups have six or less carbon atoms (e.g., C2-C6 for straight chain, C3-C6 for branched chain) in its main chain. The term "C2-C6" includes alkenyl groups containing two to six carbon atoms. The term "C3-C6" includes alkenyl groups containing three to six carbon atoms.
[0636] As used herein, the term "optionally substituted alkenyl" refers to unsubstituted alkenyl or alkenyl groups in which specified substituents replace one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonic acid, sulfamoyl, sulfonylamino, nitro, trifluoromethyl, cyano, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
[0637] As used herein, the term "alkynyl" includes an unsaturated aliphatic group similar to the alkyl described above in length and possible substitution but containing at least one triple bond. For example, "alkynyl" includes a straight chain alkynyl group (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl) and a branched chain alkynyl group. In some embodiments, a straight chain or branched chain alkynyl group has six or less carbon atoms (e.g., C2-C6 for a straight chain and C3-C6 for a branched chain) in its main chain. The term "C2-C6" includes an alkynyl group containing two to six carbon atoms. The term "C3-C6" includes an alkynyl group containing three to six carbon atoms. As used herein, "C2-C6 alkenylene joints" or "C2-C6 alkynylene joints" are intended to include C2, C3, C4, C5 or C6 chain (linear or branched) divalent unsaturated aliphatic hydrocarbon groups. For example, a C2-C6 alkenylene linker is intended to include C2, C3, C4, C5, and C6 alkenylene linker groups.
[0638] As used herein, the term "optionally substituted alkynyl" refers to unsubstituted alkynyl groups or alkynyl groups in which specified substituents replace one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonic acid, sulfamoyl, sulfonylamino, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
[0639] Other optionally substituted parts (such as optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl) include both unsubstituted parts and parts with one or more specified substituents. For example, substituted heterocycloalkyl includes those substituted by one or more alkyl groups, such as 2,2,6,6-tetramethyl-piperidinyl and 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridinyl.
[0640] As used herein, the term "cycloalkyl" refers to a cycloalkyl group having 3 to 30 carbon atoms (e.g., C3-C 12 、C3-C 10 The saturated or partially unsaturated hydrocarbon monocyclic or polycyclic (e.g., condensed, bridged or spiro) system of C3-C8 (C3-C8). Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,2,3,4-tetrahydronaphthyl and adamantyl. In the case of polycyclic cycloalkyl, only one ring in the cycloalkyl needs to be non-aromatic.
[0641] As used herein, the term "heterocycloalkyl" refers to a saturated or partially unsaturated 3-8 membered monocyclic, 7-12 membered bicyclic (fused, bridged or spiro) or 11-14 membered tricyclic ring system (fused, bridged or spiro) having one or more heteroatoms (such as O, N, S, P or Se, for example, 1, or 1-2, or 1-3, or 1-4, or 1-5, or 1-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur, or for example, 1, 2, 3, 4, 5, or 6 heteroatoms), unless otherwise specified. Examples of heterocycloalkyl groups include, but are not limited to, piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, tetrahydrofuranyl, isoindolyl, indolyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, oxirane, azetidinyl, oxetanyl, thietanyl, 1,2,3,6-tetrahydropyridinyl, tetrahydropyranyl, dihydropyranyl, pyranyl, morpholinyl, tetrahydrothiopyranyl, 1,4-diazepanyl, 1,4-oxepanyl, 2-oxa- 5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-oxa-6-azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 1,4-dioxa-8-azaspiro[4.5]decyl, 1,4-dioxaspiro[4.5]decyl, 1-oxaspiro[4.5]decyl, 1-azaspiro[4.5]decyl, 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-yl, 7'H-spiro[cyclohexane-1,5 '-furo[3,4-b]pyridinyl]-yl, 3'H-spiro[cyclohexane-1,1'-furo[3,4-c]pyridinyl]-yl, 3-azabicyclo[3.1.0]hexyl, 3-azabicyclo[3.1.0]hex-3-yl, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazolyl, 3,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidinyl, 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridinyl, 5,6,7 ,8-tetrahydropyrido[4,3-d]pyrimidinyl, 2-azaspiro[3.3]heptyl, 2-methyl-2-azaspiro[3.3]heptyl, 2-azaspiro[3.5]nonyl, 2-methyl-2-azaspiro[3.5]nonyl, 2-azaspiro[4.5]decyl, 2-methyl-2-azaspiro[4.5]decyl, 2-oxa-azaspiro[3.4]octyl, 2-oxa-azaspiro[3.4]octan-6-yl, 5,6-dihydro-4H-cyclopenta[b]thienyl, etc. In the case of polycyclic heterocycloalkyl, only one ring in the heterocycloalkyl needs to be non-aromatic (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl).
[0642] As used herein, the term "aryl" includes groups having aromaticity (including "conjugated") or polycyclic systems having one or more aromatic rings, and does not contain any heteroatoms in the ring structure. The term aryl includes both monovalent species and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, etc. Conveniently, aryl is phenyl.
[0643] As used herein, the term "heteroaryl" is intended to include a stable 5-, 6-, or 7-membered monocyclic or 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic aromatic heterocyclic ring consisting of carbon atoms and one or more heteroatoms (e.g., 1, or 1-2, or 1-3, or 1-4, or 1-5, or 1-6 heteroatoms, or such as 1, 2, 3, 4, 5, or 6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The nitrogen atom may be substituted or unsubstituted (i.e., N or NR, where R is H or other substituents, as defined). The nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., N→O and S(O)). P , wherein p=1 or 2). It should be noted that the total number of S atoms and O atoms in the aromatic heterocycle is no more than 1. Examples of heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, pyrimidine, etc. The heteroaryl group can also be fused or bridged with a non-aromatic alicyclic or heterocyclic ring to form a polycyclic system (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl). In some embodiments, the heteroaryl is thienyl or benzothienyl. In some embodiments, the heteroaryl is thienyl. In some embodiments, the heteroaryl is benzothienyl.
[0644] In addition, the terms "aryl" and "heteroaryl" include polycyclic aromatic and heteroaryl groups, for example, tricyclic, bicyclic, for example, naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzimidazole, benzothiophene, quinoline, isoquinoline, naphthyridine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.
[0645] The cycloalkyl, heterocycloalkyl, aryl or heteroaryl rings may be substituted at one or more ring positions (e.g., a ring-forming carbon or heteroatom such as N) with substituents such as alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, Aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonic acid, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or aromatic or heteroaromatic moiety. Aryl and heteroaryl groups can also be fused or bridged with non-aromatic alicyclic or heterocyclic rings to form a polycyclic system (e.g., tetralin, methylenedioxyphenyl, such as benzo[d][1,3]dioxol-5-yl).
[0646] As used herein, the term "substituted" means that any one or more hydrogen atoms on the designated atom are replaced by a selection from a designated group, provided that the normal valence of the designated atom is not exceeded, and the substitution produces a stable compound. When the substituent is an oxo or keto (i.e., =O), then 2 hydrogen atoms on the atom are replaced. There is no keto substituent on the aromatic moiety. As used herein, a ring double bond is a double bond (e.g., C=C, C=N or N=N) formed between two adjacent ring atoms. "Stable compound" and "stable structure" are intended to be robust enough to survive separation from a reaction mixture to a useful degree of purity and to be formulated as an effective therapeutic agent.
[0647] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom in the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such formula. Combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.
[0648] When any variable (e.g., R) occurs more than one time in any constituent or formula for a compound, the definition of the variable (e.g., R) at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R moieties, then the group can be optionally substituted with up to two R moieties, and R at each occurrence is selected independently of the definition of R. In addition, combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.
[0649] As used herein, the term "hydroxy" or "hydroxyl" includes a group having -OH or -O - The group.
[0650] As used herein, the term "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine.
[0651] The term "haloalkyl" or "haloalkoxy" refers to an alkyl or alkoxy group substituted with one or more halogen atoms.
[0652] As used herein, the term "optionally substituted haloalkyl" refers to unsubstituted haloalkyl or substituted haloalkyl groups with designated substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonic acid, sulfamoyl, sulfonylamino, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
[0653] As used herein, the term "alkoxy" or "alkoxyl" includes substituted and unsubstituted alkyl groups, alkenyl groups, and alkynyl groups covalently attached to an oxygen atom. Examples of alkoxy groups or alkoxyl radicals include, but are not limited to, methoxy groups, ethoxy groups, isopropoxy groups, propoxy groups, butoxy groups, and pentoxy groups. Examples of substituted alkoxy groups include halogenated alkoxy groups. The alkoxy group may be substituted with groups such as alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonic acid, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Examples of halogen-substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, and trichloromethoxy.
[0654] As used herein, the expressions "one or more of A, B or C", "one or more A, B or C", "one or more of A, B and C", "one or more A, B and C", "selected from the group consisting of A, B and C", "selected from A, B and C", etc. are used interchangeably and all refer to selection from the group consisting of A, B and / or C, that is, one or more A, one or more B, one or more C or any combination thereof, unless otherwise indicated.
[0655] It should be understood that the present disclosure provides methods for synthesizing the compounds, nucleic acid agents, and conjugates described herein. The present disclosure also provides detailed methods for synthesizing a variety of disclosed compounds, nucleic acid agents, and conjugates according to the schemes herein and the schemes shown in the Examples.
[0656] It should be understood that throughout the description, when a composition is described as having, including or comprising a particular component, it is contemplated that the composition also consists essentially of or consists of said component. Similarly, when a method or process is described as having, including or comprising a particular process step, the process also consists essentially of or consists of said processing step. In addition, it should be understood that the order of steps or the order in which certain operations are performed is unimportant as long as the present invention remains operable. In addition, two or more steps or operations may be performed simultaneously.
[0657] It should be understood that the synthetic methods of the present disclosure can tolerate a variety of functional groups and therefore can use a variety of substituted starting materials. The methods generally provide the desired final compound at or near the end of the entire method, although in some cases it may be desirable to further convert the compound into its pharmaceutically acceptable salt.
[0658] It should be understood that the compounds, nucleic acid agents and conjugates of the present disclosure can be prepared in various ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates by utilizing standard synthetic methods and procedures known to those skilled in the art or which will be apparent to the skilled artisan in light of the teachings herein. Standard synthetic methods and procedures for preparing organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or standard textbooks in the field. Although not limited to any one or a few sources, classic textbooks such as Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th Edition, John Wiley & Sons: New York, 2001; Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons: New York, 1999; R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for organic Synthesis, John Wiley and Sons (1995), which are incorporated herein by reference, are useful and recognized reference textbooks on organic synthesis known to those skilled in the art.
[0659] Those of ordinary skill in the art will note that during the reaction sequence and synthesis scheme described herein, the order of some steps can be changed, such as introducing and removing blocking groups. Those of ordinary skill in the art will recognize that some groups may need to be protected from the influence of reaction conditions via the use of blocking groups. Blocking groups can also be used to distinguish similar functional groups in molecules. The list of blocking groups and how to introduce and remove these groups can be found in Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, the 3rd edition, John Wiley & Sons: New York, 1999.
[0660] It should be understood that, unless otherwise stated, any description of a method of treatment or prevention includes the use of compounds, nucleic acid agents and conjugates to provide such treatment or prevention as described herein. It should also be understood that, unless otherwise stated, any description of a method of treatment or prevention includes the use of compounds, nucleic acid agents and conjugates to prepare a medicament for treating or preventing such a condition. Treatment or prevention includes treatment or prevention of humans or non-human animals, including rodents and other disease models.
[0661] It should be understood that, unless otherwise stated, any description of methods of treatment includes the use of compounds, nucleic acid agents and conjugates to provide such treatment as described herein. It should also be understood that, unless otherwise stated, any description of methods of treatment includes the use of compounds, nucleic acid agents and conjugates to prepare a medicament for treating such a condition. Treatment includes treatment of humans or non-human animals, including rodents and other disease models.
[0662] As used herein, the term "subject" is interchangeable with the term "subject in need", both of which refer to subjects with a disease or with an increased risk of developing a disease. "Subjects" include mammals. The mammal can be, for example, a human or an appropriate non-human mammal, such as a primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep or pig. The subject can also be a bird or poultry. In some embodiments, the mammal is a human. A subject in need can be a subject that has previously been diagnosed or identified as having a disease or disorder disclosed herein. A subject in need can also be a subject suffering from a disease or disorder disclosed herein. Alternatively, a subject in need can be a subject with an increased risk of developing such a disease or disorder relative to the general population (i.e., a subject that is prone to developing such a disorder relative to the general population). A subject in need can suffer from a refractory or resistant disease or disorder disclosed herein (i.e., a disease or disorder disclosed herein that does not respond or has not yet responded to treatment). The subject may be resistant at the beginning of treatment, or may become resistant during treatment. In some embodiments, the subject in need thereof has received all known effective therapies for the diseases or disorders disclosed herein, but all have failed. In some embodiments, the subject in need thereof has received at least one prior therapy.
[0663] As used herein, the terms "treating" or "treatment" describe the management and care of a patient for the purpose of combating a disease, condition, or disorder, and include the administration of a compound of the disclosure, or a pharmaceutically acceptable salt, polymorph, or solvate thereof, to alleviate the symptoms or complications of, or to eliminate, a disease, condition, or disorder. The term "treatment" may also include treatment of cells in vitro or in animal models. It should be understood that references to "treating" or "treatment" include the alleviation of established symptoms of a condition. Thus, "treating" or "treatment" of a state, disorder or condition includes: (1) preventing or delaying the development of clinical symptoms of a state, disorder or condition in a human who may be suffering from or susceptible to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the disease or its recurrence (in the case of maintenance treatment) or the development of at least one clinical or subclinical symptom thereof; or (3) relieving or attenuating the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
[0664] It will be appreciated that the compounds, nucleic acid agents and conjugates of the present disclosure, or pharmaceutically acceptable salts, polymorphs or solvates thereof, can also or may also be used to prevent related diseases, conditions or disorders, or to identify suitable candidates for such purposes.
[0665] As used herein, the terms "preventing," "prevent," or "protecting against" describe the reduction or elimination of the onset of symptoms or complications of such a disease, condition, or disorder.
[0666] It will be understood that the present disclosure also provides pharmaceutical compositions comprising any compound, nucleic acid agent, or conjugate described herein in combination with at least one pharmaceutically acceptable excipient or carrier.
[0667] As used herein, the term "pharmaceutical composition" is a preparation in a form suitable for administration to a subject comprising a compound, nucleic acid agent or conjugate of the present disclosure. In some embodiments, the pharmaceutical composition is in bulk dosage form or in unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a single pump on a capsule, IV bag, tablet, aerosol inhaler, or a vial. The amount of the active ingredient (e.g., a preparation of a disclosed compound or its salt, hydrate, solvate or isomer) in the composition of a unit dose is an effective amount and changes according to the specific treatment involved. It will be appreciated by those skilled in the art that it is sometimes necessary to make conventional changes to the dosage according to the age and condition of the patient. The dosage will also depend on the route of administration. It is envisioned that a variety of routes, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, buccal, sublingual, intrapleural, intrathecal, intranasal and similar routes. Dosage forms for topical or transdermal administration of the compounds of the present disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. In some embodiments, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and with any preservatives, buffers or propellants required.
[0668] As used herein, the term "pharmaceutically acceptable" refers to those compounds, nucleic acid agents, conjugates, anions, cations, materials, compositions, carriers and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0669] As used herein, the term "pharmaceutically acceptable excipient" means an excipient useful in preparing a pharmaceutical composition that is generally safe, non-toxic and not biologically or otherwise undesirable, and includes excipients acceptable for veterinary use and human pharmaceutical use. "Pharmaceutically acceptable excipient" as used in this specification and claims includes one and more than one such excipient.
[0670] It should be understood that the pharmaceutical composition of the present disclosure is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral administration, such as intravenous administration, intradermal administration, subcutaneous administration, oral (e.g., ingestion) administration, inhalation administration, transdermal (topical) administration, and transmucosal administration. Solutions or suspensions for parenteral, intradermal, or subcutaneous applications may include the following components: sterile diluents, such as water for injection, saline solutions, non-volatile oils, polyethylene glycols, glycerol, propylene glycol, or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates, or phosphates; and agents for adjusting tension, such as sodium chloride or dextrose. pH can be adjusted with acids or bases such as hydrochloric acid or sodium hydroxide. Parenteral products may be encapsulated in ampoules, disposable syringes, or multidose vials made of glass or plastic.
[0671] It should be understood that the compounds or pharmaceutical compositions of the present disclosure can be applied to the subject with many well-known methods currently used for chemotherapy. For example, the compounds of the present disclosure can be injected into the bloodstream or body cavity, or orally or applied through the skin with a patch. The selected dosage should be sufficient to constitute an effective treatment, but not so high as to cause unacceptable side effects. The patient's disease condition (e.g., disease or disorder disclosed herein) and healthy state should preferably be closely monitored during treatment and within a reasonable time period after treatment.
[0672] As used herein, the term "therapeutically effective amount" refers to an amount of a pharmaceutical agent that is used to treat, alleviate or prevent an established disease or condition, or that exhibits a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend on the subject's weight, size, and health; the nature and extent of the condition; and the therapeutic agent or combination of therapeutic agents selected for administration. The therapeutically effective amount for a given situation can be determined by routine experimentation within the skill and judgment of the clinician.
[0673] As used herein, the term "therapeutically effective amount" refers to an amount of a pharmaceutical agent that is used to treat or alleviate an established disease or condition, or that exhibits a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend on the subject's weight, size, and health; the nature and extent of the condition; and the therapeutic agent or combination of therapeutic agents selected for administration. The therapeutically effective amount for a given situation can be determined by routine experimentation within the skill and judgment of the clinician.
[0674] It will be appreciated that for any compound, the therapeutically effective amount can be estimated initially in, for example, cell culture assays of neoplastic cells or in animal models (usually rats, mice, rabbits, dogs or pigs). Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes for human administration. Therapeutic / prophylactic efficacy and toxicity can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, ED 50 (the dose that is therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio LD 50 / ED 50 Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage may vary within this range depending on the dosage form employed, sensitivity of the patient, and the route of administration.
[0675] Dosage and administration are adjusted to provide sufficient levels of active agent or to maintain the desired effect. Factors that may be considered include the severity of the disease state, the general health of the subject, the age, weight and sex of the subject, diet, time and frequency of administration, drug combination, reaction sensitivity and tolerance / response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, weekly or biweekly, depending on the half-life and clearance rate of the particular formulation.
[0676] The pharmaceutical composition comprising the active compound of the present disclosure can be manufactured in a generally known manner, for example by means of conventional mixing processes, dissolution processes, granulation processes, dragee manufacturing (dragee-making) processes, levigating (levigating) processes, emulsification processes, encapsulation processes, embedding processes or freeze-drying processes. The pharmaceutical composition can be prepared in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and / or adjuvants, and the pharmaceutically acceptable carriers help to process the active compound into a product that can be used pharmaceutically. Of course, the appropriate formulation depends on the selected route of administration.
[0677] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM(BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be a fluid that reaches the degree of easy injection. It must be stable under manufacturing and storage conditions, and must be preserved against the contamination of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium comprising, for example, water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol and the like) and a suitable mixture thereof. For example, by using a coating such as lecithin, by maintaining the required particle size in the case of a dispersion and by using a surfactant, suitable fluidity can be maintained. The effect of preventing microorganisms can be achieved by a variety of antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal and the like. In many cases, isotonic agents, such as sugars, polyols such as mannitol and sorbitol and sodium chloride, will preferably be included in the composition. By including an agent that delays absorption in the composition, such as aluminum monostearate and gelatin, the extended absorption of injectable compositions can be achieved.
[0678] Sterile injectable solutions can be prepared by incorporating the active compound in the desired amount into a suitable solvent (having a combination of one or more components listed above as required), followed by filtration sterilization. Typically, dispersions are prepared by incorporating the active compound into a sterile vehicle comprising an alkaline dispersion medium and other components required from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation method is vacuum drying and freeze drying, which produce a powder of the active ingredient plus any additional desired ingredients from its previously sterile filtered solution.
[0679] Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be encapsulated in a gelatin capsule or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with an excipient and used in the form of a tablet, lozenge or capsule. Oral compositions can also be prepared using a fluid carrier to be used as a mouthwash, wherein the compound in the fluid carrier is orally applied and gargled (swish) and spit out or swallowed. A pharmaceutically compatible binding agent (binding agent) and / or adjuvant material (adjuvant material) can be included as a part of the composition. Tablets, pills, capsules, lozenges and the like may contain any of the following ingredients or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose; a disintegrant such as alginic acid, Primogel or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetener such as sucrose or saccharin; or a flavoring such as peppermint, methyl salicylate, orange flavoring.
[0680] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressured container or dispenser which contains a suitable propellant, eg, a gas such as carbon dioxide, or a nebulizer.
[0681] For intranasal administration, the compound is delivered as a solution or solid formulation. In some embodiments, the compound is delivered as a solution as a mist, drops, or swab. In some embodiments, the compound is delivered as a powder. In some embodiments, the compound is included in a kit that also includes an intranasal applicator.
[0682] Systemic administration can also be by transmucosal means or transdermal means. For transmucosal or transdermal administration, a penetrant suitable for the barrier to be penetrated is used in the formulation. Such penetrants are generally known in the art, and include, for example, detergents, bile salts, and fusidic acid derivatives for transmucosal administration. Transmucosal administration can be achieved by using nasal sprays or suppositories. For transdermal administration, as generally known in the art, the active compound is formulated into an ointment, salves, gels, or creams.
[0683] The active compound can be prepared with a pharmaceutically acceptable carrier that will protect the compound from rapid elimination from the body, such as a controlled release formulation, including implants and microcapsule delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such preparations will be apparent to those skilled in the art. Materials can also be commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeting infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
[0684] It is particularly advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to physically discrete units suitable as unit dosages for the subject to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier. The specifications for the dosage unit forms used in the present disclosure are dictated by and directly dependent on the unique characteristics of the active compound and the specific therapeutic effect to be achieved.
[0685] In therapeutic applications, the dosage of the pharmaceutical composition used according to the present disclosure depends on the dosage, the age, weight and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the therapy, as well as other factors affecting the selected dosage. Generally, the dosage should be sufficient to cause the symptoms of the disease or disorder disclosed herein to slow down and preferably eliminate the symptoms of the disease or disorder disclosed herein, and also preferably cause the complete disappearance of the disease or disorder. The dosage can be in the range of from about 0.01 mg / kg per day to about 5000 mg / kg per day. The effective amount of a medicament is the amount of an objectively identifiable improvement as indicated by a clinician or other qualified observer. The improvement in survival and growth indicates disappearance. As used herein, the term "dosage effective manner" refers to the amount of an active compound that produces a desired biological effect in a subject or cell.
[0686] It will be appreciated that the pharmaceutical compositions may be included in a container, pack, or dispenser together with instructions for administration.
[0687] It should be understood that for compounds, nucleic acid agents or conjugates of the present disclosure that are capable of further forming salts, all such forms are also contemplated to be within the scope of the claimed disclosure.
[0688] As used herein, the term "pharmaceutically acceptable salt" refers to a derivative of a compound of the present disclosure in which the parent compound is modified by preparing an acid or base salt thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines, alkali metal or organic salts of acidic residues such as carboxylic acids, and the like. Pharmaceutically acceptable salts include, for example, conventional non-toxic salts or quaternary ammonium salts of the parent compound formed from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include, but are not limited to, salts derived from inorganic and organic acids selected from 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, glycollyarsanilic acid, hexylresorcinic acid, hyd rabamic), hydrobromic, hydrochloric, hydroiodic, hydroxymaleic, hydroxynaphthoic, isethionic, lactic, lactobionic, laurylsulfonic, maleic, malic, mandelic, methanesulfonic, naphthalenesulfonic, nitric, oxalic, pamoic, pantothenic, phenylacetic, phosphoric, polygalacturonic, propionic, salicylic, stearic, basic acetic, succinic, sulfamic, sulfanilic, sulfuric, tannic, tartaric, toluenesulfonic, and common amino acids such as glycine, alanine, phenylalanine, arginine, etc.
[0689] In some embodiments, the pharmaceutically acceptable salt is a sodium salt, potassium salt, calcium salt, magnesium salt, diethylamine salt, choline salt, meglumine salt, benzathine penicillin salt, tromethamine salt, ammonium salt, arginine salt, or lysine salt.
[0690] Other examples of pharmaceutically acceptable salts include salts of hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, muconic acid, and similar acids. The present disclosure also encompasses salts formed when acidic protons present in the parent compound are replaced by metal ions, such as alkali metal ions, alkaline earth metal ions, or aluminum ions; or coordinated with organic bases such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. In salt form, it is understood that the ratio of compound to cation or anion in the salt can be 1:1, or any ratio other than 1:1, such as 3:1, 2:1, 1:2, or 1:3.
[0691] It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same salt.
[0692] The compound or its pharmaceutically acceptable salt is administered orally, nasally, transdermally, pulmonary, inhaled, buccal, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, intrarectally, intrapleurally, intrathecally, and parenterally. In some embodiments, the compound is administered orally. Those skilled in the art will recognize the advantages of certain routes of administration.
[0693] The dosage regimen utilizing the compound is selected based on a variety of factors including: the type, species, age, weight, sex, and medical condition of the patient; the severity of the condition to be treated; the route of administration; the patient's renal and liver function; and the specific compound or salt thereof employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counteract, or arrest the progression of the condition. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to counteract or arrest the progression of the condition.
[0694] Techniques for preparing and administering the disclosed compounds of the present disclosure can be found in Remington: the Science and Practice of Pharmacy, 19th edition, Mack Publishing Co., Easton, PA (1995). In an embodiment, the compounds described herein and pharmaceutically acceptable salts thereof are used in combination with a pharmaceutically acceptable carrier or diluent in a pharmaceutical preparation. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous organic solutions. The compound will be present in such a pharmaceutical composition in an amount sufficient to provide the desired dose within the range described herein.
[0695] Unless otherwise indicated, all percentages and ratios used herein are by weight. Other features and advantages of the present disclosure are apparent from different examples. The examples provided illustrate different components and methods that can be used to practice the present disclosure. These examples do not limit the disclosure claimed. Based on the present disclosure, those skilled in the art can identify and adopt other components and methods that can be used to practice the present disclosure.
[0696] In the synthetic schemes described herein, for simplicity, compounds may be drawn with one particular configuration. Such a particular configuration should not be construed as limiting the disclosure to one or another isomer, tautomer, regioisomer or stereoisomer, nor to exclude mixtures of isomers, tautomers, regioisomers or stereoisomers; however, it should be understood that a particular isomer, tautomer, regioisomer or stereoisomer may have a higher level of activity than another isomer, tautomer, regioisomer or stereoisomer.
[0697] All publications and patent documents cited herein are incorporated herein by reference, as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. The reference to publications and patent documents is not intended as an admission that any one is relevant prior art, nor does it constitute any admission of its content or date. The present invention has now been described by way of written description, and those skilled in the art will recognize that the present invention can be practiced in a variety of embodiments, and the above description and the following examples are for illustrative purposes and are not intended to limit the appended claims.
[0698] Exemplary embodiments
[0699] Exemplary embodiment No. 1. A compound of formula (I) or formula (II):
[0700]
[0701] or a pharmaceutically acceptable salt thereof, wherein:
[0702] B is H or a nucleobase moiety;
[0703] X is H, halogen or -OR X ;
[0704] R X is H, C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 Aryl), wherein C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 Aryl) is optionally substituted with one or more R X a replace;
[0705] Each R X a is independently halogen, C1-C6 alkyl or -O-(C1-C6 alkyl), wherein C1-C6 alkyl or -O-(C1-C6 alkyl) is optionally substituted with one or more halogen;
[0706] Y is H, C1-C6 alkyl optionally substituted by one or more halogens, -P(R Y )2、-P(OR Y )(N(R Y )2)-P(=O)(OR Y )R Y 、-P(=S)(OR Y )R Y 、-P(=O)(SR Y )R Y ,-P(=S)(SR Y )R Y 、-P(=O)(OR Y)2、-P(=S)(OR Y )2, -P(=O)(SR Y )2, -P(=S)(SR Y )2 or a hydroxyl protecting group;
[0707] Each R Y is independently H or C1-C6 alkyl optionally substituted by one or more halogen or cyano;
[0708] Z is -P(R Z )2、-P(OR Z )(N(R Z )2)-P(=O)(OR Z )R Z 、-P(=S)(OR Z )R Z 、-P(=O)(SR Z )R Z ,-P(=S)(SR Z )R Z 、-P(=O)(OR Z )2、-P(=S)(OR Z )2, -P(=O)(SR Z )2 or -P(=S)(SR Z )2;
[0709] Each R Z is independently H or C1-C6 alkyl optionally substituted by one or more halogen or cyano;
[0710] R 1 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens;
[0711] R 2 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens;
[0712] R 3 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens;
[0713] R 4 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens;
[0714] Indicates single or double bonds; and
[0715] Each R 6 is independently H, halogen or C1-C6 alkyl optionally substituted with one or more halogens.
[0716] Exemplary embodiment No. 2. A nucleic acid agent or a pharmaceutically acceptable salt thereof, wherein the nucleic acid agent comprises:
[0717] An oligonucleotide comprising one or two 5'-terminal units, wherein each 5'-terminal unit is independently:
[0718]
[0719] The variables B and R 1 , R 2 , R 3 , R 4 , R 6 , X, and Z are described herein, and ## indicates an attachment to the rest of the oligonucleotide.
[0720] Exemplary embodiment No. 3. A conjugate or a pharmaceutically acceptable salt thereof, wherein the conjugate comprises:
[0721] (i) a nucleic acid agent, the nucleic acid agent comprising:
[0722] An oligonucleotide comprising one or two 5'-terminal units covalently attached to the oligonucleotide, wherein each 5'-terminal unit is independently:
[0723]
[0724] The variables B and R 1 , R 2 , R 3 , R 4 , R 6 , X, and Z are described herein, and ## indicates an attachment to the rest of the oligonucleotide; and
[0725] (ii) one or more ligands, said one or more ligands being covalently attached to the nucleic acid agent.
[0726] Exemplary embodiment No. 4. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein B is H.
[0727] Exemplary embodiment No. 5. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein B is a nucleobase moiety.
[0728] Exemplary embodiment No. 6. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the nucleobase moiety is adenine (A), cytosine (C), guanine (G), thymine (T) or uracil (U).
[0729] Exemplary embodiment No. 7. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the nucleobase moiety is a modified nucleobase.
[0730] Exemplary embodiment No. 8. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the nucleobase moiety is an artificial nucleobase.
[0731] Exemplary embodiment No. 9. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein X is H.
[0732] Exemplary embodiment No. 10. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein X is a halogen.
[0733] Exemplary embodiment No. 11. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein X is -OR X .
[0734] Exemplary embodiment No. 12. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein X is -OH.
[0735] Exemplary embodiment No. 13. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein X is -O-(C1-C6 alkyl).
[0736] Exemplary embodiment No. 14. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein X is -O-(C1-C6 alkyl)-O-(C1-C6 alkyl).
[0737] Exemplary embodiment number 15. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein X is optionally replaced by one or more R Xa Substituted-O-(C1-C6 alkyl)-(C6-C 10 aryl).
[0738] Exemplary embodiment No. 16. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein X is -O-(C1-C6 alkyl)-(C6-C 10 aryl).
[0739] Exemplary embodiment No. 17. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R X It's H.
[0740] Exemplary embodiment No. 18. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R X It is C1-C6 alkyl optionally substituted by one or more halogens or -O-(C1-C6 alkyl) optionally substituted by one or more halogens.
[0741] Exemplary embodiment No. 19. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R X is -(C1-C6 alkyl)-(C6-C6 alkyl)-substituted with one or more halogen, C1-C6 alkyl or -O-(C1-C6 alkyl) 10 aryl), wherein C1-C6 alkyl or -O-(C1-C6 alkyl) is optionally substituted with one or more halogens.
[0742] Exemplary embodiment No. 20. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R X It is -(C1-C6 alkyl)-(C6-C 10 aryl).
[0743] Exemplary embodiment No. 21. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Y is H.
[0744] Exemplary embodiment No. 22. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Y is a C1-C6 alkyl group optionally substituted with one or more halogens.
[0745] Exemplary embodiment No. 23. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Y is -P(R Y )2、-P(OR Y )(N(R Y )2)-P(=O)(OR Y )R Y 、-P(=S)(OR Y )R Y 、-P(=O)(SR Y )R Y ,-P(=S)(SR Y )R Y 、-P(=O)(OR Y )2、-P(=S)(OR Y )2, -P(=O)(SR Y )2、-P(=S)(SR Y )2.
[0746] Exemplary embodiment No. 24. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Y is a hydroxyl protecting group.
[0747] Exemplary embodiment No. 25. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Y is a silyl group.
[0748] Exemplary embodiment No. 26. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Y is triphenylmethyl (Tr) or 4,4'-dimethoxytrityl (DMTr).
[0749] Exemplary embodiment No. 27. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Y is an optionally substituted acyl or benzyl group.
[0750] Exemplary embodiment No. 28. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein at least one R Y It's H.
[0751] Exemplary embodiment No. 29. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein at least one R Y is a C1-C6 alkyl group optionally substituted by one or more halogen or cyano groups.
[0752] Exemplary embodiment No. 30. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein at least one R Y is H, and at least one R Y is a C1-C6 alkyl group optionally substituted by one or more halogen or cyano groups.
[0753] Exemplary embodiment No. 31. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein when X is -OH, then Y is not H or a hydroxyl protecting group.
[0754] Exemplary embodiment number 32. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein when X is -OH, then Y is C1-C6 alkyl, -P(R Y )2、-P(OR Y )(N(R Y )2)-P(=O)(OR Y )R Y 、-P(=S)(OR Y )R Y 、-P(=O)(SRY )R Y ,-P(=S)(SR Y )R Y 、-P(=O)(OR Y )2、-P(=S)(OR Y )2, -P(=O)(SR Y )2 or -P(=S)(SR Y )2.
[0755] Exemplary Embodiment No. 33. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein when Y is H or a hydroxyl protecting group, then X is not -OH.
[0756] Exemplary embodiment No. 34. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein when Y is H or a hydroxyl protecting group, then X is H, halogen or -OR x , and R x is C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 Aryl), wherein C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 Aryl) is optionally substituted with one or more R Xa replace.
[0757] Exemplary embodiment No. 35. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Z is -P(R Z )2.
[0758] Exemplary embodiment No. 36. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Z is -PH2.
[0759] Exemplary embodiment number 37. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Z is -P(OR Z )(N(R Z )2).
[0760] Exemplary embodiment No. 38. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Z is -P(=O)(OR Z )R Z .
[0761] Exemplary embodiment No. 39. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Z is -P(=S)(OR Z )R Z .
[0762] Exemplary embodiment No. 40. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Z is -P(=O)(SR Z )R Z .
[0763] Exemplary embodiment No. 41. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Z is -P(=S)(SR Z )R Z .
[0764] Exemplary embodiment No. 42. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Z is -P(=O)(OR Z )2.
[0765] Exemplary embodiment No. 43. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Z is -P(=S)(OR Z )2.
[0766] Exemplary embodiment No. 44. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Z is -P(=O)(SR Z )2.
[0767] Exemplary embodiment No. 45. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein Z is -P(=S)(SR Z )2.
[0768] Exemplary embodiment No. 46. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein at least one R Z It's H.
[0769] Exemplary embodiment number 47. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein at least one R Z is a C1-C6 alkyl group optionally substituted by one or more halogen or cyano groups.
[0770] Exemplary embodiment No. 48. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein at least one R Z is H, and at least one R Z is a C1-C6 alkyl group optionally substituted by one or more halogen or cyano groups.
[0771] Exemplary embodiment No. 49. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 1 It's H.
[0772] Exemplary embodiment number 50. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 1 It's a halogen.
[0773] Exemplary embodiment No. 51. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 1 is C1-C6 alkyl optionally substituted by one or more halogens.
[0774] Exemplary embodiment number 52. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 2 It's H.
[0775] Exemplary embodiment number 53. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 2 It's a halogen.
[0776] Exemplary embodiment number 54. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 2 is C1-C6 alkyl optionally substituted by one or more halogens.
[0777] Exemplary embodiment number 55. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 3 It's H.
[0778] Exemplary embodiment No. 56. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 3 It's a halogen.
[0779] Exemplary embodiment number 57. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 3 is C1-C6 alkyl optionally substituted by one or more halogens.
[0780] Exemplary embodiment No. 58. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 4 It's H.
[0781] Exemplary embodiment No. 59. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 4 It's a halogen.
[0782] Exemplary embodiment number 60. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 4 is C1-C6 alkyl optionally substituted by one or more halogens.
[0783] Exemplary embodiment No. 61. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 6 It's H.
[0784] Exemplary embodiment number 62. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 6 It's a halogen.
[0785] Exemplary embodiment number 63. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 6 is C1-C6 alkyl optionally substituted by one or more halogens.
[0786] Exemplary embodiment number 64. The compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein R 1 , R 2 , R 3 , R 4 and R 6 Each of them is H.
[0787] Exemplary embodiment No. 65. The compound according to any one of the preceding exemplary embodiments, having formula (I'-1), formula (I'-2), formula (II'-1) or formula (II'-2):
[0788]
[0789] or a pharmaceutically acceptable salt thereof.
[0790] Exemplary embodiment No. 66. A compound according to any one of the preceding exemplary embodiments, having formula (IA) or formula (II-A):
[0791]
[0792] or a pharmaceutically acceptable salt thereof.
[0793] Exemplary embodiment No. 67. A compound according to any of the preceding exemplary embodiments, having formula (I-A'-1), formula (I-A'-2), formula (II-A'-1) or formula (II-A'-2):
[0794]
[0795] or a pharmaceutically acceptable salt thereof.
[0796] Exemplary embodiment No. 68. A compound according to any of the preceding exemplary embodiments, having formula (IB-1), formula (IB-2), formula (II-B-1) or formula (II-B-2):
[0797]
[0798] or a pharmaceutically acceptable salt thereof.
[0799] Exemplary embodiment number 69. A compound according to any one of the preceding exemplary embodiments, having formula (I-B'-1), formula (I-B'-2), formula (I-B'-3), formula (I-B'-4), formula (II-B'-1), formula (II-B'-2), formula (II-B'-3) or formula (II-B'-4):
[0800]
[0801]
[0802]
[0803] or a pharmaceutically acceptable salt thereof.
[0804] Exemplary embodiment No. 70. The compound according to any one of the preceding exemplary embodiments, wherein the compound is:
[0805]
[0806] or a pharmaceutically acceptable salt thereof, wherein:
[0807] Y is -P(R Y )2、-P(OR Y )(N(R Y )2)-P(=O)(OR Y )R Y 、-P(=S)(OR Y )R Y 、-P(=O)(SR Y )R Y ,-P(=S)(SR Y )R Y 、-P(=O)(OR Y )2、-P(=S)(OR Y )2, -P(=O)(SR Y )2、-P(=S)(SRY )2 or a hydroxy protecting group (e.g., a silyl group (e.g., trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl or triisopropylsilyl), triphenylmethyl (Tr), 4,4'-dimethoxytrityl (DMTr), a substituted acyl group (e.g., an optionally substituted acetyl group) or a benzyl group);
[0808] Each R Y is independently H or C1-C6 alkyl optionally substituted by one or more halogen or cyano;
[0809] Z is -P(R Z )2、-P(OR Z )(N(R Z )2)-P(=O)(OR Z )R Z 、-P(=S)(OR Z )R Z 、-P(=O)(SR Z )R Z ,-P(=S)(SR Z )R Z 、-P(=O)(OR Z )2、-P(=S)(OR Z )2, -P(=O)(SR Z )2 or -P(=S)(SR Z )2; and
[0810] Each R Z is independently H or C1-C6 alkyl optionally substituted with one or more halogen or cyano.
[0811] Exemplary embodiment No. 71. A compound according to any one of the preceding exemplary embodiments, wherein the compound is:
[0812]
[0813]
[0814]
[0815]
[0816]
[0817] or a pharmaceutically acceptable salt thereof, wherein B is adenine (A), cytosine (C), guanine (G), thymine (T) or uracil (U).
[0818] Exemplary Embodiment No. 72. The compound according to any one of the preceding exemplary embodiments, wherein the compound is selected from the compounds described in Table E and pharmaceutically acceptable salts thereof.
[0819] Exemplary embodiment No. 73. A compound which is an isotopic derivative of the compound according to any one of the preceding exemplary embodiments.
[0820] Exemplary embodiment No. 74. The nucleic acid agent according to any one of the preceding exemplary embodiments, comprising single-stranded RNA.
[0821] Exemplary embodiment No. 75. The nucleic acid agent according to any one of the preceding exemplary embodiments, comprising double-stranded RNA.
[0822] Exemplary embodiment No. 76. The nucleic acid agent according to any one of the preceding exemplary embodiments, comprising a double-stranded RNA (eg, a double-stranded siRNA) and one or two 5'-terminal units, wherein:
[0823] The 5'-terminal unit is attached to the sense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, a double-stranded siRNA); and / or
[0824] The 5'-terminal unit is attached to the antisense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, double-stranded siRNA).
[0825] Exemplary embodiment No. 77. The nucleic acid agent according to any one of the preceding exemplary embodiments, wherein the 5'-terminal unit in the nucleic acid agent is
[0826]
[0827] or a pharmaceutically acceptable salt thereof, wherein:
[0828] Z is -P(R Z )2、-P(OR Z )(N(R Z )2)-P(=O)(OR Z )R Z 、-P(=S)(OR Z )R Z 、-P(=O)(SR Z )R Z ,-P(=S)(SR Z )R Z 、-P(=O)(OR Z )2、-P(=S)(OR Z )2, -P(=O)(SR Z )2 or -P(=S)(SRZ )2;
[0829] Each R Z is independently H or C1-C6 alkyl optionally substituted with one or more halogen or cyano.
[0830] Exemplary embodiment No. 78. The nucleic acid agent according to any one of the preceding exemplary embodiments, wherein the 5'-terminal unit in the nucleic acid agent is:
[0831]
[0832]
[0833]
[0834]
[0835]
[0836]
[0837]
[0838]
[0839]
[0840] or a pharmaceutically acceptable salt thereof, wherein B is adenine (A), cytosine (C), guanine (G), thymine (T) or uracil (U).
[0841] Exemplary embodiment No. 79. The nucleic acid agent according to any one of the preceding exemplary embodiments, wherein the 5'-terminal unit in the nucleic acid agent is selected from the 5'-terminal units described in Table N.
[0842] Exemplary embodiment No. 80. The conjugate according to any one of the preceding exemplary embodiments, comprising a single-stranded RNA (eg, a single-stranded siRNA), one or more ligands, and a 5'-terminal unit.
[0843] Exemplary embodiment No. 81. The conjugate according to any one of the preceding exemplary embodiments, comprising a double-stranded RNA (eg, a double-stranded siRNA), one or more ligands, and one or two 5'-terminal units.
[0844] Exemplary embodiment No. 82. The conjugate according to any one of the preceding exemplary embodiments, comprising a double-stranded RNA (eg, a double-stranded siRNA), one or more ligands, and one or two 5'-terminal units, wherein:
[0845] The 5'-terminal unit is attached to the sense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, a double-stranded siRNA); and / or
[0846] The 5'-terminal unit is attached to the antisense strand (eg, at the 5'-terminal position) of a double-stranded RNA (eg, double-stranded siRNA).
[0847] Exemplary embodiment No. 83. The conjugate according to any one of the preceding exemplary embodiments, wherein the 5'-terminal unit in the conjugate is:
[0848]
[0849]
[0850]
[0851]
[0852]
[0853]
[0854]
[0855]
[0856]
[0857]
[0858] or a pharmaceutically acceptable salt thereof, wherein B is adenine (A), cytosine (C), guanine (G), thymine (T) or uracil (U).
[0859] Exemplary embodiment No. 84. The conjugate according to any one of the preceding exemplary embodiments, wherein the 5'-terminal unit is selected from the conjugates described in Table C.
[0860] Exemplary Embodiment No. 85. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises a carbohydrate moiety.
[0861] Exemplary embodiment No. 86. The nucleic acid agent or conjugate according to any of the preceding exemplary embodiments, wherein the carbohydrate moiety comprises a monosaccharide, a disaccharide, a trisaccharide, or a tetrasaccharide.
[0862] Exemplary Embodiment No. 87. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the carbohydrate moiety comprises galactose or a derivative thereof.
[0863] Exemplary embodiment number 88. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0864] Exemplary embodiment number 89. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0865] Exemplary embodiment number 90. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0866] Exemplary embodiment number 91. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0867] Exemplary embodiment number 92. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0868] Exemplary embodiment number 93. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0869] Exemplary embodiment number 94. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0870] Exemplary embodiment number 95. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0871] Exemplary embodiment number 96. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0872] Exemplary embodiment number 97. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0873] Exemplary embodiment 98 The nucleic acid agent or conjugate according to any one of the aforementioned exemplary embodiments, wherein the ligand comprises
[0874] Exemplary embodiment number 99. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0875] Exemplary embodiment number 100. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0876] Exemplary embodiment number 101. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0877] Exemplary embodiment number 102. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0878] Exemplary embodiment No. 103. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises
[0879] Exemplary embodiment No. 104. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises a lipid.
[0880] Exemplary embodiment No. 105. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the ligand comprises a peptide portion.
[0881] Exemplary embodiment No. 106. The nucleic acid agent or conjugate according to any of the preceding exemplary embodiments, wherein the ligand comprises an antibody portion.
[0882] Exemplary embodiment No. 107. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the nucleic acid agent comprises an oligonucleotide.
[0883] Exemplary Embodiment No. 108. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the nucleic acid agent comprises one or more phosphate groups or one or more phosphate group analogs.
[0884] Exemplary embodiment No. 109. The nucleic acid agent or conjugate according to any of the preceding exemplary embodiments, wherein the 5'-terminal unit is attached to the nucleic acid agent via a phosphate group or a phosphate group analog in the nucleic acid agent.
[0885] Exemplary Embodiment No. 110. The nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments, wherein the nucleic acid agent comprises RNA.
[0886] Exemplary embodiment number 111. A nucleic acid agent or conjugate according to any of the foregoing exemplary embodiments, wherein the oligonucleotide is a siRNA, a microRNA, an anti-microRNA, a microRNA mimetic, an anti-miR, an antagomir, a dsRNA, a ssRNA, an aptamer, an immunostimulatory oligonucleotide, a decoy oligonucleotide, a splicing altering oligonucleotide, a triplex forming oligonucleotide, a G-quadruplex or an antisense oligonucleotide.
[0887] Exemplary Embodiment No. 112. A pharmaceutical composition comprising the compound, nucleic acid agent or conjugate according to any one of the preceding exemplary embodiments.
[0888] Exemplary embodiment No. 113. A method of regulating the expression of a target gene in a subject, comprising administering to the subject a conjugate according to any one of the preceding exemplary embodiments.
[0889] Exemplary embodiment No. 114. A method of delivering a nucleic acid agent to a subject, comprising administering to the subject a conjugate according to any one of the preceding exemplary embodiments.
[0890] Exemplary embodiment No. 115. A method of treating or preventing a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the conjugate according to any one of the preceding exemplary embodiments.
[0891] Exemplary embodiment No. 116. The conjugate according to any one of the preceding exemplary embodiments, for use in regulating the expression of a target gene in a subject.
[0892] Exemplary Embodiment No. 117. The conjugate according to any one of the preceding exemplary embodiments, for use in delivering a nucleic acid agent to a subject.
[0893] Exemplary embodiment No. 118. The conjugate according to any one of the preceding exemplary embodiments, for use in treating or preventing a disease in a subject in need thereof.
[0894] Exemplary embodiment No. 119. Use of the conjugate according to any one of the preceding exemplary embodiments in the manufacture of a medicament for regulating the expression of a target gene in a subject.
[0895] Exemplary embodiment No. 120. Use of the conjugate according to any one of the preceding exemplary embodiments in the manufacture of a medicament for delivering a nucleic acid agent to a subject.
[0896] Exemplary embodiment No. 121. Use of the conjugate according to any one of the preceding exemplary embodiments in the manufacture of a medicament for treating or preventing a disease in a subject in need thereof.
[0897] Exemplary embodiment No. 122. The method, conjugate or use according to any one of the preceding exemplary embodiments, wherein the subject is a human. Example
[0898] Example 1. Synthesis of 5'-terminal unit compound.
[0899]
[0900] ((3aR, 4R, 6R, 6aS) -6-amino-2,2-dimethyltetrahydro-4H-cyclopenta [d] [1,3] dioxol-4-yl) methanol (1-2) To a solution of compound 1-1 (50.0 g, 272.28 mmol, 1 eq, HCl salt) in MeOH (300 mL) was added TsOH (59.0 g, 310.40 mmol, 1.14 eq) and dimethoxypropane (198.5 g, 1.91 mol, 233.53 mL, 7 eq) at 25 ° C. The reaction mixture was stirred at 25 ° C under N2 for 5 h. The reaction mixture was quenched with 7M NH3 / MeOH and concentrated under reduced pressure to provide a crude residue. The residue was redissolved in 2M K2CO3 (500 mL), extracted with EA / DCM (1 / 1, 1000 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure to provide crude 1-2 (43.2 g), which was used in the next step without further purification. 1 H NMR: 400MHz, DMSO-d6, δ4.47 (d, J=6.0Hz, 1H), 4.14 (d, J=6.0Hz, 1H), 3.45-3.40 (m, 3H ), 3.38-3.23(m, 1H), 2.16-2.08(m, 2H), 1.25(s, 3H), 1.24-1.21(m, 2H), 1.08(s, 3H).
[0901] (E)-3-Ethoxy-N-(((3aS,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)carbamoyl)acrylamide (1-3) To a solution of compound 1-2 (38.7 g, 206.69 mmol, 1 eq) in DMF (230 mL) at -10°C was added isocyanate (58.3 g, 413.38 mmol, 2 eq). The mixture was stirred at 25°C for 16 h and then concentrated in vacuo to provide crude compound 1-3 as a yellow oil, which was used in the next step without further purification.
[0902] 1-((3aS,4R,6R,6aR)-6-(Hydroxymethyl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)pyrimidine-2,4(1H,3H)-dione (1-4) A solution of compound 1-3 (8.48 g, 25.83 mmol, 1 eq.) in NH3.H2O (61.4 g, 578.14 mmol, 67.47 mL, 33%, 22.39 eq.) was stirred at 90 °C for 16 h. The mixture was then cooled to 25 °C and concentrated under vacuum. The residue was purified by column chromatography (SiO2, DCM:MeOH=50:1 to 5:1) to provide compound 1-4 (37.0 g, 131.07 mmol, 63.4% yield) as a yellow solid.
[0903] 1-((1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl)pyrimidine-2,4(1H,3H)-dione (1-5) A solution of compound 1-4 (37.0 g, 131.07 mmol, 1 eq.) in AcOH (233.10 g, 3.11 mol, 222 mL, 80% purity, 23.69 eq.) was stirred at 80 °C for 3 h. The mixture was then concentrated under vacuum and co-evaporated with toluene (100 mL×3) and pyridine (100 mL×3). The residue was purified by column chromatography (SiO2, DCM:MeOH=50:1 to 5:1) to provide compound 1-5 (24.0 g, 99.08 mmol, 75.6% yield) as a yellow solid. 1 H NMR: 400MHz, DMSO-d6, δ7.67 (d, J=8.0Hz, 1H), 5.58 (d, J=8.0Hz, 1H), 4.85 (d, J=6.4Hz, 1H), 4.67-4.64 (m, 3H), 4.56 (t, J=1.4Hz, 1H), 4.36-3.98 (m, 1H), 3.71 (s, 1H), 3.45-3.38 (m, 3H), 2.01-1.92 (m, 2H), 1.27-1.23 (m, 1H).
[0904] (5aR,7R,8R,8aR)-8-Hydroxy-7-(hydroxymethyl)-5a,7,8,8a-tetrahydro-2H,6H-cyclopenta[4,5]oxazolo[3,2-a]pyrimidin-2-one (1-6) To a solution of compound 1-5 (30.0 g, 123.85 mmol, 1 eq) in DMF (300 mL) was added DPC (39.80 g, 185.78 mmol, 1.5 eq) and NaHCO (5.20 g, 61.93 mmol, 2.41 mL, 0.5 eq). The mixture was stirred at 120 °C for 16 h. The reaction was then cooled to 25 °C, poured into MTBE (3000 mL) and filtered. The residue was further concentrated under vacuum to provide crude 1-6 (27.8 g) as a brown solid, which was directly used in the next step without further purification.
[0905] 1-((1R,2S,3R,4R)-3-hydroxy-4-(hydroxymethyl)-2-methoxycyclopentyl)pyrimidine-2,4(1H,3H)-dione (1-7) To a solution of compound 1-6 (5.55 g, 24.75 mmol, 1 eq) in MeOH (55 mL) was added trimethyl borate (5.14 g, 49.51 mmol, 5.59 mL, 2 eq), trimethoxymethane (2.63 g, 24.75 mmol, 2.71 mL, 1 eq) and NaHCO3 (20.8 mg, 247.53 μmol, 9.63 μL, 0.01 eq). The mixture was stirred at 140 °C in a 100 mL autoclave for 16 h. The mixture was then cooled to 25 °C and concentrated in vacuo. The residue was purified by column chromatography (SiO 2 , DCM:MeOH=50:1 to 5:1) to provide compound 1-7 (11.0 g, 42.93 mmol, 34.7% yield) as a yellow solid. 1 HNMR: 400MHz, DMSO-d6, δ11.24 (s, 1H), 7.70 (d, J = 8.0Hz, 1H), 5.59 (d, J = 8.0Hz, 1H), 4.75-4.71 (m, 2H), 4.62 (d, J = 4.8Hz, 1H), 3.94-3.73 (m, 1H), 3.41-3.40 (m, 1H), 3.39-3.38 (m, 2H), 3.25 (s, 3H), 3.17-3.16 (m, 1H), 2.06-1.95 (m, 2H), 1.27-1.25 (m, 1H).
[0906] 1-((1R,2S,3R,4R)-4-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-hydroxy-2-methoxycyclopentyl)pyrimidine-2,4(1H,3H)-dione (1-8) To a solution of compound 1-7 (11.0 g, 42.93 mmol, 1 eq) in pyridine (110 mL) was added DMTrCl (17.5 g, 51.51 mmol, 1.2 eq) at 25 °C. The mixture was stirred at 25 °C for 1 h, quenched with MeOH (5 mL), and concentrated under vacuum. The residue was dissolved in EtOAc (200 mL), washed with aqueous citric acid (100 mL) and brine (100 mL). The organic layer was dried over Na 2 SO 4 , filtered and concentrated under vacuum to provide crude compound 1-8 (24.0 g, crude) as a yellow solid, which was used in the next step without further purification.
[0907] 1-((1R,2S,3R,4R)-4-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-((tert-butyldimethylsilyl)oxy)-2-methoxycyclopentyl)pyrimidine-2,4(1H,3H)-dione (1-9) To a solution of compound 1-8 (24.0 g, 42.93 mmol, 1 eq) in DCM (168 mL) was added imidazole (7.31 g, 107.32 mmol, 2.5 eq) and TBSCl (7.76 g, 51.51 mmol, 6.31 mL, 1.2 eq). The mixture was stirred at 25 °C for 16 h. The reaction was then extracted with DCM (200 mL), washed with aqueous NaHCO (200 mL) and brine (200 mL). The organic layer was dried over Na 2 SO 4 , filtered and concentrated under vacuum to provide compound 1-9 (28.9 g, crude) as a yellow oil, which was used in the next step without further purification.
[0908] 1-((1R,2S,3R,4R)-3-((tert-butyldimethylsilyl)oxy)-4-(hydroxymethyl)-2-methoxy-cyclopentyl)pyrimidine-2,4(1H,3H)-dione (1-10) To a solution of compound 1-9 (28.9 g, 42.92 mmol, 1 eq) in DCM (180 mL) at 0°C was added dodecan-1-thiol (17.4 g, 85.84 mmol, 20.56 mL, 2 eq) and DCA (22.1 g, 171.68 mmol, 14.10 mL, 4 eq). The reaction was stirred at 25°C for 2 h. The mixture was then washed with aqueous NaHCO3 (200 mL), extracted with DCM (200 mL), and washed with brine (200 mL). The organic layer was dried over Na2SO4, filtered, and concentrated under vacuum. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate=2 / 1 to 0 / 1) to provide compound 1-10 (9.70 g, 26.18 mmol, 61.00% yield) as a yellow solid. 1 H NMR: 400MHz, DMSO-d6, δ11.25(1H), 7.71(d, J=8.0Hz, 1H), 5.62-5.59(m, 1H), 4.79-4.73(m, 2H), 4.14-4.13(m, 1H), 3.78-3.75(m, 1H), 3.41-3.38 (m, 2H), 3.23 (s, 3H), 2.11-2.05 (m, 1H), 1.96-1.94 (m, 1H), 1.23-1.22 (m, 1H), 0.87 (s, 9H), 0.07 (d, J=5.6Hz, 6H).
[0909] To a solution of compound 1-10 (8.70 g, 23.48 mmol, 1 eq) in ACN (174 mL) was added IBX (8.55 g, 30.53 mmol, 1.3 eq). The mixture was stirred at 80 °C for 1 h and then cooled to 25 °C. The reaction was filtered and the filtrate was concentrated in vacuo to provide the crude aldehyde (7.50 g) as a white solid. The aldehyde was redissolved in THF (30 mL). At 0 ° C, t-BuOK (1M, 30.53mL, 1.5 equivalents, in t-BuOH) was added dropwise to a solution of phosphonate (9.39g, 32.56mmol, 1.6 equivalents) in THF (45mL). The mixture was stirred at 0 ° C for 0.5h. At 0 ° C, the mixture was then slowly added to the solution of the aldehyde solution prepared above. The resulting mixture was stirred at 0 ° C for 1h, and stirred at 25 ° C for another 1h. The reaction was then poured into aqueous NH4Cl (200mL), extracted with EtOAc (200mL×2), and washed with brine (200mL). The organic layer was dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=5 / 1 to 0 / 1) to provide compound 1-11 (10.2g, with ~30% phosphonate) as a yellow oil. 1 H NMR: 400MHz, CDCl3, δ 8.96 (s, 1H), 7.15 (d, J=8.0Hz, 1H), 6.81-6.69 (m, 1H), 5.80-5.71 (m, 2H), 4.44-4.43 (m, 1H), 4.18-4.07 (m, 6H), 3.85 (t, J=5. 6Hz, 1H), 3.38 (s, 3H), 2.83-2.75 (m, 1H), 2.36-2.29 (m, 1H), 1.86-1.78 (m, 4H), 1.36-1.24 (m, 7H), 0.91 (s, 9H), 0.10 (s, 6H).
[0910] To a solution of compound 1-11 (3.00 g, 5.97 mmol, 1 eq.) in MeOH (30 mL) was added NH4F (2.21 g, 59.69 mmol, 10 eq.). The reaction was stirred at 65 °C for 16 h. The mixture was then cooled to 25 °C and concentrated under vacuum. The residue was purified by column chromatography (SiO2, DCM:MeOH=50:1 to 5:1) to provide compound 1-12 (1.40 g, 3.60 mmol, 60.40% yield) as a yellow solid. 1 H NMR: 400MHz, CDCl3, δ 8.84 (s, 1H), 7.13 (d, J=8.0Hz, 1H), 6.89-6.77 (m, 1H), 5.81-5.75 (m, 1H), 4.54-4.50 (m, 1H), 4.14-4.07 (m, 5H ), 3.93-3.91(m, 1H), 3.45(s, 3H), 2.77-2.73(m, 2H), 2.36-2.28(m, 1H), 1.85-1.76(m, 1H), 1.37-1.32(m, 6H).
[0911] 2-Cyanoethyl((1R,2S,3R,5R)-5-((E)-2-(diethoxyphosphoryl)vinyl)-3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxycyclopentyl)diisopropylphosphoramidite (1-13) To a solution of compound 1-12 (1.40 g, 3.60 mmol, 1 eq) in DCM (14 mL) was added DCI (510.9 mg, 4.33 mmol, 1.2 eq) and 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite (1.63 g, 5.41 mmol, 1.72 mL, 1.5 eq) at 25° C. The reaction was stirred at 25° C. for 1 h. The mixture was then diluted with DCM (100 mL), washed with aqueous NaHCO (100 mL) and brine (100 mL). The organic layer was dried over anhydrous NaSO, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate=3 / 1 to 0 / 1, 0.1% TEA) to provide compound 1-13 (C-VP) (1.40 g, 2.38 mmol, 66% yield) as a white solid. 1H NMR: 400MHz, CD3CN, δ9.11 (s, 1H), 7.38-7.34 (m, 1H), 6.80-6.66 (m, 1H), 5. 87-5.73(m, 1H), 5.60-5.58(m, 1H), 4.62-4.58(m, 1H), 4.26-4.03(m, 1H), 4. 02-3.59 (m, 9H), 3.37-3.33 (m, 3H), 2.97-2.85 (m, 1H), 2.74-2.62 (m, 2H), 2 .33-2.24(m, 1H), 1.73-1.65(m, 1H), 1.29-1.24(m, 6H), 1.20-1.13(m, 12H).
[0912] To a solution of compound 1-11 (7.20 g, 14.33 mmol, 1 eq) in MeOH (72 mL) at 25 °C was added Pd / C (3.6 g, 10% purity) and AcOH (2.27 g, 37.77 mmol, 2.16 mL, 2.64 eq). The reaction was stirred under H2 (15 psi) at 25 °C for 2 h. The mixture was then filtered and concentrated under vacuum to provide crude compound 1-14 (7.23 g) as a yellow oil, which was used in the next step without further purification.
[0913] To a solution of compound 1-14 (7.23 g, 14.33 mmol, 1 eq.) in MeOH (72 mL) was added NH4F (5.31 g, 143.27 mmol, 10 eq.). The reaction was stirred at 65 °C for 16 h. The mixture was then cooled to 25 °C and concentrated under vacuum. The residue was purified by column chromatography (SiO2, DCM:MeOH=50:1 to 5:1) to provide compound 1.15 (3.70 g, 9.48 mmol, 66.2% yield) as a yellow oil. 11H NMR: 400MHz, DMSO-d6, δ11.2 (s, 1H), 7.74 (d, J = 8.0Hz, 1H), 5.58 (d, J = 7.6Hz, 1H), 4.67-4.63 (m, 2H), 4.00-3.96 (m, 4H), 3.73-3.71 (m, 2H), 3.26 (s, 3H), 2.08-2.01 (m, 1H), 1.81-1.70 (m, 4H), 1.51-1.44 (m, 1H), 1.23 (t, J=7.0Hz, 6H).
[0914] 2-Cyanoethyl((1R,2S,3R,5R)-5-(2-(diethoxyphosphoryl)ethyl)-3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxycyclopentyl)diisopropylphosphoramidite (1-16) To a solution of compound 1-15 (2.70 g, 6.92 mmol, 1 eq) in DCM (27 mL) was added DCI (980.2 mg, 8.30 mmol, 1.2 eq) and 2-cyanoethyl-N,N,N',N'-tetraisopropylphosphoramidite ((3 .13g, 10.37mmol, 3.30mL, 1.5 equivalents). The reaction was stirred at 25 ° C for 1h. The mixture was then diluted with DCM (100mL), washed with aqueous NaHCO (100mL) and brine (100mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=3 / 1 to 0 / 1, 0.1% TEA) to provide compound 1-16 (C-EP) (3.9g, 70% yield) as a white oil. 1 H NMR: 400MHz, CD3CN, δ9.09 (s, 1H), 7.38-7.35 (m, 1H), 5.60-5.57 (m, 1H), 4. 67-4.62(m, 1H), 4.05-4.00(m, 5H), 3.99-3.62(m, 5H), 3.34-3.31(m, 3H), 2. 69-2.66(m, 2H), 2.29-2.21(m, 1H), 2.12-2.06(m, 1H), 1.89-1.68(m, 3H), 1 .60-1.50 (m, 1H), 1.38-1.32 (m, 1H), 1.30-1.24 (m, 6H), 1.22-1.14 (m, 12H).
[0915] 2-Cyanoethyl ((1R,2S,3R,5R)-5-(2-(dimethoxyphosphoryl)ethyl)-3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxycyclopentyl) diisopropylphosphoramidite (2-16)
[0916]
[0917] Carbocyclic uridine dimethyl phosphoramidite 2-16 was prepared using a procedure similar to that described above for the preparation of 1-16.
[0918] Example 2. General procedure for oligonucleotide synthesis
[0919] Oligonucleotides were synthesized following standard oligonucleotide synthesis procedures using 2'-modified phosphoramidites (Hongene Biotech), the carbocyclic nucleotide phosphoramidites described above for the antisense strand, and Glb GalNAc phosphoramidite (PCT / US2022 / 039517) for the sense strand.
[0920] To prepare the antisense strand of the monomethyl protected carbocyclic nucleotide [5'-C-MeEPmU], the synthesized oligonucleotide was deprotected with concentrated ammonia (28 wt%-30 wt%) at 45°C for one day under standard cleavage and deprotection conditions to remove one methyl group simultaneously.
[0921] To prepare the antisense strand with fully deprotected carbocyclic nucleotides [5'-C-EPmU], the solid support column was first treated with TMSI / pyridine / CH2Cl2 at room temperature for 1 h and quenched with a 2-mercaptoethanol solution in TEA / CH3CN. The standard cleavage and deprotection conditions described above were then used to provide a fully cleaved and deprotected antisense strand.
[0922] The crude oligonucleotides were analyzed by SAX-HPLC and HR-LC-MS and purified by SAX-HPLC. The pure fractions were combined, concentrated, desalted and lyophilized to provide purified sense and antisense strands. The sense and antisense strands were then redissolved in water and annealed to provide a duplex based on a 1:1 molar ratio.
[0923] Example 3. mRNA knockdown activity of siRNA molecules incorporating 5'-carbocyclic nucleotides on target genes in mouse liver
[0924] Gene silencing activity in mouse liver was investigated using the siRNA compounds listed in Table 1. These siRNA molecules incorporated 5'-C-MeEP or 5'-C-EP and were compared to siRNA molecules containing 5'-(E)-vinylphosphonate (5'-VP) or 5'-hydroxyl group (5'-OH). Figure 1A and Figure 1B As shown in , in mouse liver, both 5'-C-MeEP and 5'-C-EP exhibited improved knockdown efficacy compared to 5'-VP and 5'-OH.
[0925] CD-1 female mice were subcutaneously administered 0.5 mg / kg siRNA molecules. The control group was given phosphate buffered saline (PBS). Four days after treatment, the animals were then hydrodynamically injected (HDI) with 20 μg of target gene 2 in pcDNA3.1(+) via the tail vein. The mice were sacrificed one day after treatment. Liver tissues were collected and incubated at 4°C for 24 h. The cells were stored overnight in PBS and subsequently transferred to -80°C for mRNA analysis after RNA removal. TM The reduction of target mRNA was measured by qPCR using a real-time PCR detection system (BioRad Laboratories, Inc., Hercules, CA). All samples were normalized to PBS-treated control animals and plotted using GraphPad Prism software (GraphPad Software Inc., La Jolla, CA).
[0926] Example 4. mRNA knockdown activity of siRNA molecules incorporated with carbocyclic nucleotides on target genes in extrahepatic tissues of mice
[0927] Gene silencing activity in extrahepatic tissues of mice was investigated using fully chemically modified siRNA molecules conjugated to specific targeting ligands for extrahepatic tissues. These siRNA molecules incorporated 5'-C-MeEP or 5'-C-EP and were compared with siRNA molecules containing 5'-(E)-vinylphosphonate (5'-VP) or 5'-hydroxyl group (5'-OH). Figure 2A-2E As shown in , in multiple extrahepatic tissues, both 5'-C-MeEP and 5'-C-EP showed improved knockdown efficacy compared to 5'-OH and at least comparable or improved activity to 5'-VP.
[0928] CD-1 female mice were subcutaneously administered 3 mg / kg siRNA molecules. A control group was administered phosphate buffered saline (PBS). Mice were sacrificed ten days after treatment. Multiple extrahepatic tissues were collected and incubated at 4°C for 24 h. The cells were stored overnight in PBS and subsequently transferred to -80°C for mRNA analysis after RNA removal. TM The reduction of target mRNA was measured by qPCR using a real-time PCR detection system (BioRad Laboratories, Inc., Hercules, CA). All samples were normalized to PBS-treated control animals and plotted using GraphPad Prism software (GraphPad Software Inc., La Jolla, CA).
[0929] Table 1. Sequence information of exemplary siRNA duplexes tested in Examples 3 and 4.
[0930]
[0931]
[0932] The lowercase letters of f / m indicate modifications of adenosine, cytidine, guanosine and uridine by 2'-deoxy-2'-fluoro (2'-F) and 2'-O-methyl (2'-OMe) sugars, respectively; s indicates a phosphorothioate (PS) bond; VP, C-EPmU, C-MeEPmU and G1b indicate chemical structures as shown below:
[0933]
[0934] Equivalent
[0935] The details of one or more embodiments of the present disclosure are set forth in the above attached description. Although any methods and materials similar or equivalent to the methods and materials described herein can be used in the practice or testing of the present disclosure, preferred methods and materials are now described. According to the specification and claims, other features, objects and advantages of the present disclosure will be apparent. In this specification and the appended claims, unless the context clearly specifies otherwise, the singular form includes plural indicators. Unless otherwise defined, all technical terms and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the field to which the present disclosure belongs. All patents and publications cited in this specification are incorporated by reference.
[0936] The foregoing description is presented for purposes of illustration only, and is not intended to limit the present disclosure to the precise form disclosed, except as set forth by the appended claims.
Claims
1. A compound of formula (I) or formula (II): or a pharmaceutically acceptable salt thereof, wherein: B is H or a nucleobase moiety; X is H, halogen or -OR X ; R X is H, C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 aryl), wherein the C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 Aryl) is optionally substituted with one or more R Xa replace; Each R Xa is independently halogen, C1-C6 alkyl or -O-(C1-C6 alkyl), wherein said C1-C6 alkyl or -O-(C1-C6 alkyl) is optionally substituted with one or more halogen; Y is H, C1-C6 alkyl optionally substituted by one or more halogens, -P(R Y )2、-P(OR Y )(N(R Y )2)-P(=O)(OR Y )R Y 、-P(=S)(OR Y )R Y 、-P(=O)(SR Y )R Y ,-P(=S)(SR Y )R Y 、-P(=O)(OR Y )2、-P(=S)(OR Y )2, -P(=O)(SR Y )2、-P(=S)(SR Y )2 or a hydroxyl protecting group; Each R Y is independently H or C1-C6 alkyl optionally substituted by one or more halogen or cyano; Z is -P(R Z )2, -P(OR Z )(N(R Z )2), -P(=O)(OR Z )R Z , -P(=S)(OR Z )R Z , -P(=O)(SR Z )R Z , -P(=S)(SR Z )R Z 、-P(=O)(OR Z )2、-P(=S)(OR Z )2、-P(=O)(SR Z )2或-P(=S)(SR Z )2; Each R Z is independently H or C1-C6 alkyl optionally substituted by one or more halogen or cyano; R 1 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens; R 2 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens; R 3 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens; R 4 is H, halogen or C1-C6 alkyl optionally substituted by one or more halogens; Indicates single or double bonds; and Each R 6 is independently H, halogen or C1-C6 alkyl optionally substituted with one or more halogens.
2. A nucleic acid agent or a pharmaceutically acceptable salt thereof, wherein the nucleic acid agent comprises: An oligonucleotide comprising one or two 5'-terminal units, wherein each 5'-terminal unit is independently: The variables B and R 1 , R 2 , R 3 , R 4 , R 6 , X and Z are described herein, and ## indicates an attachment to the rest of the oligonucleotide.
3. A conjugate or a pharmaceutically acceptable salt thereof, wherein the conjugate comprises: (i) a nucleic acid agent, the nucleic acid agent comprising: An oligonucleotide comprising one or two 5'-terminal units covalently attached to the oligonucleotide, wherein each 5'-terminal unit is independently: The variables B and R 1 , R 2 , R 3 , R 4 , R 6, X, and Z are described herein, and ## indicates an attachment to the remainder of the oligonucleotide; and (ii) one or more ligands, said one or more ligands being covalently attached to said nucleic acid agent.
4. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein B is H.
5. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein B is a nucleobase moiety.
6. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein the nucleobase moiety is adenine (A), cytosine (C), guanine (G), thymine (T) or uracil (U).
7. The compound, nucleic acid agent or conjugate according to any one of the preceding claims, wherein X is -OR X .
8. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein X is -OH.
9. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein X is -O-(C1-C6 alkyl).
10. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein X is -O-(C1-C6 alkyl)-O-(C1-C6 alkyl).
11. The compound, nucleic acid agent or conjugate according to any one of the preceding claims, wherein X is optionally replaced by one or more R Xa Substituted-O-(C1-C6 alkyl)-(C6-C 10 aryl).
12. The compound, nucleic acid agent or conjugate according to any one of the preceding claims, wherein X is -O-(C1-C6 alkyl)-(C6-C 10 aryl).
13. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Y is a C1-C6 alkyl group optionally substituted with one or more halogens.
14. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Y is -P(R Y )2、-P(OR Y )(N(R Y )2)-P(=O)(OR Y )R Y 、-P(=S)(OR Y )R Y 、-P(=O)(SR Y )R Y,-P(=S)(SR Y )R Y 、-P(=O)(OR Y )2、-P(=S)(OR Y )2, -P(=O)(SR Y )2、-P(=S)(SR Y )2.
15. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Y is a hydroxyl protecting group.
16. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein when X is -OH, then Y is not H or a hydroxyl protecting group.
17. The compound, nucleic acid agent or conjugate of any of the preceding claims, wherein when X is -OH, then Y is C1-C6 alkyl, -P(R Y )2、-P(OR Y )(N(R Y )2)-P(=O)(OR Y )R Y 、-P(=S)(OR Y )R Y 、-P(=O)(SR Y )R Y ,-P(=S)(SR Y )R Y 、-P(=O)(OR Y )2、-P(=S)(OR Y )2, -P(=O)(SR Y )2 or -P(=S)(SR Y )2.
18. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein when Y is H or a hydroxy protecting group, then X is not -OH.
19. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein when Y is H or a hydroxy protecting group, then X is H, halogen or -OR X , and R X is C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 aryl), wherein the C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 Aryl) is optionally substituted with one or more R Xa replace.
20. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Z is -P(R Z )2.
21. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Z is -PH2.
22. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Z is -P(OR Z )(N(R Z )2).
23. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Z is -P(=O)(OR Z )R Z .
24. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Z is -P(=S)(OR Z )R Z .
25. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Z is -P(=O)(SR Z )R Z .
26. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Z is -P(=S)(SR Z )R Z .
27. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Z is -P(=O)(OR Z )2.
28. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Z is -P(=S)(OR Z )2.
29. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Z is -P(=O)(SR Z )2.
30. The compound, nucleic acid agent or conjugate of any one of the preceding claims, wherein Z is -P(=S)(SR Z )2.
31. A compound according to any one of the preceding claims, having formula (I'-1), formula (I'-2), formula (II'-1) or formula (II'-2): or a pharmaceutically acceptable salt thereof.
32. A compound according to any one of the preceding claims, having formula (IA) or formula (II-A): or a pharmaceutically acceptable salt thereof.
33. A compound according to any one of the preceding claims, having Formula (I-A'-1), Formula (I-A'-2), Formula (II-A'-1) or Formula (II-A'-2): or a pharmaceutically acceptable salt thereof.
34. A compound according to any one of the preceding claims, having Formula (IB-1), Formula (IB-2), Formula (II-B-1) or Formula (II-B-2): or a pharmaceutically acceptable salt thereof.
35. A compound according to any of the preceding claims, having Formula (I-B'-1), Formula (I-B'-2), Formula (I-B'-3), Formula (I-B'-4), Formula (II-B'-1), Formula (II-B'-2), Formula (II-B'-3) or Formula (II-B'-4): or a pharmaceutically acceptable salt thereof.
36. A compound according to any one of the preceding claims, wherein the compound is: or a pharmaceutically acceptable salt thereof, wherein: Y is -P(R Y )2, -P(OR Y )(N(R Y )2), -P(=O)(OR Y )R Y , -P(=S)(OR Y )R Y , -P(=O)(SR Y )R Y , -P(=S)(SR Y )R Y 、-P(=O)(OR Y )2、-P(=S)(OR Y )2, -P(=O)(SR Y )2、-P(=S)(SR Y )2 or a hydroxy protecting group (e.g., a silyl group (e.g., trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl or triisopropylsilyl), triphenylmethyl (Tr), 4,4'-dimethoxytrityl (DMTr), a substituted acyl group (e.g., an optionally substituted acetyl group) or a benzyl group); Each R Y is independently H or C1-C6 alkyl optionally substituted by one or more halogen or cyano; Z is -P(R Z )2, -P(OR Z )(N(R Z )2), -P(=O)(OR Z )R Z , -P(=S)(OR Z )R Z , -P(=O)(SR Z )R Z , -P(=S)(SR Z )R Z 、-P(=O)(OR Z )2、-P(=S)(OR Z )2, -P(=O)(SR Z )2 or -P(=S)(SR Z )2; and Each R Z is independently H or C1-C6 alkyl optionally substituted with one or more halogen or cyano.
37. A compound according to any one of the preceding claims, wherein the compound is: or a pharmaceutically acceptable salt thereof, wherein B is adenine (A), cytosine (C), guanine (G), thymine (T) or uracil (U).
38. The compound according to any one of the preceding claims, wherein the compound is selected from the compounds described in Table E and pharmaceutically acceptable salts thereof.
39. The nucleic acid agent of any one of the preceding claims, comprising single-stranded RNA.
40. The nucleic acid agent of any one of the preceding claims, comprising double-stranded RNA.
41. The nucleic acid agent of any one of the preceding claims, comprising a double-stranded RNA (eg, double-stranded siRNA) and one or two 5'-terminal units, wherein: The 5'-terminal unit is attached to the sense strand of the double-stranded RNA (eg, double-stranded siRNA) (eg, at the 5'-terminal position); and / or The 5'-terminal unit is attached to the antisense strand (eg, at the 5'-terminal position) of the double-stranded RNA (eg, double-stranded siRNA).
42. The nucleic acid agent according to any one of the preceding claims, wherein the 5'-terminal unit in the nucleic acid agent is or a pharmaceutically acceptable salt thereof, wherein: Z is -P(R Z )2, -P(OR Z )(N(R Z )2), -P(=O)(OR Z )R Z , -P(=S)(OR Z )R Z , -P(=O)(SR Z )R Z , -P(=S)(SR Z )R Z 、-P(=O)(OR Z )2、-P(=S)(OR Z )2、-P(=O)(SR Z )2或-P(=S)(SR Z )2; Each R Z is independently H or C1-C6 alkyl optionally substituted with one or more halogen or cyano.
43. The nucleic acid agent according to any one of the preceding claims, wherein the 5'-terminal unit in the nucleic acid agent is: or a pharmaceutically acceptable salt thereof, wherein B is adenine (A), cytosine (C), guanine (G), thymine (T) or uracil (U).
44. The nucleic acid agent according to any one of the preceding claims, wherein the 5'-terminal unit in the nucleic acid agent is selected from the 5'-terminal units described in Table N.
45. The conjugate of any one of the preceding claims, comprising a single-stranded RNA (eg, a single-stranded siRNA), one or more ligands, and a 5'-terminal unit.
46. The conjugate of any one of the preceding claims, comprising a double-stranded RNA (eg, double-stranded siRNA), one or more ligands, and one or two 5'-terminal units.
47. The conjugate of any one of the preceding claims, comprising a double-stranded RNA (eg, double-stranded siRNA), one or more ligands, and one or two 5'-terminal units, wherein: The 5'-terminal unit is attached to the sense strand of the double-stranded RNA (eg, double-stranded siRNA) (eg, at the 5'-terminal position); and / or The 5'-terminal unit is attached to the antisense strand (eg, at the 5'-terminal position) of the double-stranded RNA (eg, double-stranded siRNA).
48. The conjugate of any one of the preceding claims, wherein the 5'-terminal unit in the conjugate is: or a pharmaceutically acceptable salt thereof, wherein B is adenine (A), cytosine (C), guanine (G), thymine (T) or uracil (U).
49. The conjugate according to any one of the preceding claims, wherein the 5'-terminal unit is selected from the conjugates described in Table C.
50. The nucleic acid agent or conjugate of any one of the preceding claims, wherein the ligand comprises 51. The nucleic acid agent or conjugate of any one of the preceding claims, wherein the ligand comprises 52. The nucleic acid agent or conjugate of any of the preceding claims, wherein the ligand comprises a lipid, a peptide moiety, or an antibody moiety.
53. The nucleic acid agent or conjugate of any of the preceding claims, wherein the nucleic acid agent comprises an oligonucleotide.
54. A pharmaceutical composition comprising the compound, nucleic acid agent or conjugate according to any one of the preceding claims.
55. A method of modulating expression of a target gene in a subject, delivering a nucleic acid agent to a subject, or treating or preventing a disease in a subject in need thereof, comprising administering to the subject a conjugate according to any one of the preceding claims.
56. The conjugate of any one of the preceding claims, for use in modulating expression of a target gene in a subject, delivering a nucleic acid agent to a subject, or treating or preventing a disease in a subject in need thereof.
57. Use of a conjugate according to any one of the preceding claims in the manufacture of a medicament for modulating expression of a target gene in a subject, delivering a nucleic acid agent to a subject, or treating or preventing a disease in a subject in need thereof.
Citation Information
Patent Citations
Synthetic, catalytic oligonucleotides
EP0519463A1
Modified iRNA agents
US20050107325A1
Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070123482A1
Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070213292A1
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
US20090239814A1
Cited By
Oligonucleotide terminal phosphate derivatives and method of use
WO2025191337A3
